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Abstract
In chapter two, the development of new a nanoparticulate carrier system
for gene delivery was described. The new nanocarrier consists of a blend
matrix formed by a poly (lactic-eo-glycolic acid) (PLGA) and Poly
(ethylene glycol) bis (3-aminopropyl) terminated (also known as
JeffamineTM). Nanopartic1es were formulated based on a 50:50weight
ratio of PLGA:Jeffamine using a modified emulsification-solvent diffusion
technique. The potential of these blended matrix nanoparticles for
encapsulation efficiency of Calf Thymus DNA and release profile were
also studied. The achieved encapsulation efficiency of Calf Thymus DNA
was approximately 84% for 0.4% theoretical loading with regard to total
amount of PLGA. The PLGA: Jeffamine blended nanoparticles provided
continuous and controlled release of Calf Thymus DNA. The PLGA:
[effamine nanopartic1es were also coated with PLGA-PEGMA&75and
PDMAEMA-PEGMA block copolymers using a simple physical
adsorption method. After surface coating of the nanoparticles, zeta
potential value showed significant reduction of surface charges from -38
mV to near zero value, while TEM micrographs showed a well defined
core-shell nanopartic1e.
In chapter three, A facile route to biocompatible poly (lactic acid-co-
glycolic acid)-co-poly (ethyleneglycol methacrylate) (PLGA-PEGMA)
block co-polymers was described utilising a combination of ring-opening
polymerisation (ROP) and Radical Addition Fragmentation Transfer
(RAFT) methods. A series of PLGA-PEGMApolymers varying in co-
monomer content and block length were synthesised with low
polydispersities. All the block co-polymers formed micelles in aqueous
solution as shown by dynamic light scattering, while critical micelle
concentrations were found to be in the micromolar range.
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The polymer micelles were able to encapsulate model drugs
(carboxyfluorescein and fluorescein isothiocyanate) and selected co-
polymer micelles incubated with 3T3 fibroblasts as a model cell line were
rapidly taken up as indicated by fluorescence microscopy assays.
The combination of the polymer chemistries opens the way to highly
flexible syntheses of micellar drug carrier systems.
In chapter four, multifunctional and modular block co-polymers prepared
from biocompatible monomers and linked by a bioreducible disulfide
linkage have been prepared using a combination of ring-opening and
atom-transfer radical polymerizations (ATRP).The presence of terminal
functionality via ATRP allowed cell-targeting folic acid groups to be
attached in a controllable manner, while the block co-polymer architecture
enabled well-defined nanopartic1es to be prepared by a water-oil-water
double emulsion procedure to encapsulate DNA with high efficiency.
Gene delivery assays in a Calu-3 cell line indicated specific folate-
receptor-mediated uptake of the nanoparticles, and triggered release of
the DNA payload via cleavage of the disulfide link resulted in enhanced
transgene expression compared to non-bioreducible analogues. These
materials offer a promising and generic means to deliver a wide variety of
therapeutic payloads to cells in a selective and tuneable way.
ii
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Chapter 1
Polymeric drug and gene delivery
systems
1. Introduction
The efficacy of synthetic drug compounds in therapy is strongly
dependent on their formulation into medicines and on their
distribution, localisation and accumulation in different regions in the
body. The ability to deliver a drug compound to the specific target
site (organ, tissue, cell, intracellular compartment)s remains a
challenge. A century on from Paul Ehrlich's visionary hypothesis,
for which he received the Nobel Prize in 1908, there are still no
'Magic Bullets'l against most diseases. As a result, the delivery of
drugs to the desired target sites in the body at the right time, and in
the right dose is still an unmet clinical needs, This leads to inefficient
use of drugs, undesired side effects and greater medical intervention,
with resulting burdens on patients, carer populations and healthcare
budgets. Current targeting methods for many drugs either lack
specificity or are not active for certain patient groups. As a
consequence, drug delivery systems are gaining in importance - and
many of these are based on polymers- 3. In addition, new generations
of therapeutics are emerging, and these to are often macromolecular
or polymeric in nature. For example, in 2002 and 2003 the US FDA
approved more biotechnology products (proteins and antibodies)
and drug delivery systems as marketed products than new low
1
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molecular weight drugs+, However, these new classes of drugs and
their conjugates, complexes and formulated vehicles - sometimes
considered as Nanomedicines - and the related biotherapeutics, still
urgently require technologies to ensure their specific localisation in
target sitesv 6. As a consequence, new modalities of Ismart' or active
materials ranging from bioresponsive to electroactive polymer drug
delivery systems are being developed/- 8. In this chapter, a short
introduction is given to key concepts in drug delivery, considering
the specific issues for polymers and smart materials related to the
transport and release of therapeutic compounds, and highlighting
some exciting recent examples where polymers have been developed
to help target and deliver drug molecules. The focus is primarily on
soluble polymers and nanoparticles rather than hydrogels, as there
are numerous reviews on responsive hydrogels available9-19, and the
design concepts in the soluble and nanoparticle polymer systems
best exemplify the key responses that can be engineered into I smart'
materials.
1.1. Drug Delivery - Examples, Challenges And Opportunities For
Polymers
In general, drug delivery aims at optimising therapy by delivering
bioactive agents at specific sites or specific rates to the patient20, The
field has evolved from simple topical waxes21 and delayed release
formulations to the targeted delivery of therapeutic agents to specific
cells and subcellular compartmentsss, Traditional approaches to drug
delivery have been based on simple formulation parameters. For low
molar mass compounds (Mw < 1000), which still represent the main
focus for the pharmaceutical industry, the goal is to deliver the drug
to the pharmacological receptor or biochemical target with as little
2
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complexity in the formulation as possible. Since many of these
compounds are relatively lipophilic and can partition across
membranes, the drug delivery system needs to address the
biopharmaceutical requirements of the dosing route, and these
involve a variety of physical and biochemical barriers. Delivery is
ultimately dependent both on the physicochemical properties of the
drug and on the physiology of the body, thus a brief consideration of
these factors and the common dosing routes is needed to put
polymer-mediated drug delivery in context.
1.1.1.Oral Drug Delivery Systems
The oral route is the most widely used for drug administration and is
likely to remain the most favoured route in the future owing to good
patient compliance, familiarity and a long history of successful
development in the pharmaceutical industry23,24.However, as many
candidate therapeutics in development are increasingly of higher
molar mass and poorer aqueous solubility compared to existing
drugs, the systems for formulating and delivering these candidates
are becoming more complex. For conventional oral delivery water-
soluble drugs can be formulated into tablets or capsules with
controllable erosion or breakdown profiles to determine rate and site
of drug release in the GI tract25.The types of polymers used in these
systems are relatively simple, and include cellulose and derivatives
e.g. 2-hydroxy-propylmethy1cellulose (HPMC) and sodium
carboxymethy1cellulose, which are often combined with other
materials such as poly(N-vinylpyrollidone) and poly(methacrylic
acid/methacrylates) for optimal formulation properties=. There are a
great number of potential variations possible in these drug delivery
materials, and many have been successfully commercialised.
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However, in the case of many poorly-soluble drugs and for targeting
specific sites in the body, current matrices do not exhibit the right
balance of functional behaviour. For the new candidate drugs,
polymers that have one set of properties in the oral cavity and
another type of behaviour in designated areas of the GI tract may
offer an answer to the delivery problem. Drugs of poor aqueous
solubility can be formulated or conjugated to polymers that are
soluble at high pH, but hydrolyse at low pH to enable drug transport
from the oral cavity to the stomach=. The change in polymer
properties can be in response to the local environment or induced by
external stimuli such as charge, pH, light and temperaturev- 28.
1.1.2. Parenteral Drug Delivery
For parenteral drug delivery, e.g. intravenous (i.v.) or intramuscular
(i.m.) injection, polymers can be used to enhance solubility, either
directly, or through the formation of higher order systems, such as
micelles which can carry a water-insoluble drug molecule in their
hydrophobic cores28, 29. Polymers can also be used for parenteral
drug delivery in the form of micro- and nano-particles'", as long as
they meet the necessary criteria for injectable formulations of being
sterilisable and stable against aggregation. The latter point is
particularly important as material injected into the blood stream
rapidly passes into the heart and then round the pulmonary
circulation - any particles larger than+ 5 J.1mcan lodge in pulmonary
capillaries resulting in embolismt'. Thus, even for relatively simple
polymers in parenteral use, careful consideration must be given to
biopharmaceutics and formulation requirements - for more complex
responsive polymers the properties in the in vivo environment must
be very tightly defined in order to prevent unintended adverse
4
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reactions. Nevertheless, the potential advantages of using 'smart'
nanopartic1es for parenteral delivery remain, as it can be envisaged
that a polymer surface coating that enables prolonged circulation in
the bloodstream, but which can be actuated to expose a binding
moiety in response to a biological or external signal. Targeting in this
case could be direct and instantaneous. Another facet of parenteral
drug delivery is the implanted device, and this is perhaps the most
promising and most readily commercialised area for responsive
and/ or active polymers=+. For an implanted vehicle or depot, drug
release rate is controlled by dissolution and/ or diffusion in the
formulation, or for solid polymer implants by diffusion and/ or
degradation of the polymer. For more complex polymer hydrogelsv,
the release can be controllable by the linking chemistries, and these
can be made responsive to a wide variety of stimuli such as
enzymatic action, redox potential as well as those noted above for the
oral route.
1.1.3. Topical and Transdermal Drug Delivery
For other routes of delivery, the formulation considerations relating
to polymers are less restrictive than for the parenteral route.
Typically, for local rather than systemic activity, polymers can be
used to enhance the efficacyof topical drug delivery systems through
solubility enhancement and/or skin hydration=. For transdermal
delivery, polymers can have several roles, either as solubility
modifiers, permeation enhancers'" or as aids in iontophoresis. The
presence of multiple-charged species is a prerequisite for
iontophoretic movement of drug molecules through the skin, so can
be considered as an actuation process in its own right. However,
clinically, iontophoresis is still a niche area in drug delivery and
s
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other routes are currently more attractive for development of
responsive polymer systems, although some examples have been
developed38,39.
1.2. Gene therapy
The ability to manipulate genes and gene expression has
tremendous therapeutic potential in the treatment of many of
inherited and acquired diseases. Advances in molecular biology and
human genome projects have provided important information on
genetic control of cellular processes and disease pathogenesisw,
Therefore, identification of genes involved in disease and cellular
processes can be novel targeted in therapeutic approaches for the
treament of many inherited and acquired diseases via manipulation
of targeted genes in diseased cell populations41,42.
The purpose of gene therapy is to manipulate cellular processes by
altering gene expression, in specific cell populations via delivery of
DNA, RNA, or antisense sequences. Originally, gene therapy was
designed to treat inherited genetic disorders such as cystic fibrosis
and haemophilia, but recently the applications of gene therapy have
also expanded for acquired disease conditions such as HIV, cancer
and wound healing43-45.
In the first example of inherited disorders, the cellular process can be
restored via replacing the deficient genes, whilst acquired diseases
such as HIV can be treated by changing the expression of a gene to
stimulate desirable cellular events such as stimulation of immune
response= ".
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Generally, gene therapy and manipulation of genes can be carried
out in two different approaches, either in vivo or ex vivo. The ex vivo
approach includes isolation of cells from the patient, genetic
modification of the cells and finally implantation of them back into
the patient. The advantage of this approach is high transfection
efficiency, but the procedure is very costly and can not be done in all
cases=.
The second approach in gene therapy is in vivo, in this case the
therapeutic gene is inserted into the patient using a gene delivery
system (vector), this being more challenging and requiring many
variables to be controlled in order to build-up a safe and efficient
gene delivery system. There are two types of vectors to use in in vivo
gene therapy, viral vectors and non-viral vectors49•
Viral vectors are considered to be the most efficient delivery vector
owing to their known ability to effectively pass the biological
barriers and reach cells. The design of viral gene delivery system
involves removal of a section of the genome to prevent replication
and encoding a therapeutic gene into their genome.
Viral vectors, despite their ability to deliver therapeutic genes
efficiently, have drawbacks and limitations in their applications. The
major hurdles in using viral vectors as gene delivery vectors are:
limited space to insert genes in their genome, induction of immune
response against the viral proteins, possible recombination with
wild-type viruses, difficulties experienced in large-scale
pharmaceutical productions= 51. Therefore, interest in introducing
non-viral vectors has hugely increased.
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Non-viral approaches involve either plasmid DNA or
oligonucleotides which are generally considered to be safe. However,
comparing non-viral gene delivery vector to viral gene vectors, they
are significantly less efficient and this has remained as difficult
challenge to overcome and improve the therapeutic applications.
1.2.1. Nucleic Acids delivery and challenges for in vivo gene
therapy
The use of nucleic acids in therapy involves many hurdles, including
difficulties in formulating the delicate biopolymer drug and the high
chances for degradation en route to the target. For DNA-based
therapies the target is the cell nucleus= 51, whereas for RNA, delivery
to the cytoplasm is required=, Many designed polymeric nucleic acid
delivery systems have been developed by analogy with viruses
vectors. The requirements for these vectors are stringent: for
example, for DNA, the nucleic acid (which can be several million Da
in molar mass) must be condensed to a small size, and protected
from serum and intracellular nucleases. The DNA must be delivered
to the target cell, cross the external cell membranes passively or
actively, leave the endosomal compartments (avoiding degradative
enzymes and escaping traffic to the lysosomes), then it must
translocate into the nuclear compartment ready for transcription. The
vector must thus protect the DNA and help transport it across
multiple cell barriers, yet release it at the correct location. In
addition, for an injectable DNA delivery formulation, the vectors
with encapsulated/ complexed DNA must be capable of extended
circulation in the bloodstream in order to have a chance to reach their
cellular target. They must also be small enough to gain access to
tissues and cells - typically this will put a size limit of <250 nm for
8
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the hydrodynamic diameter of the vector system in circulation. For
commercial development, it is also desirable for a gene delivery
vector to have flexible tropisms, so that one vector can be adapted for
application across a wide range of disease targets. Above all, the
vectors must be safe, i.e. non-toxic, non-immunogenic and fully
cleared from the body after use. It is the safety factor which has
hampered the development of viral DNA and RNA delivery systems
to date, as although viruses have evolved to be very successful in
overcoming cell barriers, their therapeutic use is dependent on
deactivation of their infective properties. Immune reactions are also a
major problem that needs to be solved for longer term use of viral
vectors in nucleic acid delivery. A fuller discussion of viral gene
therapy is beyond the scope of this thesis54, but the safety issues
associated with viruses have prompted intense research into
synthetic viral mimics. Transfection efficiency, acute and long-term
toxicity and in vivo fate are all important challenges for synthetic
polymer vectors as well as viral systems. Considering all the
demanding requirements it is perhaps not too surprising that there
are no successfully commercialised synthetic gene delivery vectors in
the clinic so far. Described later in this chapter are some of the more
specific challenges facing polymeric gene delivery vectors, but it
should be noted that there are still a large number of these systems in
the research and development stages, most likely as a result of the
change in treatment paradigms that will occur should successful
gene therapies reach the clinic.
To achieve efficient gene delivery, the naked DNA has to pass
through extra-cellular barriers and become internalised by the
desired cell population.
9
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Because of the existence of many barriers extra-cellularly and inter-
cellularly the efficiency of naked DNA delivery is significantly
hampered.
The main hurdles are the presence of extra-cellular endonucleases,
enzymes with the ability to degrade naked DNA within 30minutes=.
The extensive uptake by scavenger receptors on the liver also leads
to rapid clearance of DNA from the blood circulation and this
prevents the distribution into different organs and tissues56,57.
Furthermore, because of its size and surface charges, DNA is unable
to pass across the cell and nuclear membranes. The plasmid DNA is
typically 103 to 104base pairs in length (converting this into lenght
distance for a stretched DNA of 104base pairs multiplied by O.34nm
base pair distance results in a total lenght of 3.4J.1m),has a
supercoiled tertiary structure in aqueous solutions, a molecular
weight of 106-107-Daand an effective hydrodynamic diameter of
greater than 100nm49• The surface charge density of naked DNA,
which has zeta potentials ranging from -30 to -70 mV, creates
repulsion between the DNA and the negatively charged cell surface.
This negative surface charge density most likely limits the uptake of
DNA by cells.
Therefore, all these hurdles and barriers have inspired the
development of gene delivery systems that can protect the DNA
from degradation and at the same time transport the DNA through
extra and intracellular barrieres efficiently to reach to nuclei and to
exert their therapeutic effect.
A number of mechanical techniques have been used to enhance the
delivery of naked DNA, among these techniques are gene gun,
hydrostatic pressure, electroporation, continuous infusion, and
sonication58-61.
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1.2.2.Nonviral gene delivery systems
1.2.2.1.Cationic based gene delivery systems
There are two different types of non-viral gene delivery systems,
cationic lipid62, 63 and cationic polymer delivery systems= 65. Both
cationic lipids and polymers are capable of condensing DNA via
charge-charge interactions which lead to reduction in size and
surface negative charge. In addition to reduction in size and negative
surface charge, they can also protect the DNA from degradation by
nuclease enzymes.
1.2.2.1.1.Cationic lipid
Cationic lipids to condense DNA were first used by FeIgner et a166•
Cationic lipids structures are composed of several parts, including a
hydrophobic segment, a linker and a positively charged end-group.
The chemical compositions of cationic lipids are mainly fatty acids
(derived from oleic and myristic acid) or cholestrol groups in
combination with a charged components",
Different parts of cationic lipid structures provide different
functionalities, for example, the hydrophobic segment mimic the
physical properties of lipid bilayers. The linker is responsible for
biodegradablity and more importantly the positively charged end-
group is responsible for interaction with the negatively charged
phosphate groups on the DNA backbone, leading to condensation
and packaging of DNA into smaller size68,69.
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The structure of the most widely studied cationic lipids as gene
delivery systems are summarised in Figure 1-1.
There are a number of cationic lipid based formulations that have
been used in many in vitro transfection of DNA and some of them are
commercially available. Examples of commerically available cationic
lipids are Lipofectin® (a 1:1 mixture of DOTMA and DOPE),
Transfectam®, LipofeACETM,LipofectAMINETM,and LipoTAXITM70.
Cationic lipids
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DOPE
DOPC
Chol
Figure 1-1. Structure of common lipids used as materials for gene
therapy. Cationic lipids: DOTMA: (2,3-bis(oleoyl)propyl)- trimethyl)
ammonium chloride; DMRIE: 1,2-dimyristyloxypropyl-3-dimethyl-
hydroxyethyl ammonium bromide; DODAB: dioctadecyldimethyl
ammonium bromide; DOTAP: 1,2-diacyl-3-trimethylammonium
propane; DC-Chol: 3[N-(NO,NO-dimethylaminoethane)- carbamoyl)
cholesterol. Neutral Lipids: DOPE: dioleoylphosphatidyl
ethanolamine; DOPC: dioleoylphosphatidyl choline; Chol:
cholesterol.
Synthesis of several novel cationic lipids derivatives revealed that
the transfection efficiency of these derivates varies by changing the
head group or the length of the linker. It has been reported that
multivalent headgroups, such as spermine, in aT-shape
configuration tend to be more effective than their monovalent
counterparts at facilitating gene transfer"- 72, 67, 73, 69. On the other
hand, increase in gene delivery activity was enhanced by increasing
the length of the linker'".
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Interaction of cationic lipids with DNA results in the formation of a
condensed structure which has been termed a 'lipoplex', in which
the DNA is hidden within the cationic lipid74, 75. The colloidal
properties of the lipoplex such as stability and size are usually
determined by the charge ratio (+ / -) between the lipid/ DNA76. The
charge ratio (+ / -) is the ratio between the number of amine groups
on the cationic lipids in relative to phosphate groups on DNA
backbone. The charge ratio (+ / -) has a crucial effect on the packaging
of DNA, as neutral charge (ratio of 1:1 lipid to DNA) is avoided
because it results in formation of large aggregates". It has also been
noticed that the order of addition effect on the lipoplex size74,76, by
adding DNA to the lipid, a gradual increase in size was noticed,
whereas, adding cationic lipid to DNA did not change the particle
size until the positive charge of the lipid exceeded the negative
charges on the DNAbackbone and at this point rapid increase in size
were noticed=.
The net charge on the lipoplex is important for in vivo and in vitro
transfection owing to their interaction with other components (e.g.
medias, serum, glycoproteins) which can hamper the transfection
efficiency.
In the case of in vitro transfection studies, a positive charge ratio
results in increasing the interaction with the cell membrane, and thus
enhancement the transfection, whereas the net charge ratio for in vivo
studies is more problematic owing to the presence of multivalent
anionic species in serum, which can interact with the lipoplex and
enhance the fusion of the lipid together, which lead to increasing the
particles size'". Other components of serum such as large polyanions
(e.g Heparin) can compete with DNA to bind with the cationic lipid
and displace the DNA in the Iipoplex'",
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To overcome this problem which is associated with the colloidal
stability of the lipoplex due to charge neutralisation, incorporation of
polyethyleneglycol phosphatidylethanolamine (PEG-PE) in to
cationic lipids has been successful. PEG prevented the aggregation
and interaction with the serum components and led to increased the
stability of the lipoplex78-8o.
1.2.2.1.2.Cationic polymers
Synthetic cationic polymers and their derivatives for gene delivery
include synthetic peptidessl- 82, poly-L-Iysine (PLL)83,polyamines
(such as polyethylenimine (PEl)) and polyamidoamine dendrimers,
and poly(vinylimidazole) derivatives84-86.These polycations self-
assemble with DNA to form charge-neutralised or cationic
complexes, dependent on charge ratio. Higher transfection
efficiency and serum sensitivity have been achieved with polycation
systems compared to lipoplexes'". Although gene transfer in some
polycation vector systems, such as poly-L-Iysine, is rather low
compared to viral vectors, the use of the multiply-charged
polyethylenimine (PEl) has led to an effective gene delivery in many
cell lines. To date, PEl remains the most effective polymer for gene
delivery. It has been shown to target DNA in vivo and in vitro, to
promote nuclear targeting, and to facilitate DNA escape from
endosomes'". The action of PEl in part depends on its pH-responsive
character, but PEl homopolymer is toxic at levels required for high
transfection, and thus other candidate polymers with pH or other
responsive characteristics are required for medical use. An emerging
area of research is the use of synthetic polymers that are able to bind
DNA in a reversible manner employing functionality that bestows
15
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polymer conformation and hydration changes as well as DNA
recognition.
In order for non-viral systems to be effective vectors, the polymer
must not only condense and deliver DNA intact to the target site, but
must also enable nucleic acid to be transported through the cell
membrane, and be translocated from the cytoplasm to the nucleus.
Many researchers have now investigated DNA complexed by
electrostatic interactions to cationic polymers as a method by which
the therapeutic gene can be transportedw, In most cases these
cationic polymers form condensed complexes with DNA that both
contract the nucleic acid to facilitate cellular uptake, and which
protect it from serum and cytosolic nuclease degradation.
Mechanisms of DNA condensation, cellular uptake and transport to
the nucleus, as well as strategies to reduce toxicity, improve
transfection potential and nuclear targeting of polycation-mediated
delivery systems are discussed below.
1.2.2.2. Mechanisms Of Non-Viral Polycation-Mediated DNA
Delivery
DNA condensation is a naturally occurring process in vivo, and is
important for cellular processes, such as DNA replication and
transcription. DNA condensation by polycations is of great
importance if external DNA is to reach the nucleus of target cells.
Although the DNA condensation is important during cell division,
but would hinder DNA replication and transcription, during which it
has to be unbound; DNA undergoes rounds of condensation and
decondensation, depending on the phase of in the cell cycle. DNA is
condensed by electrostatic neutralisation of the negative charges
along the phosphate backbone by the positively charged polycation.
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At a certain critical extent of charge neutralisation (around 90 % for
polycations) DNA is condensed into small, tightly packed
nanoparticles of between 20-200 nm diameter, through localised
bending, resulting in the formation of a variety of condensed DNA
structures, often reported to be toroid, rod-like, or spheroidal'v,
Indeed, it has been proposed by Pollard et al that nuclear trafficking
of complexed DNA is dependent more on the spherical morphology
of condensed DNA, rather than on the ionic interactions". This work
was confirmed by Liu et al who observed that small, spherical
complexes were more efficient for receptor-mediated uptake'<. As
well as localised changes in DNA structure, factors such as reduction
in DNA segment interactions, as result of polycation binding, and
DNA-solvent interactions contribute to its condensation into various
morphologies. Several molecules of plasmid DNA may become
incorporated into the condensed structure, and thus it is often
difficult to distinguish condensation from aggregation or
precipitation. The size and morphology of condensed particles are
dependent on many thermodynamic and kinetic factors90•
The formation of these particles is crucial for entry through the cell
membrane, protection from nucleases, and consequent transfection
ability. The process of DNA condensation is reversible, and can be
defined as the dramatic decrease in volume (1<J4fold) occupied by a
DNA molecule, usually with a finite size, and orderly morphology.
There has been much experimental and theoretical investigation into
the organisation of DNA into its condensed state, and the formation
and arrangement of compacted DNA structures, including toroids,
rods, and intermediate structures. As DNA condenses, it undergoes a
coil-globule transition. Detailed fluorescence studies indicate that
rods and toroids are formed as a result of the coil-globule transition
of DNA. Once a toroid has reached a certain critical size, it can no
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longer package DNA in the usual way, and the remaining coil
condenses into an irregular globular structure=.
Many polymers are able to condense DNA to these toroidal and
contracted nano/microsphere structures in vitro and the importance
of efficient condensation for transfection has been demonstrated's.
There are a number of factors that influence DNA condensation and
the size of polymer-DNA complexes. For example, low molecular
weight linear PEl forms much larger complexes with DNA than
higher molecular weight and branched PEl, and these complexes
possess lower transfection abilities.
1.3.Cellular Uptake Pathways in Nonviral Gene Delivery System
In general, the therapeutic effect of any drug is exerted upon
reaching the desired site of action. If this does not occur, the drug
will have no therapeutic activity or may produce adverse effects
through interaction with undesirable targets. In the case of gene
therapy, reaching the targeting site is far more complicated since
large, charged DNAmolecules are difficult to transport in the body95.
For DNA therapy, the targeting site is nucleus. Cell membranes
which amphiphilic in nature (hydrophilic on the outside), present a
restricting barrier specially for large, hydrophilic and charged
molecules. Therefore, a suitable gene delivery system is required to
achieve an efficient cellular uptakes of such molecules.
These barriers which include binding to the cell surface, traversing
the plasma membrane, escaping lysosomal degradation, and
overcoming the nuclear envelope=. As described in section (1.2.2.
chapter 1), the most commonly used materials in preparations of
nonviral gene delivery systems include cationic lipids and cationic
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polymers, Introduction of some functionalities onto these delivery
systems can enhance the cellular uptake, such as using targeting
ligands to increase cellular uptake through receptor-mediated
endocytosis (endocytosis refers to a process of cellular uptake of
macromolecules and solutes into membrane-bound vesicles derived
by the invagination and pinching off of pieces of the plasma
membranejw ?", peptides to enhance endosomal escape" and nuclear
localisation signals to enhance nuclear deliveryv'. Endocytosis can be
classified into two categories, phagocytosis (the uptake of large
particles) and pinocytosis (uptake of fluids and solutes)lOO,
Phagocytosis also differs from pinocytosis in that it occurs only in
mammalian cells, whereas pinocytosis occurs in all cells-?'. In
addition, there are four morphologically different pinocytic
pathways which include clathrin-mediated endocytosis, caveolae
based endocytosis, macropinocytosis, and clathrin/ caveolae-
independent endocytosis-w. The difference between these pinocytic
pathways are composition of the coat, size of the detached vesicles
and fate of internalised particles, (Figure 1-2),
Figure 1-2. Endocytosis pathways in nonviral gene delivery systems,
The endocytic pathways differ with regard to the size of the
endocytic vesicle, the nature of the molecules to be internalised
(ligands, receptors and lipids) and the mechanism of vesicle
formationt?'.
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The detailed mechanisms underlying the different uptake pathways
are beyond the scope of this thesis, However, it is important to note
that endocytosis pathways are considered to be the main mechanism
for the internalisation of most nonviral gene delivery system into the
cells-?". The uptake mechanisms also directly or indirectly influence
intracellular traffic pathways which dictate the fate of the vectors.
Intracellular traffic refers to the process after internalisation in which
the molecules tend to be trapped in intracellular vesicles which
eventually fuse with lysosomes where they are degraded or released
into the cytoplasm. Thefore, designing a suitable gene delivery
system is required to increase the cellular uptake and improve the
intracellular fate of the vector. A schematic of clathrin-mediated
endocytosis as shown in the (Figure 1-3).
ligand
V
y,: Recycling
Figure 1-3. Receptor (clathrin)-mediated endocytosis'". The ligand
binds to a specific cell surface receptor. This results in the clustering
of the ligand-receptor complexes in coated pits on the plasma
membrane.
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The coated pits then invaginate and pinch off the plasma membrane,
aided by dynamin, to form intracellular clathrin-coated vesicles. The
c1athrin coat then de polymerizes, an endosome forms. Molecules
entering by this pathway experience a drop in pH from neutral to pH
5.9 to 6 in the lumen of early endosomes, with a further reduction to
pH 5 during the progression from late endosomes to lysosomes. The
low pH in endosomes causes the ligands to dissociate from the
receptors and recycle back to the cell membrane. The vesicles then
fuse with other late endosomes and eventually fuse with lysosomes
in which the particles are degraded.
1.3.1. Cellular Uptake Of Non-Viral Polymer-DNA Complexes
If the DNA-polymer complex carries an overall positive charge, it is
able to interact with the negatively charged cell surface receptors of
the plasma membrane, and is taken up into the cell by endocytosis.
After binding to cell surface receptors on the cell membrane, the
complex is enveloped by invaginations and fusion of the cell
membrane and this in turn form endosomes. The endosomes
originate from areas of the cell membrane that are rich in two main
types of specialised cell membrane components: coated pits and
caveolae'", Caveolae are thought to mediate DNA uptake to muscle,
while coated pits are invaginations surrounded by membrane-
associated proteins, including specialised cell-surface receptors, for
specific cellular uptake (receptor-mediated endocytosis). Once inside
the membrane-bound endosome, any material (~ 250 nm diameter) is
usually processed by cellular mechanisms. Thus polymer-nucleic
acid complexes must be strictly controlled in terms of their size to be
therapeutically active'".
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Endosomes become fused with golgi hydrolytic vesicles to form
endolysosomes, and ingested material is broken down by hydrolytic
enzymes activated by the acidity (pH 5-6) inside the active lysosome.
As proton ions are pumped into the endolysosomes, an influx of
chloride ions occurs, which relieves the accumulated proton
gradient. The osmolarity within the lysosome increases, as a result of
the influx of chloride ions. The resulting influx of water causes the
endo-lysosome to swell, and eventually burst, after degradation of
ingested material.
The most common uptake pathway into the cell for non-targeted
polymers occurs via passive endocytosis, and indeed has been shown
to be the pathway for both PEl (polyethyleimine) and PLL (poly L-
lysine)l04, 105. It is also likely that transfection occurring via
endocytosis takes place for many polymers through calcium-
mediated cell anchorage to the extracellular matrix. The normal
process of endocytosis and digestion by lysosomes, is potentially a
barrier to non-viral delivery systems that rely on non-specific cellular
mechanisms to gain entry into the cell. A non-viral vector must be
able to avoid degradation by lysosomes if it is to access the nucleus
and be transcribed. Cationic polymers such as PEl, are only partially
protonated in the serum and cytosol, but become fully protonated at
low pH within the endolysosome as they accept and buffer the
proton ions that are pumped into the vesicle. The buffering action of
PEl raises the pH within the endolysosome, resulting in inactivation
of hydrolytic enzymes. In addition, the increased charge of
protonated PEl results in an influx of chloride ions and water to
counter the increase in osmotic pressure inside the endolysosomes
and this can act to burst the membranes.
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It is likely that PEl and other polymers complexed to DNA are
released from the lysosome as it ruptures before the hydrolytic
enzymes can become activated, and degrade the nucleic acid. The
overall process by which PEl escapes through its protonation and
endosomolysis is often termed the 'proton sponge' mechanism'Pv-'".
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Figure 1-4. Schematic of cellular uptake of non-viral vector-DNA
complexes, and evasion from lysosomal degradation. Diagram (a)
shows the general proposed method, and diagram (b) illustrates
more detailed mechanism of endolysosomal escape. In diagram (b),
the top figures outlines normal lysosomal degradation through active
hydrolytic enzymes. Due to the buffering capacity of many
polycations, hydrolytic enzymes are not activated, and the DNA-
polymer complex is able to escape degradation.
Transfection of polymer-DNA complexes usually requires actively
dividing cells, and transfection efficiency is enhanced prior to
mitosis, when the nuclear membrane has been broken down.
Therefore gene therapy with non-viral cationic vectors is
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advantageous in delivery to e.g. brain tumours, where normal cells
do not divide and therefore are not transfected, but malignant cells
undergo active cell division and are able to be targeted and
destroyed. Brunner et al, demonstrated that linear PEl was not
dependent on the cell cycle for transfection.108, 109
1.3.2. Nuclear Transport and Entry
After evasion from the endolysosome, DNA must traffic to the cell
nucleus for transcription to take place. The mechanisms by which
this is achieved in polymer-DNA complexes are complex are not
fully understood. Suggested mechanisms include tracking through
the cytoskeleton, while polymers that possess nuclear localisation
sequences, may be carried to the nucleus via importins. Work by
Godbey et al, has shown that intact PEl-DNA complexes are able to
enter the nucleus as discrete particles (possibly vesicular in
structure)110,111, Both PEl and PEl-DNA were shown to enter the
nucleus, with a suggested mechanism involving coating of
complexes with a lipophilic layer, which then fuses with the nuclear
membrane. This coating may arise from the remains of the
membrane-bound endolysosome or through electrostatic binding of
anionic phospholipids to the cationic complex. Both coating
mechanisms have been shown to take place with cationic liposomes
and it is not unreasonable that nuclear uptake occurs in the same
manner for other cationic polymers.
For the design of polymer gene delivery vectors, it might be assumed
that a mechanism must be encoded into the polymer to allow
dissociation of the DNA from its polymer complex if it is to be
successfully transcribed.
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However, some studies of PEl-DNA complexes have reported the
complexes to be present in the nucleus in undissociated form, and
thus unpackaging of the complexes must occur within the nucleus
for these systems112,113. Although the mechanisms remain unclear,
DNA polymerase may be involved, and it has been postulated that
once inside the nucleus, polyanions such as endogenous DNA
replace the transfected DNA within the complex in a polyion-
exchange reaction, releasing the therapeutic DNA within the nucleus.
Synthetic polycations such as these may also behave in a way that
mimics nuclear homing devices. Polycations may also be removed
during transcription of nucleic acid by polymerases. Indeed, when
injected directly into the nucleus, DNA complexed to PEl can be
transcribed as efficiently as naked DNA. This was demonstrated by
the work of Bieber et al114 who showed that DNA tightly complexed
with PEl (at high N:P ratios) was transcribed DNA as well as naked
DNA, and more efficiently as more loosely associated complexes at a
low N:P ratios. This group therefore proposed that DNA does not
need to be dissociated from its polycation before it is transcribed'P:
116. It can thus be concluded that nuclear localisation rather than
DNA unpackaging in the nucleus is a key limiting factor in polymer-
mediated gene delivery, and as a consequence, design criteria for
new polymer vectors, especially those that invoke responsive or
activated mechanisms, need to take into account the need for nuclear
targeting. Nuclear transport can be enhanced by modification of
synthetic polymers with nuclear localisation signal peptides117•119, or
with transcription factors, but of course this adds to the design and
synthesis complexity of the vector system.
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1.4. Applications of biodegradable polymers as gene delivery
system
Biodegradable polymers provide potential advantages over non-
degradable polymer for use in drug or gene delivery systems because
of their good safety profile. Degradation of the polymer leads to non-
toxic products which can be easily eliminated from the cell.
Moreover, the degradation of the polymer can be used as a tool to
control the release of the drug or biomolecules from the delivery
system.
Polymer composed of lactide and glycolide such as poly (lactic acid),
poly (glycolic acid) and the copolymers of lactic and glycolic acid,
i.e., poly (lactide-co-glycolide). (PLGA) are most widely used in
many biomedical applications (e.g. suture and implants or drug
delivery (e.g peptide and proteins)l20.PLGApolymers produce lactic
acid and glycolic acid upon hydrolytic degradation, these two
substances are naturally occuring in metabolic pathways of the body,
therefore, their applications as drug and gene delivery systems are
generally considered to be safe. PLGA polymers are commercially
available from various vendors as good manufacturing practice
(GMP)-grade.
The major supplier for PLGAof GMP grades are Purac (Trade name:
Purasorb); Absorbable Polymers International, a wholly owned
international subsidiary of Durect Corporation (Trade name: Lactel):
Alkermes (Trade name: Medisorb); Boehringer Ingelheim (Trade
Name: Resomer). PLGA polymers have been approved by US FDA
for human use. PLGA polymers can also be synthesized by ring
opening polymerization of lactide and glycolide. The degradation
rate of the polymer can be controlled via the molecular weight of the
polymer and also through lactide:glycolide ratio.
26
Chapter 1 Introduction
Usually low molecular weight and high content of glycolide
accelerate the degradation rate. PLGA polymer composed of 50:50
ratio of lactide to glycolide is known to have a faster biodegradation
rate in a bout 50-60 days, whereas other combinations of
lactide:glycolide ratio of : 75:25, or 80:20 are shown to have
significantly longer degradation rate.
1.5.Micro- and nanopartic1es based gene delivery system
Polymer based micro and nanoparticles provide several advantages
for the delivery of macromolecules such as DNA. Polymeric delivery
systems provide protection against nuclease degradation by
encapsulation of the drug and macromolecules in the polymeric
matrix121. Control over the release of drug or macromolecules (e.g.
DNA) into a particular tissue or organs can be achieved via careful
tailoring and choice of the polymers and thus controlling the rate of
release from the delivery system.
The rate of release can be designed to occur rapidly for bolus
delivery or can be adjusted to obtain release over a long period of
time (sustained release). Sustained release of certain therapeutic
molecules is extremely important particularly in the case of drugs
with short half-lives or with narrow therapeutic windows in which
case the release can be adjusted to maintain the concentration of the
drug in circulation at desirable level.
Incorporation of plasmid DNA and oligonucleotides into a matrix of
polymer micro and nanoparticles has been investigated widely.
Various natural and synthetic polymers can be formulated as
matrices and microspheresl22/123,
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There are a few parameters affecting the release of DNA from the
polymer delivery systems, chemical composition of the polymer
(esters) affects the degradation time and can be used to control the
release rate. Secondly, physical properties such as size, mass and
porosity can also affect the release of DNA121. The structures of some
polymers that have been used in micro particle formation for DNA
delivery are shown in Figure 1-2
Polyladic acid ( PLA)
o
Poly (Iactic-co-glycolic acid) (pLGA)
HO
polyanhydride Ethylene co-vinyl acetate (EVAc)
Figure 1-5. Structure of polymeric materials used for gene delivery.
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PLGA-based polymers have been widely used in developing
micro/ nanoparticles for encapsulating therapeutic molecules for
controlled release applications due to their inherent advantage over
conventional devices including the extended release rates from days
to months124-127.Macromolecules such as proteins, peptides, plasmid
DNA, human growth hormone factor, etc, have been successfully
incorporated into PLGA based micro/nanopartic1esl28-130. There are
list of FDA approved controlled released products based on PLGA in
the market (table 1-1).
Table 1-1. PLGA-based microparticles available in market.
Product name Active ingredient Company applications
Lupron Depot®
Leuprolide
TAP Prostate cancer
acetate
Pediatric
Nutropin
Growth hormone Genentech
growth
Depot® hormone
deficiency
Suprecur® MP Buserelin acetate Aventis Prostate cancer
Decapeptyl®
Triptorelin
Ferring Prostate cancer
pamoate
Sandostatin Octreotide
Novartis Acromegaly
LAR®Depot acetate
Somatuline® LA Lanreotide Ipsen Acromegaly
Trelstar™ Depot
Triptorelin
Pfizer Acromegaly
pamoate
Periodontal
Arestin® Minocyc1ine Orapharma
disease
Risperidal®
Risperidone J &Johnson Antipsychotic
Consta™
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Generally, micro - and nanopartic1es are classified based on their
sizes, microparticles have diameter in the range of 1 to 250 J.1m,
whilst the size of nanopartic1esare considered to range between 10 to
100nm.
It has been reported that microparticles with diameters larger than 1
J.1mare internalised mainly through phagocytosis preferentially by
antigen presenting cells (such as macrophages and dendritic cells),
but not by other cells, therefore, biodegradable DNA microparticles
have been especially investigated for (DNA) vaccination purposes
against viruses and tumours as antigen presenting cells play a
pivotal role in initiating of immune responses.
On the other hand, the submicron sized nanopartic1es offer
important advantages over microparticles in that their cellular
uptakes are relatively higher. Studies showed that nanoparticles of
100 nm size have higher cellular uptake by 2.5 fold when compared
to 1J.1mand 6 fold higher when compared to 10J.1mmicroparticles in
Caco-2 cell llnes-'". Similar results were also obtained were tested in
a rat in situ intestinal loop model. The efficiency of uptake of l00nm
size particles was 15-250 fold greater than larger size (1 and 10 J.1m)
microparticlesw.
1.5.1. Fabrication of DNA loaded PLGA nanopartides, challenges
and opportunities
There are a number of approaches described for encapsulating
plasmid DNA within PLGAbased nanoparticles, these include spray
drying, phase separation methods and double emulsion
techniques133-136.Initially, these approches have been used in
encapsulation of peptide and proteins within the PLGAbased micro
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and nanoparticles. The double emulsion technique refers to a process
where the peptide, proteins, or plasmid DNA are dispersed in the
organic phase to make a water-in-oil emulsion using homogenisation
or sonication. In the phase separation method, the particles are
produced by extracting the organic solvent or adding non-solvent to
induce coacervation, whilst in spray drying techniques, the particle
formulation is achieved by atomising the emulsion through a stream
of hot air to induce rapid solvent evaporation. In addition to the
approaches mentioned above, plasmid DNA can also be coated on
the surface of PLGAparticles.
1.5.1.1.Double Emulsion Technique
Double emulsions are typically formed by mixing or dispersing of an
aqueous solution of DNA with a solution of PLGA dissolved in an
organic solvent. The dispersion of the DNA solution is usually
performed by using sonication or homogenisation techniques.
This results in the formation of first or primary emulsion in which
the aqueous droplets containing DNA are suspended in the organic
phase. The size of the droplet formed by sonication or
homogenisation can be optimised by adjusting the amount of the
shear force used for dispersion process.
The primary emulsion is then mixed with a second aqueous solution
that contains surfactants. Surfactants are usually used to prevent the
aggregation of aqueous droplets (coalescing). The addition of
primary emulsion with the solution of surfactant results in
precipitation of polymer around the aqueous droplets and finally the
evaporation of the organic solvents lead to the formation of solid
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particles in which the DNA is embedded and trapped in the
polymeric matrix of the particles.
PLGA based particles are sensitive to moisture and undergo
hydrolysis upon contact with water molecules, therefore, it is
important to keep the final particles free of moisture. Drying of the
particles can usually be done by using lyophilisation or freeze drying
for long-term storage. Sometimes, addition of cryoprotective sugars
(usually sucrose or glucose) can be added to the formulation to
preserve the DNA supercoiling during the drying processl-".
n aqueous phase (pDNA)
.iII§ EmulsificationSonication primary emulsion (W/O)
evporation of organic solvent
Organic phase (PLGA)
particle collection
aqueous solution (surfactant)
Figure 1-6. Encapsulation of DNA in PLGA nanoparticles using
double emulsion technique.
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One of the major drawbacks of double emulsion technique is usually
due to the shear force used to disperse the aqueous solution of DNA
in the organic phase. The shear force can damage the DNA and
reduce the integrity and, eventually, the biological activity. In
addition to that, contact of DNA with the organic phase also can
damage the DNA therefore it is important to keep the amount of the
shear force to minimum to retain the DNA supercoiling which
represent the most stable form of DNA.
There are some methods that can be used to minimise the DNA
damage by utilising shear force during dispersion process.
Condensation of DNA can be carried out with cationic polymers such
as poly(L-lysine) as described before to reduce the size of the DNA
and make it less exposed to shear force. Poly(L-lysine) is capable of
condensing the DNA into smaller particular shape while preserving
the supercoiling of the DNA and retaining its biological activity138,
139.Another technique that can be used to reduce the damage of DNA
by shear force is to conduct the dispersion of the DNA solution in
organic phase of PLGA at reduced tempeture to generate a more
viscous solution that can be less affected by the shear force during
dispersion process'V.
Another drawback of utilising double emulsion techniques to
encapsulate DNA within the PLGA particles comes from the
observation of low encapsulation efficiences of DNA in the particles.
This is partly due to, the leakage of DNA from the aqueous droplets
during the formation of the primary emulsion and secondly, during
the evaporation of the organic solvent.
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1.5.1.2.Spray Drying Technique
In spray drying techniques, the DNA loaded particles are produced
by combining emulsification steps with spraying via an atomizer
through a steam of hot air. Initially, the DNA solution is mixed with
PLGA solution in organic solvent using shear force to form droplets
of DNA in the PLGA solution. Finally, the particles are formed by
spraying the suspension of DNA droplets in PLGA solution through
an atomizer in the presence of hot air. During spraying of the
suspension through the hot air, the organic solvent and water
moisture evaporate which results in the formation of dried solid
particles loaded with DNA. In spray drying techniques, there are a
number of factors contributing to the particles size of the final
products such as the flow rate through the atomizer, temperature of
the air and size of the DNA dropletstw.
In spray drying processes, the addition of primary emulsion into a
second aqueous phase is absent, which could be an advantage over
double emulsion techniques because of the loss of DNA in the latter
technique. However, the mechanical, thermal stress effects upon the
integrity of DNA could be disadvantage of the system.
Furthermore, in this way the plasmid DNA may indeed be better
protected during the preparation of the particles, one should note
that in vivo DNA associated to the surface may become more easily
degraded and may result in a significant burst release.
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1.5.1.3 Adsorbtion of DNA on surface of PLGA particles
In this technique particles are also made by double emulsion
technique in the absence of DNA to produce empty PLGA particles,
but in the second aqueous phase of double emulsion technique, the
particles are suspended in solution of cationic agents which coat the
outer surface of the particles. By incubation of these positive surface
charges particles with solution of DNA, the DNA binds to the
external surface through electrostatic interaction. In this type of
procedure usually the loading efficiency of DNA is limited to 1%
(weight! weight)141.
1.5.2. Challenges associated with PLGA particles as nonviral gene
delivery systems
Generally, nonviral gene delivery systems are significantly less
efficient in comparison to viral gene delivery system. Therefore, for
PLGA particle system to be considered as relatively efficient gene
delivery systems they should fullfil some basic requirements. First of
all, considering the low transfection efficiency of nonviral delivery
systems, the particles should be able to carry a high amount of DNA
which is termed as "loading efficiency". Secondly, as has been
mentioned earlier, the integrity of DNA or the supercoiled structure
of DNA should be preserved during the PLGA particle formulation
Le. all the detrimental conditions of high shear forces and thermal
stress should be avoided or reduced to minimum to avoid any
damage to DNA142.
3S
Chapter 1 Introduction
Considering the in vivo transfection efficiency, the PLGA particles
should be able to protect the DNA from extracellular nuclease
enzyme to avoid the rapid degradation before reaching the desired
site of action. Finally, premature release of DNA from the particles,
termed as "burst release", should be kept to as low as possible to
maximise the amount of the payload at the site of action.
Another problem associated with PLGA nanoparticles is the
hydrolysis of the PLGA backbone upon contact with water
molecules. The hydrolysis process involves water molecules carrying
out a nucleophilic attack on the ester bonds between the lactide and
glycolide units in the backbone of PLGA polymer generating lactic
and glycolic acid units143• This result in the degradation of the
polymer and subsequently may lead to substantial reduction in pH
and generation of acidic climate in the PLGAmatrix where the DNA
molecules are embedded. The formation of the acidic climate may
cause degradation of DNA, compromising the biological integrity
and eventually its therapeutic effectl36,l44.
It has been reported that the interaction between the PLGA based
particles with the in vivo components can also compromise their
efficiency as drug and gene delivery system. When these particles
are administered intravenously, they can be easily recognised by the
body's defence system. Mononuclear phagocyte system (MPS)
identify PLGA based particles and rapidly clear them from blood145•
The mechanism that involves the recognition of PLGA based
particles by phagocyte can be attributed to the hydrophobic
properties of the particles that allow the adsorption of blood
components on their surface, such as opsonins, this is regarded as the
first step toward elimination of the particles from blood.
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It has also been reported that particles made of PLGA undergo
significant aggregation and flocculation in biological media which
are rich in enzymes (e.g gastrointestinal fluid)146.
Finally, PLGA particles often have slow release profiles which could
be a problem in some applications such as vaccinations in which the
subsequent release of antigen from the particles is required to obtain
an optimum immune response.
Therefore, there is a clear indication to develop a new type of
biodegradable particle that can match all the basic requirements of
an efficient carrier for gene delivery. Ideally, the new particulate
gene delivery system should fullfil the following criteria:
Requirements of efficient particulate gene delivery system
• The integrity of DNA preserved throughout the formulation
process
• Efficient and high incorporation of DNA within the particles
• Degradation of the matrix of the particles should not generate
any hostile ( e.g. internal acidic environment) that can
compromise the biological activity of DNA
• Absence or minimised premature release of DNA in
circulation and enhanced release inside the cell
• Development of surface-modified nanoparticles to achieve
longetivity in blood circulation
• Specific targeting, the particles loaded with DNA should be
able to deliver the payload inside the desirable cell population.
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1.6. Application of polymers for designing advanced
nanoparticulate gene delivery system
1.6.1. Poly(ethylene oxide and derivatives
The term poly(ethyle oxide) (PEO) and poly(ethylene glycol) (PEG)
refer to the same material, although the term PEO is usually
preferred when describing high molecular weight polymer. The
derivatives of PEO which are composed of poly(ethylene oxide)-
poly(propylene oxide) (PEO-PPO) units are named commercially as
poloxamers and poloxamines. The difference between the two
molecules are mainly in their chain length and PEO, PPO contents.
Furthermore, Poloxamines differ from poloxamers in that a molecule
of ethylendiamine links the components together. The structures of
these two polymers are shown in figure.
HO~1H
EO n
Poly(ethylene glycol) or Poly(ethlylene oxide)
Poloxamer
Poloxamine
Figure 1-7. Chemical structure of PEG and some commercial
derivatives Poloxamers, Pluronics and Poloxamines.
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The potential of PEO and its derivates ( poloxamers and
poloxamines) as biomaterials has been widely investigated.
Poloxamers and poloxamines have relatively good biocompatiblity
and low toxicity which make them very attractive biopolymers to use
in many applications such as drug and gene delivery system.
However, these polymers are not biodegradable which make their
application for drug delivery dependent on the molecular weight.
High molecular weight PEO of about 7000 kDa is known to be
acceptable for application of oral drug delivery system147, 148, whilst
the lower molecular weights ( preferably 5 - 10 kDa) have been
suggested for use in parenteral adminstrationtw 150.
The potential of poloxamers, in this particular case, have also been
investigated for use as gene delivery systems. It has been shown that
poloxamer polymers (Pluronic® L61 and PluroniC® F127) have the
ability to complex with DNA molecules and to protect the plasmid
DNA from nuclease enzyme which resulted in enhancement of gene
expression 151, 152.
Another potential application of PEO and its derivatives (poloxamers
and poloxamines) is for surface modification of drug and gene
delivery systems such as micelles, liposomes and nanoparticles. As
has been mentioned earlier, uncoated drug delivery systems such as
PLGA particles suffer a rapid blood clearance after their intravenous
administration owing to the fact that opsonins adsorb on the surface
through hydrophobic interactions and consequently they are taken
up by mononuclear phagocyte system (MPS) and finally eliminated
from circulation.
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Therefore, PEO and its derivatives have been of interest for use in
surface modifications of drug delivery systems, this is due to their
neutral charges, hydrophilicity and flexible chains which can form a
II steric shield" on particle surfaces.
1.6.1.1.Surface modification of PLGA based particles with PEO
and its derivatives
Incorporation of PEO and its derivatives into PLGA based particles
offer potential advantages to improve their efficiency as drug and
gene delivery systems. Originally, PEO and its derivatives were
incorporated into PLGA particles for two main reasons. Firstly,
preventing the hydrophobic PLGA particles from interaction with
each other causing aggregation, this is prevented by providing the
particles with a protective hydrophilic stealth. As a result of that,
opsonisation and rapid clearance of PLGA particles from the blood
circulation can also be avoided.
Secondly, coating of PLGA particles with functional PEO can
facilitate the introduction of ligand (targeting moiety) on the surface
of particles to produce an active-targeting delivery system153,154. In
addition to that, by blending of PEO and its derivatives with PLGA
based particles, it is believed that it is possible to improve the
stability of encapsulated molecules. In addition, co-incorporation of
other PEG based components, such as cationic Jeffamines or
poloxamines, provides a more friendly environment for DNA in the
matrix of the particles by buffering the acidification that occurs
during degradation of PLGA polymer, more importantly, they can
enhance the encapsulation efficiencyand release profile.
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There are two main approaches to incorporate PEa and its
derivatives, poloxamers and poloxamines, into PLGA based
particles. The first approach includes physical entrappment or
adsorption of PEa and its derivatives into or onto PLGA particles.
The second approach includes chemical modifications of PLGA
polymer via covalent linking with PEa. Illustration is shown in
Figure 1-8.
matrix
hydrophilic chains
1
(a) hydrophobic
PPO chains
PEGreservoir
biodegradable
matrix
(c)
PEGchains
Figure 1-8. Schematic view of various structure of nanoparticles
made of PLGA with PEa and its derivatives (poloxamers and
poloxamines), ( continued next page).
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(a) Poloxamers/poloxamines blended with PLGA (b)
poloxamers/ poloxamines physically adsorbed on PLGA
nanoparticles (c) and (d) Nanoparticles made of PEG-PLGA
copolymers.
1.6.1.2.Adsorption of PEO and its derivatives on surface of PLGA
particles
One of the approaches used in surface modification of PLGA
particles is simple physical adsorption of poloxamers and
poloxamines. It has been shown that the adsorption of these
polymers on PLGAparticles surfaces resulted in stabilisation of the
particles in biological media and also extended the circulation
time155, 156. Poloxamers and poloxamines can easily adsorb on the
hydrophobic surfaces of PLGA particles by anchoring the PPO
segments on to the surface. The hydrophilic segments of the
polymers protrude toward the aqueous media.
It has been reported that the adsorption of poloxamers and
poloxamines can affect the biodistribution of the particles, particles
coated with these polymers were mainly taken up by macrophages of
regional lymph nodes, this could be used as a design in a drug
delivery system for targeting the lymphatic system such as in
vaccination157,158.
One of the main drawbacks of this approach comes from the
displacement of poloxamers and poloxamines polymers from the
surface of PLGA particles by serum proteins159• This effect on
stability of the particles, prompts the particles toward aggregation
and, finally, opsonisation and elimination from circulation.
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The alternative approach would be to coat the particles with PEO-
based polymers via chemical modifications. In this way it is possible
to covalently link the PEO polymers to PLGA polymers that form the
matrix of the particles or via synthesis of copolymers of PLGA with
PEO using polymerisation techniques.
1.6.1.3. Blend of PEO and its derivatives within the matrix of PLGA
particles
In this approach poloxamers and poloxamines are physically mixed
with PLGA polymer to form particles of blended-type matrices. This
type of particles are usually prepared by using double emulsion
techniques to encapsulate hydrophilic molecules within the matrix. It
has been shown that particles of PLGA and poloxamers blend matrix
are able to stabilise the encapsulated molecules and improve the
release profilel60, 161.
Two types of blend matrices have been mentioned. First, the particles
are prepared by double emulsion-solvent extraction/ evaporation
technique. In this example the poloxamers were added to the internal
aqueous phase and during precipitation of PLGA polymers, the
poloxamers were entrapped in the form of small reservoirs. This type
of preparation is important particularly when the encapsulating
molecules are co-dissolved with the poloxamers in the internal
aqueous phase162•
More recently, double emulsion solvent diffusion techniques have
been investigated to prepare particles with a blend matrix of
poloxamers and PLGA polymers. In this particular case, both PLGA
and poloxamers/poloxamines are co-dissolved in the organic phase
and the co-precipiration upon addition to miscible organic solvent.
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The formation of this type of blend matrix is based on the hydrogen
bonding between the poloxamers / poloxamines and PLGA163, 164
Figure 1-9.
aqueous phase (pDNA)
----l:.-.- nanoparticle
formation
solvent diffusion
Organic phase (PLGA + poloxamer)
ethanol
Figure 1-9. Encapsulation of pDNA into PLGA/poloxamer blend
nanoparticles by modified emulsification-solvent diffusion.
1.6.2. Chemical modification of PLGA polymer via covalent linking
with PEO
Surface modifications of PLGA particles with poloxamers and
poloxamines using physical adsorption technique have been shown
to be an inefficient approach to provide stability to the particles, due
to displacement of the polymers from the surface of the PLGA
particles by serum componentsl-". Therefore, an alternative approach
to surface-modify the PLGA particles with stable PEG chains
includes covalent attachment of PEG to PLGA polymers.
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One of the approaches to perform this covalent attachments of PEG
to PLGA is via ring opening polymerisation technique (ROP).
Monomethoxy-poly(ethylene glycol) is used as initiator to
polymerise the monomers of lactide and glycolide in the presence of
stannous octoate as catalyst149• A series of PEG-PLGA copolymers
with different compositions have been prepared by changing the
weight ratio of the polymerisation components to generate
copolymers with different solubilities and hydrophilicities. The
synthesis of triblock copolymers have also been investigated such as
synthesis of PLGA-PEG-PLGA or PEG-PLGA-PEG165,150.
The prepared copolymers of PEG-PLGA are amphiphilic in nature;
PEG chains are soluble in water and represent the hydrophilic parts
whereas PLGA parts are hydrophobic and insoluble in water.
Copolymers of PEG-PLGA have been used to prepare nanoparticles
using emulsion techniques in exactly analogous ways as described
before such as solvent evaporation of solvent diffusion techniques.l66,
167Because of differences in solubilities of PEG and PLGA polymers,
a phase separated structure can be formed at the interphase of
organic phase and aqueous phase during particle preparation
process. The PEG chains project toward the aqueous medium while
covering the PLGA solid core forming "core-shell" particles149.
It has been reported that the organisation of PEG-PLGA copolymer
within the matrix of the particles depends on the preparation
techniques. Using double emulsion-solvent evaporation techniques,
part of the PEG chains are likely to be physically oriented toward the
internal aqueous phase during the formation of primary emulsion.
Thus, upon precipitation of PLGA polymer during the addition to
external phases, small PEG reservoirs are formed.
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The PEG reservoirs in the matrix of PLGA particles can offer
numerous advantages, PEG reservoirs can increase the stability of
encapsulated hydrophilic molecules by providing a more compatible
environment such as in the case of encapsulation of DNA or proteins.
They may increase the encapsulation efficiency of the hydrophilic
molecules by reducing the leakage of the molecules to external
aqueous phase during PLGA precipitation process. Finally, the PEG
reservoirs are associated with water molecules which may have an
effect on the degradation of the solid core of the particles and
influencing the release profile of hydrophilic molecules from the
particlesl68• Example of these effects have been confirmed in the case
of encapsulation of tetanus toxoid which retained biological activity
when incorporated in the matrix of PLGA-PEG-PLGA micro particles
and PLA- PEG nanoparticlestw.
1.7. Synthesis of amphiphilic block co-polymers
Recently, considerable interest has been paid to synthesis of
amphiphilic block copolymers. The difference in solubility of the
hydrophobic to hydrophilic block leads to self-assembly in aqueous
media to form polymeric micelles with controllable sizes.
The biomedical applications of these block copolymer micelles have
rapidly increased as it has been realised that a novel carrier systems for
the targeting of poorly soluble drugs might be realised block co-
polymers have a unique ability to encapsulate large of amount of
insoluble drugs in the hydrophobic core and the ability to tune
hydrophobic and hydrophilic balance enables control over drug release
and biodistribution 170,171.
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The distribution of these polymeric micelles in the body may be
dependent upon their size and surface charge. In this regard, the ability
to control the size and surface charges of these nanocarriers also has
crucial effect on in vivo therapeutic efficacy170.Since the discovery of
living free radical polymerisation methods, block copolymers have
become easily accessible with control over the molecular weight of the
block copolymer and the ratio between the blocks. Block co-polymers
can also be obtained with narrow molecular weight distribution. The
main types and most widely used living free radical polymerisation
techniques are atom transfer radical polymerisation (ATRP) and
reversible addition fragmentation transfer (RAFT)l72, 173.
As has been mentioned earlier, materials based on poly(ethylene
glycol) (PEG), poly(lactic acid) (PLA), (PGA) and their co-polymers
have been widely explored for biomedical use, particularly for drug
delivery174,175.The 'stealth' properties of PEG, which have been utilised
to enhance pharmaceutical profiles of therapeutics ranging from small
molecules to proteinsv 176,177,can be combined with the controllable
biodegradability of PLA/PGA co-polymers (PLGA) to yield highly
effective carriers for a variety of drug compounds'P.
PLGA-PEG block co-polymers can form micelles in aqueous solutions
or can be produced as nanopartides with solid cores, enabling them to
encapsulate drugs with widely differing solubility propertiesl79, 180.
However, fine-tuning of the properties of these co-polymers is more
difficult owing to the limited availabilities of PEGs with appropriate
functional chain ends and ranges of molar mass.
47
Chapter 1 Introduction
By contrast, PEG side-chain polymers, exemplified by PEG-
methacrylate (PEGMA),can be synthesised via a variety of routes, and
very fine manipulation of properties can be exerted through controlled
polymerisation strategies.
Controlled radical polymerisations, primarily ATRP 181,182 and
RAFT183,184,have enabled PEG-methacrylates and co-polymers with
finely controlled properties to be produced185,186. One of the aims of
this work was to show that a combination of ring-opening
polymerisation with RAFT agent initiated growth of PEG-
methacrylate can yield co-polymer micelles with controllable
properties, and with promise as drug-encapsulation and release
systems.
1.7.1. Ring Opening Polymerisation technique
As was mentioned above, the biodegradable polymers poly(D,L-
Iactide-co-glycolide) (PLGA) have considerable importance in several
medical applications including the controlled release of drugs187,
absorbable sutures, and tissue engineering'w, The advantages of
PLGA for these applications stem from the polymer's
biocompatibility, degradation, processability, mechanical strength,
and its approved use by the FDA for in vivo use189•
PLGA polymer can be synthesised via one of two mechanisms, either
condensation reaction with lactide and glycolide monomers, ring
opening polymerisation of lactide and glycolide. The
polycondensation method is known to be an equilibrium, and it is
difficult to remove the liberated water and this limits the molecular
weight of the polymer.
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However, this problem can be circumvented by an azeotropic
distillation process as patented by Mitsui Toatsu Chemicals Inc190,191.
The ring-opening polymerisation of lactide and glycolide allows for a
much higher control of the polymerisation than polycondensation.
As a result, ROP is the most widely used method for the synthesis of
well-defined materials. In practice, a suitable polymerisation
conditions allow for the controlled ring opening polymerisation of
lactide and glycolide, and the mean degree of polymerisation (DP)of
the resulting polymers is usually equal, or at least proportional, to
the monomer conversion times the monomer to initiator molar ratio.
Polymerisation can occur either in bulk or solution; however, bulk
polymerisation is desired when the end product is intended for
medical applications. Bulk polymerisation eliminates the use and
potential residual presence of organic solvents such as toluene,
benzene, or chlorobenzene in the polymer192.In addition to that,
compared to condensation reactions, ROP is much more convenient
for the control of monomer sequences, for example during block
copolymer synthesis as well as of the polymer chain ends193.ROP of
lactide and glycolide requires a suitable catalyst to open the rings
and initiate the polymerisation in a controllable manner.
The most widely used catalyst for industrial preparation of lactide
and glycolide polymers is tin (II) bis (2-ethylhexanoate), (Figure 1-
10). Usually referred to as tin (II) octanoate, Sn (Oct) 2, is
commercially available, easy to handle, and soluble in common
organic solvents and in melt monomers. It is highly active (typical
reaction times in bulk at 140-180 °C range from minutes to a few
hours) and allows for the preparation of high-molecular-weight
polymers (up to lOS or even 106 Da in the presence of an alcohol)194.
Sn (Oct)2has been accepted as a food additive by the U.S.FDA.
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Sn(Octh
Figure 1-10. Structure of tin (II) octanoate [Sn (Oct) 2.
Other catalysts mentioned to be efficient in Rap are aluminium (III)
isopropoxide [AI (ai-Pr) 3], and zinc (II) lactate [Zn (Lact) 2].Sn (Oct)
2 is known to be more active than Al (Oi-Pr) 3which usually needs a
longer reaction time. Zn(Lact)2 is relatively good polymerisation
catalyst and its known to be more active as AI(Oi-Pr)3195,196.
It has been reported that Rap polymerisation is faster and better
controlled when Sn(Oct)2was combined with a protic reagent such as
alcoholl'".
The coordination-insertion mechanism for the Rap of cyclic esters
was first formulated in 1971 by Dittrich and Schulz197• Support for
this mechanism has been obtained theoretically for Sn(Oct)2-
catalyzed Rap of Lactide in the presence of methanoP98.
The mechanism of reaction is described as two molecules of
methanol coordinated to Sn (Oct) 2. Both coordinations occur in an
associative fashion, i.e., with retention of the two octanoate moieties
(hydrogen bonds are formed between the alcohol and octanoate
ligand). A weak complexation of lactide occurs; the latter
coordination step induces a proton migration from methanol to the
nearby octanoate ligand, so that the alcohol ligand is converted into
an alkoxide. Subsequently, the insertion occurs in.two steps, namely,
so
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nucleophilic attack of this alkoxide on the coordinated lactide
followed by ring opening
Figure 1-11. Predicted Mechanism for the Sn (Octjz-catalyzed ROP of
lactide in the presence of methanol (R= Me)l93,
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1.7.2.Living radical polymerisation
1.7.2.1.Atom transfer radical polymerisation (ATRP)
R'
Figure 1-12.Principle of ATRPtechnique'w.
ATRP is a multicomponent reaction which consists of a transition
metal species (Mt=)capable of expanding its coordination sphere and
increasing its oxidation number, a complexing ligand (L), and a
counterion to form covalent or ionic bond with the metal centre.
Other factors also important are solvent and temperature.
The alkyl halogen bond RX homolytic cleavage occur by the
transition metal complex (Mtn /L) and this generates the
corresponding higher oxidation state metal halide complex
(Mtn+lX/L)( this process occur with the rate constant of activation
Kact) and an organic radical R·.Polymer chains grow by addition of
organic radical R· to monomers in a manner which is similar to
conventional radical polymerisationsw 201with a rate constant of (Kp).
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Termination occurs as in free radical polymerisation via coupling or
disproportionation (Kt) or reversible deactivation (kdeact) by
(Mtn+1X/L)which forms a halide-capped dormant polymer chain.
The rate of polymerisation can be obtained from the magnititude of
the equilibrium constant (Keq) which can be derived from an
activation constant (Kact) and the deactivation constant (Kdeact) as
described in the equation below:
Equation of equilibrium constant in ATRP system
«; =Kact/ Kdeact
When the equilibrium constant Keq is too small, in this case, ATRP
will not occur or will occur very slowly. Whereas if the equilibrium
constant is too large, this will result in a large amount of termination
due to a high radical concentration. Consequently, a large amount of
deactivating higher state oxidation metal complex will drive the
equilibrium toward dormant species which result in slower
polymerisation, but better control.
The atom transfer step is the key elementary reaction and is
responsible for the uniform growth of the polymeric chain. In a well
controlled ATRP, no more than a few percent of the polymer chains
undergo termination. Typically, no more than 5% of the total
growing polymer chains terminate during the initial stage of the
polymerisation. As has been mentioned earlier, ATRP is composed of
several components including monomers. It has been mentioned that
a variety of monomers have been successfully polymerized by ATRP
technique. Examples of those monomers are mainly vinyl based
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monomers such as styrenes, (meth)acrylates, (meth)acrylamides, and
aerylonitrile.
These monomers contain substituents to stabilise the propagating
radical, and each monomer has their own radical propagation rate,
therefore, it is important for a specific monomer, to adjust the
concentration of propagating radicals and the rate of radical
deactivation to maintain control over the polymerisation.
Using ATRP techniques, it is possible to pre-determine to a
reasonable degree the M.W. of the final polymer via the degree of
polymerisation (DP) which is set by the initiator concentration. Also,
in a typical ATRP the molecular weight increases linearly with
conversion and it is therefore possible to terminate the
polymerisation at any point of time in order to achieve the desired
molecular weight.
1.7.2.2. Radical addition-fragmentation termination polymerisation
(RAFT)
After the intial report by the CSIRO group in 1998 the reversible
addition fragmentation chain transfer (RAFT) has been recognised as
one of the most versatile methods for imparting living characteristics
to radical polymerisation and also providing control over the
molecular weight and dispersity.
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R'· + y-R 4 kad'!,
~ k·add
Reactive'"
double bond t
Zmodifies addition .,d
fragmentation rates
1 3
Figure 1-13. mechanism of addition fragmentation chain202.
The RAFT agents are unsaturated compounds with general structure
(1) shown in the (Figure 1-13). They act as transfer agent by a two-
step addition-fragmentation mechanism.
In compound (1), the double bond (C=X) is reactive toward radical
additon. The reactivity of the raft agent toward the propagating
radical and the stability of the intermediate radical (2) is depends on
a substituent Z. Whereas both A and X groups often referred to CH2
or S. The group R is regarded a homolytic leaving group to generate
R· which is capable of efficiently re-intiation of the polymerisation.
Therefore, both compound (1) and compound (3) are considered as
active transfer agents under the polymerisation condition203,202.
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The general mechansim of RAFTpolymerisation is shown as below
Initiation
Initiator -- .....~ I· __;_:M,;__.....~
reversible chain transfer/propagation
kadd
k.add
5 6
reinitiation
M M •
kj •
chain equilibration/propagation
P~ + SyS-Pn kaddP Pm-S'fS-Pn k·addP Pm-SyS Pn·
kaddp
+GJk, k·addPZ Z Z6 7 6
term ination
Pn· + Pm· k,.. dead polymer
Figure 1-14.The general mechanism of RAFTpolymerisationw-,
The general mechanism for RAFT process involves a sequence of
addition-fragmentation equilibria as shown in (Figure 1-14).Similar
to conventional radical polymerisation, the radical is generated by
the initiator.
The generated radical is added to the transfer agent to form an
intermediate compound which is subsequently followed by
homolytic cleavage of the R group to form a new radical R·. Re-
initiation by R· produce a new propagating radical Pm·.
S6
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Due to the rapid equilibrium between the active propagating radicals
(Pn• and Pm·) and the corresponding dormant species 6 provides
equal probability for all chains to grow and allows for the production
of narrow polydispersity polymers. When the polymerisation is
completed or (stopped), the majority of the polymer chain will retain
the RAFT agent (thiocarbonylthio end group). The key element of
RAFTpolymerisation is that the thiocarbonylthio groups are retained
in the polymeric product and this is characterstic of the living nature
of the RAFT polymerisation. The RAFT agent at the end of the
polymer chains also allows for synthesis of block copolymer
synthesis even in one-step synthesis (assuming that all initial
monomers are consumed before addition of the second).
As was mentioned earlier, the efficiency of the RAFT agents relies on
both substituents Rand Z groups. Almost all types of monomers can
be polymerised by the RAFT process but a suitable RAFT agent is
required to polymerise a specific monomer.
Generally, dithiobenzoates and other aromatic dithioesters, aromatic
dithiocarbamates, trithiocarbonates are regarded as very efficient
RAFT agents whereas for R groups, cyanoalkyl or cumyl moieties are
the most common particularly for methacrylate based monomers due
to their good captodative character204•
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1.S.Aim of the thesis
The aim of this thesis was to develop advanced nanocarriers based
on synthetic biodegradable and biocompatible polymers with
tailored physicochemical properties to fulfill the requirements of an
ideal drug and gene delivery system.
In chapter two, the initial goal was the development of new a
nanoparticulate carrier system for gene delivery purpose. The
primary objectives were first, to formulate a blend matrix
nanocarrier based on PLGA and polyethylene glycol derivatives
(Jeffamine™). Secondly, to study the impact of the new blend system
on the encapsulation efficiency of DNA, as well as the release profile.
Finally, to coat the surface of particles with hydrophilic polymers to
provide protective shells to enhace particles stability, as well as to
increase compatiblity with blood components.
In chapter three, by exploiting modern polymerisation techniques
(controlled living polymerisation techniques), the aim was to
synthesise amphiphilic block copolymers based on PLGA and PEG-
methacrylates to fine-tune properties and to use these copolymers in
formulation of drug and gene delivery systems. It has been
hypothesised that the new synthetic route would overcome the
difficulties associated with the traditional methods to prepare PEG-
PLGA copolymers owing to the limited availabilities of PEGs with
appropriate functional chain-ends and ranges of molar mass. It has
also been considered that by simply changing the length of the blocks
and polymer compositions, the size, encapsulation efficiency and
releasing profile of the nanocarrier systems can be easily tuned.
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In chapter four, the ultimate aim was to develope multifunctional,
bioresponsive and cell targeted nanocarriers, in a single construct,
based on biodegradable and biocompatible PLCA and PEC-
methacrylate copolymers that can be potentially used for drug and
gene delivery systems.
The main objective of this work includes:
1- The synthesis of block copolymers based on PLCA and PEC-
methacrylates using a combination of ROP and ATRP.
2- Synthesis of PLCA-S-S-PLCA block copolymers.
3- Incorporation of functionalities such as disulfide bridge
between the blocks in the copolymer.
4- Functionalisation of block copolymers with a targeting
moiety.
5- Combining the two copolymers using a double emulsion
technique to formulate functionalised core-shell nanoparticles
with DNA encapsulated in the matrix.
6- Examine encapsulation efficiency of pDNA.
7- Examine release profile in redox environment.
8- Study cellular uptake and viability on a clinically relevant cell
lines.
9- Examination of incorporated fucntionalites on in vitro
transfection efficiency.
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Chapter 2
Nanoparticulate gene delivery system
2. Introduction
The success of gene therapy is largely depends on the availability of an
efficient gene delivery system, which will be able to protect and deliver
the DNA into targeted tissue and cellst+, From this point of view, viral
vectors are considered as the II gold standard" and able to achieve the
highest transfection efficiency'', This is related to their natural ability to
cross extracellular and intracellular barriers effectively. However, viral
vectors have several drawbacks in their application as gene delivery
system, such as the induction of an immune response against the viral
proteins, possible recombination with wild-type viruses, limitations in
the size of inserted DNA, and difficult large-scale pharmaceutical grade
productione",
On the other hand, non-viral gene delivery displays potential
advantages over viral gene delivery systems owing to their reduced
toxicity, ease of scale-up, storage stability and improved quality
control10-12.1t should be noted, however, that the efficiency of non-viral
gene delivery is still far below that of the viral ones.
One of the strategies aimed at the construction of a successful non-viral
gene delivery has been the designing and preparation of polymeric
micro- and nanoparticlests.
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Poly (Dl.-lactide) (PLA) and poly(lactic-co-glycolic acid) (PLGA)
polymers have been widely used to prepare polymeric particles owing
to their approved track record by the FDA for use as vehicles for drug
and protein deliveryl+w, Moreover, there are several ways to load the
PLGA based particles with the therapeutic agents, physical entrapment,
adsorption or chemical conjugation to PLGA matrix15• PLGA-based
particles have also been shown to be able to escape from the endosomal
compartments through surface charge reversion and to release the
payload in cytoplasm in controlled manner17-20•
PLGA-based particles are able to encapsulate plasmid DNA, protect it
from nuclease degradation and increase its stability2l-23. In addition,
PLGA particles sized in the range of less than 10 urn can be efficiently
phagocytosed by antigen presenting cells (APCs), therefore, their
application for genetic vaccination has been widely explored24/25• An
example of this is the intramuscular immunisation of p55 Gag plasmid
adsorbed on PLGA/ ceytltrimethylammoniumbromide (CTAB)
particles, which results in induction of potent immune response26.
The mechanism of cellular uptake of PLGA particles is size
dependents': therefore, special interest has been paid to nanoparticles
which are able to cross the biological barriers more effectively, hence
improving the transport of encapsulated molecules. It has been
mentioned that the cellular uptake of nanoparticles is non-specific and
occurs either through clathrin vesicles, or by fluid-phase pinocytosis".
Upon internalisation of the nanoparticles, they are transferred to
endosomal compartment where destabilisation of the membrane occurs
owing to surface charge reversion on PLGA particles. After escape from
the endosomal compartments, the PLGA particles release the
encapsulated molecules into the cytosol in a controlled mannerv,
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Despite the advantages of PLGA particles for use in gene delivery
systems, particularly nanoparticles, there are significant barriers in the
development of PLGA delivery systems. One of the main issues in a
PLGA delivery system is the difficulty experienced with encapsulation
of hydrophilic molecules like DNA within the hydrophobic matrices of
PLGA particles. In an attempt to improve the encapsulation of DNA
within PLGA nanoparticles, several methods have been introduced
such as spray drying and oil in water solvent evaporation techniquesw
28,29. However, during the encapsulation process of DNA using these
methods, the DNA is liable to be damaged, and, also, degradation of
PLGA polymer will result in the formation of an acid climate by the
accumulation of the oligomers within the particles22.28. Because of the
hurdles and problems mentioned above, other approaches have been
explored to improve the efficiency of PLGA to encapsulate and release
the DNA whilst keeping the biological actively high.
There are several methods used in preparation of PLGA particles which
including:
• spray-drying
• emulsion/ evaporation
• double emulsion/ evaporation
• salting out
• solvent displacement/ nanoprecipitation
• emulsion-diffusion-evaporation techniques
The choice of these methods to prepare PLGA particles is mainly
dependent upon the targeted size (particular size required) and the
loading efficiency. For instance, in the case of genetic immunisation
application, the particle size is required to be in the range of 1 - 10 um
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because the particles within this size range are shown to be taken up
very efficientlyby antigen presenting cells (APCs)3o.
Different particle sizes are required if the targeting cells are
nonphagocytic cells, particles need to be in a size range of less than 300
nm, and uptake of these particles size is mediated by clathrin-
endocytosis'", (see section 1.3. in chapter one).
One of the commonly used methods to encapsulate DNA in the matrix
of PLGA particles is the double-emulsion-solvent evaporation
technique. This method consists of three main phases, an internal
aqueous phase which usually contain a known amount of DNA to be
loaded, an intermediate organic phase in which the PLGA polymer is
dissolved and, finally, an external aqueous phase containing a known
concentration of surfactant that will be used to stabilise the particles
and prevent their aggregation22.32, 33.
In the process of PLGA particle preparation using double-emulsion-
solvent evaporation technique, there are several parameters that affect
on the particle size. Among these parameters, stirring rate and
surfactant concentrations have been mentioned. PLGA particles have
been prepared by this method and poly vinyl alcohol (PVA) chosen as
surfactant in the external phase. By varying the concentration of PVA
from 9% to 0.1% (w/w), the size of the particles has been controlled 1.6
- 9.7 um, during which the stirring rate was fixed at 3400 round per
minutes(rpm). However, the size of the particles decreased by
increasing the stirring rate from 3400 to 1000 rpm whilst keeping the
concentration of PYA surfactant at 0.1% (w/W)34,35.Therefore, the size
of the particles can be optimised by changing the parameters of a given
method.
The approach of using double-emulsion-solvent evaporation technique
to encapsulate DNA in the matrix of PLGA particles has many
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concerns, particularly, the loading efficiency and preservation of
biological activity of DNA during formulation process.
In the double emulsion technique, in order to obtain smaller size
particles, usually a high shear force has to be utilised such as
homogenisation or sonication. Theses high shear forces have a
detrimental effect on DNA molecules and may compromise the
biological activity. It has been reported that homogenisation and
sonication used during emulsion techniques can convert supercoiled
DNA into linear or circular conformation. Supercoiled DNA is known
to be the most stable form and can produce a higher level of
transfection compared with linear or open form DNA36,37.Despite that,
there are some reports indicating that after extraction, plasmids with a
low supercoiled fraction have a biological activity which is equal or
slightly less to DNA in supercoiled formation27,38,39.
In contrast, the usage of sonication during emulsification technique has
a much higher detrimental effect on the integrity of encapsulated DNA.
Sonication can convert the double stranded DNA into a single stranded
version=. The mechanism by which this damaging effect occurs is
related to the formation of gaseous bubbles during sonication;
(dispersion by sonication is based on shear force which originated by
cavitations which causes the solvent as well as the molecules to become
intensely agitated), upon collapse of these bubbles the medium
becomes intensively agitated and results in the breakdown of the
double stranded DNA. This is in addition to production of H~ in the
process of water sonolysisw. which could also be very harmful+'.
There are other modified methods derived from double emulsion
techniques that can be utilised in the preparation of PLGA particles.
These methods use the least amount of shear force to obtain particles
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within nanoscale ranges. The spontaneous emulsification solvent
diffusion method has been mentioned as one of the methods that
require minimum shear force to produce nanoparticles42-44. The
principle of this method was described in chapter one as an organic
phase which consists of two organic solvents, one which has poor water
miscibility properties (e.g. dichloromethane) and the other of which has
good water miscibility (e.g. acetone). Upon the addition of these organic
solvents into an aqueous medium (non solvent to PLGA polymer),
acetone rapidly diffuses out into the aqueous medium, precipitating the
dissolved PLGA polymer in the organic phases at the interfacial face
and this diffusion results in the formation of particles in a nanoscale
range.
As described above, the spontaneous emulsification solvent diffusion
does not require the use of high shear forces to produce PLGA
nanoparticles. It has been mentioned that using this type of emulsion
technique usually results in particles within the size range of 200 nm to
300nm44.
In addition to spontaneous emulsification solvent diffusion methods,
other approaches that do not use high shear force to produce
nanoparticles have also been reported, such as cryopreparation
modification of the emulsion technique". The temperature of the
internal aqueous phase that contains the DNA is lowered to freezing
point in order to obtain solid particles. This has been shown to be able
to preserve the DNA structure from the effects of high shear forces.
Other approaches include the condensation of DNA with cationic
polymers in the internal phase.
More recently, a modified technique has been developed which is based
on solvent diffusion and solvent displacement. This technique allows
obtaining nanoparticles composed of PLGA blended with
poloxamers/ poloxamines polymers. The effect of this blending
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technique on particle size, loading efficiencies and release profile has
been studied in some details which are described below.
Csaba et al, have designed a new vector which has a potential
application for DNA encapsulation, with controlled and continuous
release features. Their work has been mainly focused on how to
overcome the problems associated with DNA encapsulation in PLGA
nanoparticles (Le. structural and biological activity of DNA). In this
system, they incorporated amphiphilic polymers which have the ability
to interact with DNA by hydrogen bonds, and which can also protect
DNA from degradation, thereby facilitating the gene expression45,46,
(see Figure 1-9 in chapter one).
One of the most effective polymers used in this study was the group of
polyoxyethylene derivatives (poloxamers and poloxarrdnesrv.One of
the advantages of this system is that it provided an optimal condition
for DNA encapsulation and protected the DNA from the acidic climate
during degradation of PLGA nanoparticles. Equal amounts of
poloxamers or poloxamines have been mixed with PLGA polymer to
prepare nanopartic1es by an emulsion-diffusion-evaporation technique.
This technique uses steric stabilisation with ethylene and propylene
oxides of the polymer backbone rather than the addition of extra
surface active agents to stabilise the emulsion droplets.
Also, characterisation of PLGA blended nanopartic1es, formed with
poloxamers or poloxamines for size, zeta potential, encapsulation
efficiency and biological activity have been studied.
The result showed that the size of nanopartic1es blended with
poloxamers were around 163±5 nm with PI (polydispersity) of 0.135
and 185±6 nm with PI 90.195 for Pluronic F68 and L121 respectively, on
the other hand, the size of nanoparticles made with poloxamine
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(tetronic 90S) were 174±5 run with PI = 0.271 and (tetronic 904) 168±9
run with PI = 0.179.
Zeta potential showed highly negatively charged surface particles, for
(Pluronic F6S) - 0.43±6.4 mY, Pluronic L121 - 30±S mY, whilst for
(tetronic 90S) - 26.9 ± 1.2 mV and (tetronic 904) - 38±3.3 mY.
For encapsulation of plasmid DNA and characterisation of loading
capacity of the particles, the model of plasmid encoding green
fluorescent protein (pEGFPs) was used. Their results after theoretical
loading of 0.4% DNA showed the encapsulation efficiency of
35.2±13.2% for Pluronic F68 and 31.3±3.S% for Pluronic L121. On the
other hand the data for tetronic 90S was 32.2±3.7% and for tetronic 904,
44.1±4.3%, in terms of encapsulation efficiencies (i.e. the amount of
DNA loaded into particles compared to that in solution.
It was also suggested that the presence of certain surface active agents,
such as TweenSO or poly (vinyl alcohol), will have positive effects on
the encapsulation of hydrophilic DNA molecules in a hydrophobic
polymer matrix. This effect may be understood by their interaction with
DNA that could make it more hydrophobic, and this could facilitate the
incorporation of the plasmid into the particle matrix.
Another interesting point which they have shown in the study by
Alanso is that the presence of amine groups in the poloxamines
structure (which have the ability to be protonated at ambient pH) is
thought to facilitate interaction with DNA.
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Also, high encapsulation efficiency in tetronic PLGA blends might be
attributed to the combination of hydrophobicity and electrostatic
interaction.
Despite the introduction of different approaches that have been used to
develop nanoparticulate gene delivery systems, the design of an
effective gene delivery system remains a challenge, and currently-
developed systems also require further optimisation to produce
nanoparticles highly loaded with DNA. Likewise, surface modification
of the particles is needed to increase stability and prolong circulation
time. In an attempt to produce an optimised gene delivery system, we
have proposed a new blended system based on PLGA and another
hydrophilic polymer, Jeffamine (Poly (ethylene glycol) bis (3-
aminopropyl) terminated), to facilitate high encapsulation efficiency
whilst improving the release profile. Moreover, we have also surface-
coated the PLGA blended particles to highly hydrophilic polymers to
provide stability with a view to obtaining longer circulation upon
intravenous injection.
2.1. Aims and Objectives
The overall aim of this chapter is to focus on the development of a novel
nanoparticulate gene delivery system to enhance encapsulation and
improve release profile of DNA; using a combinatory approach to
fabricate blended-matrix PLGA and surface functionalised
nanoparticles.
Objectives and Hypotheses:
Objective one: To fabricate blended PLGA: Jeffamine nanoparticles
using double emulsion technique, loading DNA on the blended
particles and to characterise releasing profile.
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Hypothesis: The addition of slightly positive charged excipient
polymers (e.g. Jeffamine®) into PLGAbased nanoparticles can improve
encapsulation efficiency and release profile of biomolecules such as
DNA.
Objective two: To coat the surface of blended PLGA: Jeffamine
nanoparticles with amphiphilic block copolymers using conventional
physical adsorption technique.
Hypothesis: the hydrophilic chains of coated block copolymers on the
surface of PLGA:Jeffamine nanopartic1es enhance colloidal stabilisation
by providing steric "stealth" properties.
2.2. Materials and Methods
2.2.1. Instrumentation
Poly (lactide-co-glycolide) molar ratio 50:50from Boehringer Ingelheim
(Mw....ll,OOODa),Poly (ethylene glycol) bis (3-aminopropyl) terminated
(Mn 1500 Da, Sigma-Aldrich), and Calf thymus DNA purchased from
Invitrogen (average size of S 2000 bp, concentration 1Omg/ml in
DNase-free, RNase-free distilled deionised water). Methylene chloride
(HPLC grade), ethanol (absolute, for HPLC, ~99.8% (Sigma-Aldrich),
and DNase, RNase-FREEwater (MPBiomedicals, LLC).
PDMAEMA-b-PEGM~7s (Mn = 32.5 kDa and 1.3) was prepared and supplied
by Dr. Wenxin Wang at NUl Galway.
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2.2.1.1. Dynamic light scattering (DLS)
Values of the mean hydrodynamic radius of the nanoparticles were
determined via scattered light recorded at 90° angle to incident
radiation in Dynamic Light Scattering (DlS) ) using a Viscotec Model
802 instrument equipped with an internal laser (825-832 nm) with a
maximum radiation power of 60mW.
Description of dynamic light scattering (DlS): when light hits smaIl
particles, the light scatters in all directions. Using a laser as the source
of light (which is monochromatic and coherent) one can monitor the
time-dependent fluctuation in the scattering intensity. The fluctuations
are owing to the fact that smaIl molecules or particles in the solutions
are undergoing random movements which is named as "Brownian
motion". The distances between the particles or molecules are changing
constantly with time.
Therefore, the intensity of scattered light is also changing with time.
This can be used to obtain information about the times scale
movements of particles as follows:
With the assumption that the particles are spherical and non-
interacting, the mean radius (RH>is obtained from the Stokes-Einstein
equation:
Where RH is the hydrodynamic radius, Iq, is the Boltzmann constant, Tis
the temperature and 'I is the viscosity of the solvent. The speed of
movement is inversely proportional to particle size (the smaller the
particles are, the faster they move, or diffuse), and the speed can be
detected by analysing the time dependency of the light intensity
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fluctuations scattered from the particles when they are illuminated with
a laser beam.
To determine the particle size, the samples were diluted with the same
medium in which the particles are suspended (water or buffer), filtered,
and at least five measurements of each sample taken. The mean
diameter size and standard deviation were calculated. Data processing
was performed with the software program OmniSize2.
2.2.1.2. Zeta Potential
Zeta potential (~) measurements of the nanoparticles were performed
by laser Doppler anemometry using a Malvern Zetasizer 2000 equipped
with a 10 mW He-Ne laser operating at a wavelength of 633 nm.
Measurements were performed at 25 ± 0.10 C, on samples appropriately
diluted with the medium described each time. Measurements were also
taken in low ionic strength buffer, 1 mM PBS buffer adjusted to pH 7.4.
The mean value and standard deviation for each sample was calculated
from at least five measurements.
2.2.1.3. Transmission Electron Microscope
Morphology of the particles was examined using Transmission Electron
Microscope (TEM) (Ieol Iem 1010 electron microscope, Japan). A sample
of particle suspension was diluted with a solution of phosphotungstic
acid (3% ve]», pH 7.4) and observed under TEM. One drop of sample
was placed for one minute on a copper grid coated with a formvar
carbon film. The excess of sample was wicked away with the aid of
filter paper prior to imaging by TEM.
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2.3. Polymer Synthesis
A Series of polymers and copolymers based on PLA, PLGA and
PEGMA were synthesised and labeled from P1 - PS (see table 3-1 in
chapter three). In this chapter only P4 and PSare mentioned.
2.3.1. Synthesis of BSTSE-PLGA polymer (P 4)
BSTSE-PLGA,Poly (DL-Iactide-co-glycolide)was synthesised by ROP
(ring opening polymerisation) using 2-
(benzylsul£anylthiocarbonylsul£anyl) ethanol (BSTSE)as initiator. First,
DL-Iactide (2.1g, 0.015moles), glycolide (1.7g, 0.015moles), and BSTSE
(0.15g,0.0005moles) were added to a polymerisation tube and purged
with argon several times before being heated in an oil bath to 80 OCand
purged with argon for a further two hours. The reaction mixture was
then heated to 140OCin order to conduct the polymerisation in the melt
phase. At this point, tin (II) (2-ethylhexanoate) (0.022g,0.00005moles)
was added, and the mixture was stirred for 24 hours. The
polymerisation tube was then removed from the oil bath and cooled
down to room temperature. The polymer was recovered by dissolution
in THF and precipitated in methanol (this was repeated three times to
remove unreacted monomer).
The precipitate was filtered and dried under reduced pressure to yield
a brown-yellow BSTSE-PLGAproduct (yield 92% weight of product).
The molecular weight of the polymer and polydispersity index was
determined by gel permeation chromatography using chloroform as
eluent.
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2.3.2.Synthesis of PLGA-PEGMA co-polymer (P 8)
The PLGA-PEGMA block copolymers were prepared by RAFT
polymerisation. BSTSE-PLGA (1.2g, 0.0001 moles), Poly (ethylene
glycol) methyl ether methacrylate (Mn 475 1.35g, 0.002 moles) and
AIBN (0.003g,0.000018moles) were added into a round bottom flask,
the flask purged with argon several times, followed by addition of
anhydrous THF (5m1)under an argon atmosphere. The polymerisation
mixture was allowed to stir until the components were completely
dissolved. The mixture was then heated in an oil bath to 80 CCand
stirred for 24 hours. The polymerisation product was dissolved in THF
and reprecipitated three times in methanol, and the filtrate was dried
under reduced pressure (yield 80%).The product was characterised by
IH-NMR. GPC with chloroform as the eluent was used to calculate the
molecular weight and polydispersity of the final block copolymers. This
polymer was used for coating the NPl nanopartic1es (see section 2.4.3)
2.4.Particle preparation
2.4.1. Particle preparation of blank PLGA (uncoated) nanoparticles
(NPl)
PLGA nanoparticles were prepared by double emulsion technique as
mentioned elsewhere48, using commercially available PLGA. Firstly,
PLGA (11kDa, 50:50ratio) (100mg) was dissolved in (2mL) methylene
chloride (OCM)and stirred gently until completely dissolved.
This organic solution was then mixed by vortex agitation for 30 s with a
small aqueous phase (200 ul), Then, the obtained emulsion was poured
onto a polar phase (25ml ethanol) under moderate magnetic stirring,
leading to immediate polymer precipitation in the form of
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nanopartic1es. The formulations were diluted with 25 ml of milli-Q
water and the stirring was maintained for 10 minutes more. After
solvent evaporation under vacuum at 30°C (Rotavapor, Buehl R-114,
Switzerland) nanoparticles were collected and concentrated in 1mM
PBS buffer. The size distribution of the different nanopartic1es was
analysed by dynamic light scattering (DLS), surface charge was
measured by Malvern Zetasizer 2000 and the morphology of the
particles was analysed by Transmission Electron Microscope.
2.4.2. Particle preparation of blended PLGA: Jeffamine nanopartides
(NP2), loaded with Calf Thymus DNA (NP3)
The Calf Thymus loaded PLGA:Jeffamine blended nanoparticles (NP3)
were prepared by double emulsion. First, PLGA (50mg) and 5Jeffamine
(50mg) (PEGbis-aminopropyl) were dissolved in methylene chloride (2
mL) and stirred gently until completely dissolved.
Aqueous solution of DNA (200p.1of 1mg/ml) was added to the polymer
solution (0.4% of DNA to the total amount of PLGA) and mixed by
vortex agitation for 30 seconds (primary emulsion formed).
The primary emulsion so obtained was poured onto a polar phase (25
ml Ethanol) under moderate magnetic stirring which resulted in
immediate polymer precipitation in the form of nanoparticles. The
formulations were diluted with 25 ml of 1mM PBS buffer and the
stirring was maintained for 10minutes more.
After solvent evaporation under vacuum at 30°C (Rotavapor, Buehl R-
114, Switzerland) nanopartic1es were collected and concentrated in
1mM PBS. For the complete elimination of adsorbed Calf Thymus
DNA, nanopartic1es were extensively washed by a two-step procedure
consisting of gel filtration (PO-tO desalting column with Sephadex G-
25, Amersham Biosciences, Spain) and of particle
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isolation/ resuspension by centrifugation (15 min, 8000 RCF, 10 °C,
Beckman J2-21 centrifuge). Blank PLGA: Jeffamine nanoparticles (NP2)
were prepared using the steps above and using only DNAase free water
instead of Calf Thymus DNA solution.
The size distribution of the different nanoparticles was analysed by
dynamic light scattering (DlS), surface charge was measured by
Malvern Zetasizer 2000 and morphology of the particles were analysed
by Transmission Electron Microscopy.
a)
b) o
HO
Polymer structures of a) Jeffamine (Poly (ethylene glycol) bis (3-
aminopropyl) terminated, b) PLGA poly (lactic-co-glycolic acid)
2.4.3. Adsorption of PLGA-PEGMA475 block copolymer on the surface
Blended PLGA: Jeffamine nanopartides (NP4)
Nanoparticles were prepared using method described in section 2.4.2 in
Chapter 2 (preparation of NP3). Except that the obtained formulations
were diluted in PLGA-PEGM.A&75(PS) diblock copolymer (1% wIv) and
incubated overnight under moderate stirring. For the complete
elimination of free PLGA-PEGM.A&75diblock copolymer, nanoparticles
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were extensively washed by a 2-step procedure consisting of gel
filtration (PD-l0 desalting column with Sephadex G-25, Amersham
Biosciences, Spain) and of particle isolation/ resuspension by
centrifugation (15 min, 8000 RCF, 10°C, Beckman J2-21 centrifuge).
The size distribution of the different nanoparticles was obtained by
dynamic light scattering (DlS), surface charge was measured by
Malvern Zetasizer 2000 and morphology of the particles was analysed
by Transmission Electron Microscopy.
2.4.4. Adsorption of pDMAEMA-PEGMA475 block copolymer on the
surface PLGA: Jeffamine blended nanopartides (NP5)
Nanoparticles were prepared by the method as mentioned in (section
2.4.2) for (NP3). But the obtained formulations were diluted in PEGMA-
PDAEMA diblock copolymer (1% w/ v) and incubated overnight under
moderate stirring.
For the complete elimination of free PEGMA-pDAEMA ( this diblock
copolymer was supplied by NUl galway) diblock copolymer,
nanoparticles were extensively washed by a 2-step procedure consisting
of gel filtration (PD-l0 desalting column with Sephadex G-25,
Amersham Biosciences, Spain) and of particle isolation/ resuspension
by centrifugation (15 min, 8000 RCF, 10°C, BeckmanJ2-21 centrifuge).
The size distribution of the different nanoparticles was analysed by
dynamic light scattering (DlS), surface charge was measured by
Malvern Zetasizer 2000 and morphology of the particles was analysed
by Transmission Electron Microscopy.
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)
Structure of polymer pDMAEMA-b-PEGMA475
2.4.5. Determination of plasmid DNA encapsulation efficiency
The theoretical loading of Calf DNA was 0.4% (w/w) in regards to the
total amount of PLGA in the nanoparticles. For the determination the
actual amount of encapsulated cDNA, encapsulation efficiency was
calculated from the amount of the free Calf Thymus DNA present in the
aqueous phase of the formulation (obtained by centrifugation without
particle washing). The amount of this Calf Thymus DNA was
determined by spectrophotometry (UV-Visible Spectrometer, UV-1603
Shimadzu, Spain) using standard calibration curve of Calf Thymus
DNA in DNAase free water at 260 nm.
2.4.6. Release profile of plasmid DNA from the nanoparticIes
The in vitro release of cDNA from blended PLGA: Jeffamine
nanoparticles (NP4) were investigated as follows. Nanoparticles (10
mg) were suspended in PBS buffer (1.5 ml, lmM) at 37 CC under
continuous agitation. At various time intervals, the supernatant was
withdrawn and fresh buffer was replenished. The amounts of Calf
Thymus DNA in
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The supernatant were determined by UV spectrophotometry at 260 nm.
The experiments were performed in triplicate.
2.5. Results and Discussion
2.5.1. Polymers syntheses and characterisation (P 4 and P 8)
Series of PLA, PLGA polymers and PLGA-PEGMA block copolymers
were prepared by combining ring opening polymerisation (ROP) and
reversible addition fragmentation transfer (RAFT) and referred to as PI
to P8 (chapter 3). However, in this chapter only the syntheses of BSTSE-
PLGA (P4) polymer and PLGA-PEGMA475copolymer (P8) (which latter
was physically adsorbed on blended PLGA: [effamine nanoparticles)
are described.
BSTSE (Raft agent)
5
V)l"-'_"OH5 5..9
BSTSE-PLGA (P4)
R= H, CH3
PLGA-PEGMAm (PS)
Figure 2-1. Syntheses of Polymers (P4 and P8), (i) Sn (II), 140«; 24 h,
(ii) THF, AIBN, 80 °C 24 h, (see Materials and Methods section)
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The properties of BSTSE-PLGA (P4) and PLGA-PEGMA475 (P8)
copolymers synthesised by ROP and RAFT are summarised in table 2-1,
describing the molecular weight and molecular weight distributions
based on results obtained from gel permeation chromatography.
Table 2-1. Characteristics of PLGA-PEGMA475 diblock copolymer
synthesised by ROP and RAFT process
Entry Polymer
8Mn
(theo)*103
Mn
(GPC)*103
Mw
(GPC)*103
MwlMn
P 4 BSTSE-PLGA
P 8 PLGA-PEGMA
9.6
27
13.3
27.1
20.1
48.1
1.5
1.7
a was calculated by multiplying the conversion with the targeting
molecular weight.
cocu
( a
d
[ppm]
Figure 2-2. IHNMR spectrum of BSTSE-PLGA P 4 with Mn (GPC) =13.3
K, PDI= 1.5 in CDCb.
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The structure of the PLGA polymer end-capped with BSTSE was also
confirmed from IH NMR spectrum obtained in (CDCh). The peaks
which are labelled in Figure 3-4 referred to the protons of the backbone
of PLGA polymer (a-c) and the end group for BSTSE (d). 0 = 5.18 (m, 1H,
CH- C=O), 4.82 (m, 2H, CH2- C=O), 1.58 (d, 3H, CH3-CH), 7.3-7.4 (m, 5H,
Ph).
Owing to the low intensity of the phenyl proton adsorptions compared
to the protons of the PLGA in the IH NMR spectrum, it was difficult to
calculate the molecular weight via IH-NMR alone, however Using the
integration on the spectrum, it was possible to confirm the 50:50 ratio of
lactic to glycolic acid units in the polymer which was the target in the
synthesis of the polymer.
b
a
e
, I
[ppm]
Figure 2-3. IHNMR spectrum of PLGA-PEGMA P 8 with Mn (GPC)
=2.7k, PDI= 1.5 in CDCh.
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From the IH NMR spectrums of PLGA-PEGMA475 block copolymer, it
was possible to characterise the structure by assigning the peaks as
shown in (Figure 3-5).The peaks labelled from e-g were assigned to the
protons on the PLGA block. The peaks labelled (h) were assigned to
PEGMA units.
s = 5.18 (m, 1H, CH- C=O), 4.82 (m, 2H, CH2-C=O), 3.94-4.14(m, CH2,
CH2-O-C=O), 3.4-3.8(m, CH~20), 1.58 (s, 3H, CH3), 1.6-1.9(m,CH2),
0.7-1.3(s, CH3).
s
c:('0
"§ 3
o
.0
-c
\
6
1
7 85
Retention time I minutes
Figure 2-4. GPC chromatographs for polymers (see Table 2-1) in
chloroform eluent.
The GPC results showed a decrease in retention time of PLGA-PEGMA
in comparison to the GPC curve of the first block (BSTSE-PLGA). This
was a preliminary indication that the second block (PEGMA) was
inserted to the polymer chain between the trithiocarbonate unit and
PLGA.
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2.5.2. Fabrication of nanoparticles and characterisation
Conventionally, PLGA nanoparticles have been prepared by double
emulsion technique W/ D/W (water in oil in water) to encapsulate
hydrophilic molecules such as DNA and protein. High shear forces (e.g.
homogenisation or sonication) that have been utilised to obtain particles
sizes in the nanometre size range have been reported to have a negative
effect on the integrity of the molecules (shear-induced degradation) and
resulted in compromising their biological activity.
Recently, Csaba et al46, have introduced a modified double emulsion
technique to encapsulate plasmid DNA under a mild conditions in
which nanoparticles are formulated without using any shear forces. In
addition to a modified double emulsion technique, they have also
prepared blend nanoparticles composed of PLGA and PED derivatives
using the modified emulsion technique. Mixing of PED with PLGA
polymer in the initial steps of the emulsion technique was believed to
provide a protecting environment for DNA during nanoparticle
preparation and release.
However, these types of nanoparticle showed low encapsulation
efficiency and lacked the stealth properties which are necessary to
prolong circulation time and prevent early elimination from blood
MES.
Based on these requirements, in this chapter of the thesis, a new
nanoparticle composition was formulated which was composed of
PLGA blended with Jeffamine. PLGA: Jeffamine blended nanopartic1es
were compared to classical PLGA nanopartic1es. The DNA
encapsulation efficiency of this new nanopartic1e composition was also
studied in addition to adsorption of two different amphiphilic block
copolymer on the surface of the blended nanoparticle to formulate
1/ core-shell" nanopartic1es.
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2.5.2.1.Fabrication of PLGA nanoparticles (NP1, NP2)
Physicochemical characteristics (particle size, surface charge and
morphology) were studied for two different types of nanoparticle
formulation, PLGA nanoparticles NPI and PLGA: Jeffamine blended
nanoparticles NP2. These two formulations were different mainly in
their matrix composition; the matrix of NPI was only composed of
PLGA polymer whereas the matrix of NP2 contained a mixture of
PLGA and Jeffmaine polymers. Both types of nanoparticles were
formulated using double emulsion technique (schematic illustration of
this technique is shown in Figure 2-5).
(A)
................_------------------ .
Aqueous phase 0(eDNA solution)
Organic phase _ .,
----- ., ., .;
(DCM + PlGA andl or Jeff:·~i~~;·-· ·-·--.. -III
A
cDNA solution added into organic phase
to form primary emulsion
(B)
Polar phase (Ethanol)
Primary emulsion added to ethanol
( polar phase); precipitation of PLGA
(C)
B Evaporation of organic solvent;
formation of nanoparticles
i Primary emulsion (W/O)
ii Secondary emulsion (W/OIW) c
Figure 2-5. Preparation of nanoparticles using double emulsion
technique.
In (A) cDNA in water is added into dichloromethane (DCM) containing
either PLGA alone or with Jeffamine.
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Addition of this primary emulsion to ethanol (B) results in collapse of
the hydrophobic core as the DeM partitions into the bulk phase.
Solvent evaporation (e) yields the final nanoparticles.
In order to compare the properties of PLGA based nanopartic1es and
PLGA: Jeffamine blended nanopartic1es a double emulsion technique
was utilised as illustrated in Figure 2-1. To accomplish this, an aqueous
solution (in this case only PBS buffer solution was used) was added into
dichloromethane (organic phase) containing only PLGA (NP1) or PLGA
and Jeffamine (NP2). A mild vortex was needed to form the primary
emulsion which consisted of water droplets suspended in the organic
phase of DeM. Owing to the hydrophilic nature of Jeffamine, it is most
likely that some of the polymer was around the water droplets.
Addition of the primary emulsion to a more polar phase (ethanol)
resulted in the immediate formation of nanopartic1es as
dichloromethane diffused from the inner oil phase to be replaced by
ethanol, a non-solvent for the PLGA block. Owing to rapid precipitation
of PLGA polymer in the polar phase (ethanol), the diffusion and escape
of Jeffamine from primary emulsion into external phase is believed to
be less likely to occur.
The final nanopartic1es of NP1 and NP2 were obtained after
evaporation of the organic solvent under the same conditions and these
particles were of low size polydispersity, but the surface charges were
slightly different. In NP1 nanoparticles the zeta potential was slightly
higher presumably due to surface negative charges owing to a high
presence of PLGA carboxylic groups on the surface (Figure 2-8).
Whereas in NP2 the zeta potential value was slightly less negative
which may have been because some of Jeffamine polymers (which carry
protonated amines) were localised at the surface and masking the
negative carboxylic groups of the PLGA polymer.
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Several batches of nanoparticles were prepared via this double
emulsion technique and their size distributions are shown in Figure 2-6.
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Figure 2-6. Mean Particle Size of nanoparticles prepared by double
emulsion technique: NPI represent PLGA nanoparticles, NP2
nanoparticles composed of PLGA: Jeffamine blend, NP3 represent
cDNA loaded NP2 nanoparticles, NP4 and NP5 represent NP2
nanoparticles surface modified with PLGA-PEGMA475 and PEGMA-
pDMAEMA diblock copolymers respectively.
As shown in Figure (2-6) the mean size of NP2 was slightly larger than
NPI although both were prepared via the same method and under the
same conditions, (p = 0.629, there is no significant difference between
the sizes of NPI and NP2). The difference in mean size may have
resulted from incomplete mixing of hydrophilic Jeffamine and
hydrophobic PLGA in the matrix and also Jeffamine polymers were
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more likely to have entrapped some water molecules in the matrix of
the nanoparticles resulting in a slight increase in the size of NP2.
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NPl
Figure 2-7. Schematic illustration of different PLGA based nanoparticle
formulations.
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Figure 2-8. Mean zeta potential values of nanopartic1es prepared by
double emulsion technique: NPl represents PLGA nanopartic1es, NP2
nanopartic1es composed of PLGA: Jeffamine blend, NP3 represent
cDNA loaded NP2 nanoparticles, NP4 and NP5 represent NP2
nanopartic1es surface modified with PLGA-PEGMA475and PEGMA-
pDMAEMA diblock copolymers respectively.
As it shown in (Figure 2-7), the surface of NP2 nanoparticles was coated
with PLGA-PEGMA475and PEGMA-PDMAEMA475and generated NP3
and NP4 respectively. The method of coating involved simple physical
adsorption on the surface. Physical adsorption of the diblock
copolymers were successful and confirmed by measuring the surface
charge (zeta potential). As shown in (Figure 2-8), the zeta potential
values changed from -30 mV to near zero owing to the formation of
hydrophilic shell of PEGMA polymer chains around the surface of the
nanopartic1es.
2.5.2.2.Preparation of Calf Thymus loaded nanopartic1es (NP3)
The encapsulation of Calf Thymus DNA in PLGA: Jeffamine blended
nanoparticles (NP3) resulted in slight change in the hydrodynamic
diameter and zeta potential value (Figure 2-6, 2-8). The hydrodynamic
diameter size of NP2 increased from 226 nm to 261 nm upon the
incorporation of Calf Thymus DNA in the matrix of the nanopartic1es.
Similar results have been shown by other groups where the size of the
blended matrix nanoparticles increased upon encapsulation of plasmid
DNA. This effect could be explained by the fact that, as compared to
other polymers such as poloxamers or poloxamines, Jeffamine consists
of a long PED backbone with two amine groups at the end of each
chain. This particular characteristic of Jeffamine may lead to different
kind of interaction with the negatively charged DNA, hence different
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architectural organisation of Calf Thymus DNA and Jeffamine polymer
may occur.
With regard to surface charge of Calf Thymus loaded PLGA: Jeffamine
blended nanoparticles (NP3), a slight increase in zeta potential value
has been observed comparing to unloaded PLGA: Jeffamine blended
nanoparticles (NP2) after incorporation of the Calf Thymus DNA in the
nanoparticles. Similar effects have been reported by other groups
where the surface charge of the nanoparticles became more negative
upon loading with Plasmid DNA. This result could be explained by the
fact that the blended polymers may have different orientations owing to
the presence of Calf Thymus DNA, in addition to that , during the
addition of the primary emulsion to a more polar phase (ethanol),
hydrophilic molecules of DNA in the aqueous droplet may diffuse
from the droplet into external phase and some of these may entrap on
the surface as a result of rapid precipitation of PLGA polymers in non-
solvent ethanol during the solvent diffusion and particles formulation.
The combination of the PLGA and Jeffamine polymers with the double
emulsion method resulted in efficient encapsulation of Calf Thymus
DNA. The extent of incorporation was 84.4 % of the DNA in solution,
corresponding to a theoretical loading of 0.4%with respect to the mass
of polymer in the emulsion (- 4ug DNA per mg of polymer).
Recovery of DNA from the nanoparticles following treatment of the
dried copolymers with 0.5%N NaOH indicated that 3.5ug/mg of Calf
Thymus DNA had been encapsulated as determined by UV
spectroscopy and comparison to standard absorption values at 260nm.
Itmust be noticed that cDNA was loaded on NP3 only and it was not
incorporated into NP4 or NP5, as the latter nanoparticle systems were
designed to test the surface fuctionalisation. These systems were tested
separately to avoid the influence of surface fuctionalisation on
encapsulation efficiency of cDNA and vice versa.
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Figure 2-9. Calibration of Calf thymus DNA in water.
2.6. Surface modification of PLGA: Jeffamine blended nanoparticles
with diblock copolymers (NP4 and NP5)
The negative surface charges of uncoated PLGA nanoparticles (NPl),
PLGA: Jeffamine blended nanoparticles (NP2) and Calf Thymus loaded
PLGA: Jeffamine nanoparticles (NP3) can provide weak colloidal
stability through charge-charge repulsion mechanism. However, to
make these particles suitable for intravenous administration, the surface
of the particles should be coated with hydrophilic polymers such as
poly (ethylene glycol). Uncoated particles are easily recognised by
mononuclear phagocyte (MPS); this can be attributed to the
hydrophobic properties of the particle forming polymers that favour
the adsorption of blood components, which is a step before elimination
from the blood.
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Physical adsorption of PEG based polymers have been used to coat the
surface of PLGA based nanoparticles for two main reasons, first to
provide steric stabilisation to the particles (i.e. preventing them to
interact with each other) and secondly to provide a protective
hydrophilic stealth to prevent the interaction of these hydrophobic
particles with blood components such as proteins and enzymes.
To accomplish this, two different diblock copolymers have been
prepared, PLGA-PEGMA475 and PEGMA-pDMAEMA diblock
copolymers. Owing to the high encapsulation efficiency of PLGA:
Je££amineblended nanoparticles (NP2), as discussed in section 2.8.2 of
the chapter two, the (NP2) formulation has been selected to be used for
surface modification with these two diblock copolymers separately.
Using the double emulsion technique, after the formation of
nanoparticles in the polar phase (ethanol), the particles were diluted
with (1% wIv) solution of PLGA-PEGMA475or PEGMA-pDMAEMA
diblock copolymers in 1mM PBS buffer solution. This resulted in the
formation of coated nanoparticles NP4 and NP5 respectively.
Considering the amphiphilic nature of these two diblock copolymers,
some of them may form micelles in aqueous solution. This has been also
reported by another group thus further study is required to investigate
how these polymers behave during the physical adsorption process. In
a similar way the nanoparticles were subjected to the steps of washing,
centrifugation and passing through PD-10 desalting column to remove
unabsorbed diblock copolymers.
The mechanism of adsorption of PLGA-PEGMA475copolymers varies
from PEGMA-pDMAEMA copolymer. The PLGA-PEGMA475
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copolymer consists of a hydrophobic block of PLGA polymer linked
with a hydrophilic block of PEGMA475,whereas the PEGMA-
pDMAEMA copolymer consists of one positively charged block linked
to a hydrophilic PEGMA block. Owing to the difference in nature of the
diblock copolymers, their physical adsorption mechanism varies, as
follows.
In the case of PLGA-PEGMA475,the hydrophobic PLGA block anchors
onto the surface of PLGA nanoparticles via hydrophobic interaction
and allows the hydrophilic PEGMA block to be projected toward the
aqueous medium, thus overlying the surface of the PLGA based
nanoparticles. Whereas in the case of PEGMA-pDMAEMA, the
pDMAEMA block, which is positively charged (owing the presence of
amine groups), interacts with the negative surface charges of PLGA
based nanoparticles, thus masking the surface of the nanopartic1e via
electrostatic interactions.
Surface coating of (NP2) nanopartic1es with PLGA-PEGMA475 or
PEGMA-pDMAEMA diblock copolymers have resulted in slight
increase in the particle size but substantial decrease in negative surface
charges ( Figure 2-6, 2-8). The size of particles increased from 226run to
251 run and 276 run after the adsorption of PLGA-PEGMA475 and
PEGMA-pDMAEMA respectively to generate (NP4) and (NP5)
formulation.
The sizes of (NP4) were slightly smaller than those of (NP5), maybe
owing to the fact that the positive charge of pDMAEMA can also attract
more water molecules and thus expand the hydrodynamic diameter. In
addition to that, the hydrophobic interaction of PLGA block with the
surface of the nanoparticles is stronger than the electrostatic interaction
of pDMAEMA, thus the polymer chains are more compacted on the
surface.
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In respect to surface charges after physical adsorptions of the diblock
copolymers, the zeta potential value of (NP2) nanoparticles changed
from - 30 mV to -1.2 mV (NP4) and +4 mV (NP5) for adsorptions of
PLGA-PEGMA475 and PEGMA-pDMAEMA diblock copolymers
respectively. The overlaying of the nanoparticles with these
copolymers resulted in the formation of the so called "core-shell"
structure.
The TEM micrographs of NP2, NP4 and NP5 (3% phosphotungstic acid
negative staining) showed the particles to be spherical in shape and
particle sizes determined from TEM micrographs were slightly smaller
than the hydrodynamic diameters recorded by dynamic light scattering
(DlS), most likely due to air-drying of the nanoparticles on the copper
grid leading to collapse of hydrated (PEGMA475)segments on the outer
shells. (Figure 2-10).
The TEM micrographs of uncoated nanoparticles NP2 appeared to have
higher polydispersity and the particles seemed to be aggregated upon
drying on the copper grid. Meanwhile, the nanoparticles of NP4 and
NP5 were of better defined spherical shape with low polydispersity and
the nanoparticles were not aggregated upon drying on the grid. This
particular characteristic of NP4 and NP5 can be explained by the fact
that the surface of the particles were overlaid by PLGA-PEGMA475 and
PEGMA-pDMAEMA diblock copolymers which provided sterlc
stabilisation and thus prevented the particles from interacting with each
other, hence no aggregation occurred.
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Figure 2-10. Transmission Electron Micrographs (TEM) of a) control
(PBS buffer added onto the copper grid), b) NP2 of PLGA: Jeffamine
blend), c) NP4 (NP2 nanoparticles surface modified with PLGA-
PEGMA47S),d) NP5 (NP2 nanoparticles surface modified with PEGMA-
pDMAEMA).
2.7. In vitro release profile of Calf Thymus DNA from nanoparticles
(NP3)
Generally, the releases of hydrophilic molecules such as DNA or
proteins from biodegradable nanoparticles follow a mechanism in
which the degradation of the polymers leads to erosion of the matrix.
This in turn results in formation of an aqueous channel through which
the hydrophilic molecules are diffused out.
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In conventional PLGA nanopartic1es, the releases of encapsulated
molecules (e.g. DNA, protein) follow a tri-phasic release pattern. This
characterised by an initial burst release owing to the presence of loosely
associated DNA with the surface. Surface localisation of the molecules
may occur in the organic solvent evaporation phase which causes the
molecules to escape towards the external medium.
The second phase is characterised by little or no release until significant
degradation of PLGA and erosion of the matrix polymer occurs. Then
this is followed by a third phase consisting of controlled release of the
macromolecules from the matrix through generated aqueous channels.
Upon degradation of the PLGA polymer, an acidic environment is
generated which affects the integrity of encapsulated DNA or protein.
To overcome this problem, blended matrix nanoparticles consisting of
PLGA polymer physically mixed with Jeffamine polymer have been
prepared. The release profiles from the blend nanoparticles were
investigated. The in vitro release experiment showed that incorporation
of Jeffamine in PLGA nanoparticles has a significant effect on the
release pattern of the encapsulated molecules.
As can be observed in (Figure 2-11), the blended matrix nanoparticles
(NP3) provided continuous release of eDNA. Similar results have been
observed by Csaba et al, in which different blended nanoparticles based
on PLGA and PEO derivatives were prepared and the release of DNA
investigated and shown to be of a similar pattern.
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2.8.Conclusion
In conclusion, it has been shown that it is possible to prepare PLGA
nanoparticles with higher encapsulation efficiency and an improved
release profile using a blend of PLGA with Jeffamine polymer, (up to
84.4% encapsulation of DNA compared to only 44.1% reported for
blended PLGA: Tetronic 904 by Csaba et al), (table 2-II). The
combination of double emulsion technique and this new blend system
also generated particles within the nanoscale range. Moreover, the
surface of the particles were modified with highly hydrophilic polymer
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(PEGbased polymer) in order to provide the particle system with steric
stabilisation, thereby reducing the surface charge, which can interact
with blood component upon intravenous injection.
Table 2-11. Comparisons of PLGA nanoparticles blended with
different excipients, (mean ± S. D., n = 3)
Entry Type of exclplents Theo. DNA loading (%) Diameter Size E.E.(nm) (%)
1 without 0.4 234 ± 13 32.9
2 Pluronic F68 0.4 183 ± 6 35.2
3 Pluronic L121 0.4 217 ± 5 31.3
4 Tetronic 908 0.4 269 ± 11 32.0
5 Tetronic 904 0.4 161 ± 7 44.1
6 Jeffamine 1500 0.4 261 ± 6 84.4
The advantage of incorporating Jeffamine polymer (Poly (ethylene
glycol) bis (3-aminopropyl) terminated) over other amphiphilic
copolymers such as poloxamers and poloxamines lies in the ability of
this polymer to display accessible low positive charges at the end,
which, perhaps, enable them to bind with DNA through electrostatic
interaction. Owing to the good miscibility of Jeffamine within the
hydrophobic matrix of PLGA nanoparticles, it was possible to achieve
higher encapsulation efficiencies and an improved release kinetic.
Therefore, PLGA blended nanoparticles can be introduced as potential
carriers for DNA delivery systems.
Despite the successful results shown for higher encapsulation efficiency
and improved release profile of DNA using blended PLGA: Jeffamine
particulate system, there is still concern over surface fuctionalisation of
the nanoparticles using physical adsorption of PEG-based block
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copolymers. This type of physical surface coating is very likely to be
displaced, for example by blood components upon intravenous
injection, which may lead to disturbance of colloidal stability and
eventually aggregation of the particles.
Therefore, there is a clear indication for the development of more
advanced nanoparticulate system of core-shell type structure, using
block copolymers, in which the outer shell is covalently linked to the
core; hence the colloidal stability can be preserved upon mixing with
other components.
Since the discovery of controlled living polymerisation (CLP)
techniques, access to well-defined block copolymers has dramatically
increased. To prepare PLGA based block copolymers that can be used
to fabricate core-shell type nanoparticles, we have, therefore, focused
on the synthesis of PLGA-PEGMA475 type copolymers via combination
of ring opening polymerisation (ROP) and reversible addition
fragmentation transfer (RAFT). The advantage of this synthetic route
lies in the flexibility of the system to obtain well-defined biocompatible
block copolymers. The detail of synthesis PLGA based block copolymer
is discussed in chapter three.
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Chapter3
Synthesis of biodegradable and
biocompatible co-polymer micelles
3. Introduction
Recently considerable interest has been paid to the synthesis of block
copolymers with an amphiphilic nature. The difference in solubility of
the hydrophobic to hydrophilic block leads to self-assembly in aqueous
media to form polymeric micellest-'. In the presence of water, the
hydrophobic segments tend to decrease their contact with water,
because of their insolubility, and are attracted toward each other. In the
mean time, the hydrophilic segments separate from each other and
interact more with water molecules to form an outer shell that covers
the hydrophobic core'.
The biomedical applications of these block copolymer micelles have
rapidly expanded into novel carrier systems for targeting of poorly
soluble drugs5-7. These polymeric micelles as drug delivery carriers
offer several unique characteristics owing to the submicron size range,
Le. escape from renal excretion, passive targeting to solid tumours, and
prolonged circulation in the blood stream. Moreover, they have fairly
good thermodynamic stability in aqueous media due to the relatively
low critical association concentration (CAC) 8-11. Another advantage of
polymeric micelles is their ability to encapsulate large amounts of
insoluble drugs in the hydrophobic core.
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The distribution of these polymeric micelles in the body may depend on
their size and surface charge12-14.
In this regard, the ability to control the size and surface charge of these
carriers has a crucial effect on in vivo therapeutic efficacy12,14.Critical
micelle concentration (CMC) in these polymers can be defined as that
concentration below which only single chains are present but above
which both single chains and micellar aggregates can be found. Many
techniques are available for the determination of critical micelle
concentrations. In principle, one can use any physical property which
depends upon the particle size or the number of particles. Such
properties as the surface tension, electrical conductivity, osmotic
pressure, interfacial tension, or light scattering as a function of
concentration have been used for this purpose. Critical micelle
concentrations can also be determined from the change in the spectral
characteristics of some dye probes added to the surfactant solution15-17.
Many amphiphilic block copolymer micelles being studied for drug
delivery applications have a hydrophilic block to form the outer shell;
perhaps inmost cases the hydrophilic block consists of biocompatible
poly (ethylene oxide)18-20.The presence of PEO blocks on the outer shell
of the polymeric micelles has been shown to prevent opsonisation and
subsequent recognition by macrophages of the reticuloendothelial
system (RES)21.This, in tum, provides a prolonged blood circulation,
which enables the micelles to localise passively in tissues and organs
before being eliminated from the body.
The hydrophobic core of the micelles can be utilised as a reservoir for
encapsulation of various therapeutic or diagnostic agents such as
hydrophobic drugs20•
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Designing the core of the polymeric micelles with a biocompatible
polymer is an extremely attractive option for drug delivery applications
considering the safety of the system.
There are several biocompatible and/ or degradable hydrophobic
polymers that have been used to design the core of the polymeric
micelles, among these polymers are poly (propylene oxide) (PPO)22.23,
poly (p-benzyl L-aspartate) (PBLA)24,poly (y-benzyl-L-glutamate)
(PBLG)25,polycaprolactone (PCL)26,poly (lactic acid) (PLA)27,and poly
(D, L-Iactide) (PDLLA)28.
Generally, the size of spherical block copolymer micelles range in size
from 10 nm to 100 nm29, and, as mentioned earlier, the size of the
micelles is directly related to the circulation time and biodistribution.
Smaller sizes improve the circulation time as well as decreasing the
chance of uptake by RES.
Therefore, those factors determining the size of the polymeric micelles
are extremely important for the overall efficiency as a drug delivery
system. The length and molecular weight of the core-forming block
polymer is a crucial factor that not only determines the size of the
micelles but also plays a role in achieving efficient encapsulation of the
hydrophobic drug molecules.
The term "loading efficiency" has been used to determine the amount
of the drug that can be incorporated into the core of polymeric micelles.
There are several factors that affect loading efficiency, which include
total molecular weight and concentration of the copolymer, the nature
and concentration of the solute (drug), the length and nature of the
corona forming block, and the method of preparation of the delivery
system22.Depending upon the ratio of hydrophilic to hydrophobic
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The type of structure formed is related to the inherent curvature of the
molecule, which can be estimated through calculation of its
dimensionless packing parameter, p.
Materials based on poly (ethylene glycol) (PEG), poly (lactic acid)
(PLA), poly (glycolic acid) (PGA) have been widely used in various
biomedical applications owing to their biocompatibility and
biodegradability. The syntheses of block copolymers derived from
these materials have been extensively explored for use as drug delivery
systemss- 32.Depending on the molecular weight of the blocks, PEG-
PLA copolymer can form micelles in aqueous solutions because of their
amphiphilic nature. In addition, they can also be used to produce
nanopartic1es with solid cores, enabling them to encapsulate drugs with
widely differing solubility properties. The "stealth" properties of
PEG33,34,which have been utilised to enhance pharmaceutical profiles
(e.g. prolong circulation time) of therapeutics ranging from small
molecules to proteins, can be combined with controllable
biodegradability of PLA/PGA co-polymers (pLGA) to produce highly
effective carriers for a variety of drug compounds=.
Conventionally, diblock copolymers based on biodegrable and
biocompatible materials such as poly (L-Iactic acid) (PLA), poly (DL-
lactic-co-glycolic acid) and polyte-caprolactone) (PCL) have been
prepared by ring opening polymerisation using a hydrophilic PEG
segment as macro-initiator to produce an A-B type di-block copolymer
structure.
Hyuk Sang Yoo et al, described the synthesis of diblock copolymer
composed of poly(DL-lactic-co-glycolicacid) (PLGA) and polyethylene
glycol (PEG)which self assemble in aqueous media to form a micellar
structure.
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The diblock copolymer PLGA-PEG was prepared by Ring opening
polymerisation (Rap) using monofunctional PEG (using a fixed
molecular weight 2kDa) and tin (II) (2-ethylhexanoate) as macro-
initiator and catalyst, respectively. The hydrophobic drug doxorubicin
(DaX) (antitumor agent) was encapsulated in the core of the micelles
using conjugation technique36.
Similarly, Xintao Shuai et al explored the synthesis of diblock
copolymers of poly (e-caprolactone) (PCL) and monomethoxy poly
(ethylene glycol) (MPEG) with various compositions. They have shown
that the amphiphilic block copolymers peL-PEG self-assembled into
nanoscopic micelles and their hydrophobic cores used to encapsulate
doxorubicin (OOX). In the same manner, the diblock copolymers PCL-
PEG with various compositions were prepared by Rap in which the
MPEG (fixed molecular weight) was used as macro-initiator in the
presence of tin (II) (2-ethylhexanoate) as catalyst'".
However, optimisations of the carrier system based on PEG and
PLA/PGA co-polymers to fine tune the pharmaceutical carriers are
difficult and limited to the availability of PEGs with appropriate
functional chain ends and ranges of molar mass. In addition,
functionalisation of the PEG-PLA/PGA carriers with monofunctional
PEG or heterobifuntional PEG is difficult and very costly.
Alternatively, PEG -methacrylate (PEGMA), can be synthesised via a
variety of routes, particularly via living radical polymerisation
techniques which allow for fine manipulation of the properties through
controlling the molecular weight of the block.
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Since the discovery of living free radical polymerisation methods, block
copolymers are now more easily accessible with control over the
molecular weight of the block copolymer and the ratio between the
blocks. This can be obtained with narrow molecular weight
distribution. The main and widely-used types of living free radical
polymerisation techniques are atom transfer radical polymerisation
(ATRP)and reversible addition fragmentation transfer (RAFT)38-42.
The usage of controlled radical polymerisations, primarily ATRP43-45
(Atom Transfer Radical Polymerisation) and RAFT46,47 have enabled
PEG-methacrylate and co-polymers with exciting new properties to be
produced= 49. Here is shown a combination of ring-opening
polymerisation with RAFT agent initiated growth of PEG-methacrylate
to yield co-polymer micelles with controllable properties, and with
promise as drug-encapsulation and release systems.
o 0
.....)l )l Sn(II), 140 Qc
I" -0 + (0 -----
O~ Oy ~Sls-",oH
o 0 V
BSTSE
D,L·Lactic acid
Glycolic acid
Figure 3-2. Synthesis of PLGA polymer, PLGA-PEGMA block
copolymer and assembly into micelles.
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3.1. Aims and Objectives
The primary aim of this chapter was to utilise the advanced
controlled/"living" polymerisation techniques to synthesize well-
defined block copolymers to be used in fabrication of core-shell type
nanostructures as drug delivery modalities.
Objectives and Hypotheses:
Objective one: To synthesize a series of biocompatible PLA/PLGA-
PEGMA block copolymers, combining ring opening polymerisation
(ROP) with Radical Addition Fragmentation Transfer (RAFT) techniques. And
also, preparation of micellular type nanostructures, using the synthesised block
copolymers.
Hypothesis: Amphiphilic block copolymers based on PLA/PLGA-
PEGMA can self assemble in aqueous medium to form core-shell type
nanostructures. The hydrophilic chains will be extended in the aqueous
medium to provide colloidal stability, whereas the core will be served
as a reservoir to encapsulate hydrophobic drug molecules.
Objective two: To study the release profile of carboxyfluorescein as
chosen hydrophobic molecules from fabricated micellular
nanostructures, and to investigate the effect of molecular weight of the
amphiphilic PLA/PLGA-PEGMA block copolymers on the release
profile pattern of carboxyfluorescein.
Hypothesis: Hydrolytic degradation of PLA/PLGA blocks in the
micellular nanostructure allows the release of carboxyfluorescein from
the micelles in a controlled release manner. The release profile of
carboxyfluorescein can be fine tuned by changing the molecular weight
of the copolymers as well as the diameter size.
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3.2. Materials and Methods
3.2.1. Instrumentation
NMR (1Hand 13C)spectra were recorded on a Bruker 400 spectrometer
at 399.8 MHz (1H) and 100.5 MHz (13C)using CDCh as solvent.
Molecular weights and molecular weight distributions were
determined using a Varian/Polymer Laboratories GPC-SOinstrument
with triple detection (RI, viscometry and MALLS).The samples were
chromatographed using chloroform as solvent with a flow rate of 1mL
mirr! and the molecular weights were calibrated to polystyrene
standards. Dynamic light scattering (DLS) data were obtained on
Malvern Zetasizer 2000 and Viscotek DLS instruments. Particle size
distributions via DLSwere derived from correlation functions obtained
using OmniSIZE 2.0 software. Diffusion coefficients and hydrodynamic
radii were calculated using the Stokes Einstein equation assuming
particles were spherical and non-interacting.
Distributions shown are based on particle masses. Fluorescence spectra
were recorded using a Varian Cary Eclipse fluorescence
spectrophotometer equipped with a Peltier apparatus for temperature
control.
DL- Lactide and glycolide were obtained from Purac biochem. The
monomers were recrystallised from ethyl acetate prior to use. Poly
(ethylene glycol) methyl ether methacrylate (Mw 475) and tin (II) 2-
ethylhexanoate were purchased from Sigma. The radical initiator, N, N-
azobis (isobutyronitrile) (AIBN, 98%, Aldrich) was recrystallised from
ethanol. Solvents were all of HPLC grades. All other reagents were
purchased from Fisher Scientific or Aldrich and used as received.
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3.2.1.Polymer syntheses
3.2.1.1Synthesis of BSTSE (RAFTagent) (1)
Synthesis of 2-(Benzylsulfanylthiocarbonylsulfanyl) ethanol (BSTSE).To
a solution of potassium hydroxide (13g, 250mL, 0.23moles) was added
20mL of 2-mercaptoethanol (0.23moles). 30mL of carbon disulfide was
then added dropwise and the orange solution was stirred for 5 hours.
The mixture was then heated to 80 °C and 39.6 g benzyl bromide (0.23
moles) was added. After reaction for a further 12 hours, the mixture
was cooled and the aqueous phase extracted with chloroform (3 x 200
mL). The organic layers were then dried over anhydrous magnesium
sulphate, filtered and the solvent evaporated. The product was purified
by passing through a silica column with hexane/ ethyl acetate as eluent
(7:3)to yield a yellow liquid (70%yield).
3.2.1.2.Synthesis of BSTSE-PLApolymer (P 1)
PLA, Poly (DL-Iactide) was synthesised by ROP (ring opening
polymerisation) using BSTSEas initiator. First, DL-Iactide (2.8g, 0.02
moles), and BSTSE (0.15g, 0.0005 moles) were added to a
polymerisation tube and purged with argon several times before being
heated in an oil bath to 80 OCand purged with argon for a further two
hours. The reaction mixture was then heated to 140 OCin order to
conduct the polymerisation in the melt phase. At this point, tin 2-
ethylhexanoate (0.022g,0.00005moles) was added, and the mixture was
stirred for 24 hours. The polymerisation tube was then removed from
the oil bath and cooled down to room temperature. The polymer was
recovered by dissolution in THF and precipitated in methanol (this was
repeated three times to remove unreacted monomer). The precipitate
was filtered and dried under reduced pressure to yield a brown-yellow
product (yield 90%). The molecular weight of the polymer and
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polydispersity index was determined by gel permeation
chromatography using chloroform as eluent.
3.2.1.3. Synthesis of BSTSE-PLGA polymer (P 2)
PLGA, Poly (DL-Iactide-co-glycolide) was synthesised by an exactly
analogous route to synthesis of Pl. First, DL-Iactide (1.6g, 0.01 moles),
glycolide (1.3g, 0.01moles), and BSTSE(0.3g, 0.001moles) were added
to a polymerisation tube and purged with argon several times before
being heated in an oil bath to 80 <C and purged with argon for a further
two hours. The reaction mixture was then heated to 140 <C in order to
conduct the polymerisation in the melt phase. At this point, tin (II) (2-
ethylhexanoate) (0.049g,0.0001moles) was added, and the mixture was
stirred for 24 hours. The polymerisation tube was then removed from
the oil bath and cooled down to room temperature. The polymer was
recovered by dissolution in THF and precipitated in methanol (this was
repeated three times to remove unreacted monomer). The precipitate
was filtered and dried under reduced pressure to yield a brown-yellow
product (yield 95%). The molecular weight of the polymer and
polydispersity index was determined by gel permeation
chromatography using chloroform as eluent.
3.2.1.4. Synthesis of PLA-PEGMA copolymer (P 5)
The PLA-PEGMA block copolymers were prepared by free radical
polymerisation mediated by the macro-RAFT agent (BSTSE-PLA).
BSTSE-PLA(0.66g,0.00012moles), Poly (ethylene glycol) methyl ether
methacrylate (Mn 475 1.46g, 0.003 moles) and AIBN (0.004g, 0.00002
moles) were added into a round bottom flask, the flask purged with
argon several times, followed by addition of anhydrous THF (5ml)
under an argon atmosphere.
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The polymerisation mixture was stirred until the components were
completely dissolved. The mixture was then heated in an oil bath to 80
OCand stirred for 24 hours. The polymerisation product was dissolved
in THF and reprecipitated three times in methanol, and the filtrate was
dried under reduced pressure (yield 8S%).
The product was characterised by IH-NMR. GPC with chloroform as
the eluent was used to determine the molecular weight and
polydispersity of the final block copolymers.
3.2.1.5. Synthesis of PLGA-PEGMA copolymer (P 6)
The PLGA-PEGMA block copolymers were prepared by exactly
analogous route to PS. BSTSE-PLGA (0.66g, 0.00012 moles), Poly
(ethylene glycol) methyl ether methacrylate (Mn 47S1.44g, 0.003 moles)
and AIBN (0.004g, 0.00002 moles) were added into a round bottom
flask, the flask purged with argon several times, followed by addition
of anhydrous THF (Sm1) under an argon atmosphere. The
polymerisation mixture was stirred until the components were
completely dissolved. The mixture was then heated in an oil bath to 80
OCand stirred for 24 hours. The polymerisation product was dissolved
in THF and reprecipitated three times in methanol, and the filtrate was
dried under reduced pressure (yield 8S%). The product was
characterised by IH-NMR. GPC with chloroform as the eluent was used
to calculate the molecular weight and polydispersity of the final block
copolymers.
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3.2.1.6. Preparation of Blank PLGA-PEGMA micelles
The PLA and PLGA-PEGMA polymeric micelles were prepared as
follows: copolymer (5Omg) was dissolved in acetone (3ml), and then
distilled water (10ml) was added to the solution under stirring. Mixing
was continued in order to facilitate evaporation of the acetone.
Residual acetone was then completely removed by rotary evaporation
under reduced pressure. The remaining aqueous solution was slightly
cloudy, confirming the formation of micelles. The final micelle
concentration was 5mg.mL-l. The mean hydrodynamic radii of the
polymeric micelles were determined by dynamic light scattering (DLS).
3.2.1.7. Determination of critical micelle concentration (CMC) of
PLGA-PGMA micelle
The CMC of PLGA-PEGMA copolymer micelles was determined using
pyrene as a hydrophobic fluorescent probe, as previously described.v
Briefly, an aliquot of pyrene solution (6 x 10-6 M in acetone, 1mL) was
added to 6 vials, and the acetone evaporated at 60 CC. The aqueous
solutions containing copolymer of various concentrations were then
added (10 mL) to the vials containing pyrene. The final concentration of
pyrene in each vials was 6 x 10-7 M. The solutions were kept at room
temperature for 24 h to reach the pyrene solubility equilibrium in the
aqueous phase. Emission was carried out at 390 nm, and excitation
spectra were recorded over the range 240 - 360 nm. From the pyrene
excitation spectra, the intensities at 337 nm were analysed as a function
of the polymer concentrations. The CMC value was determined from
the intersection of the two curves.
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3.2.1.8.Dynamic light scattering
The PLA and PLGA-PEGMApolymeric micelles (PS,PS)were prepared
as mentioned before. The micelles solution was filtered with a 1 pm
pore-size filter to eliminate dust contamination. A 60 pl. aliquot was
added in a quartz cuvette and the sample was examined on a Viscotek
802 dynamic light scattering instrument. Scattered light coming from a
50 mW laser source (830 nm) was recorded from an internal light
detector aligned at 9oo from source. From standard auto correlation
functions, measured correlation coefficients were related to
hydrodynamic radii at varying temperatures via the Stokes-Einstein
equation, RH = KbT/6mt D, where RH is the hydrodynamic radius, kb is
the Boltzmann constant, T is the temperature and 1'/ is the viscosity of
the solvent. The size distribution of the scattering particles was
determined by the average mass number of the particles.
3.2.1.9.Microscopy
Scanning Electron Microscope samples were prepared by placing a
droplet of an aqueous micelles solution (pS, PS) on a carbon grid and
left to dry for a few minutes at room conditions. Standard plasma
coating with gold was performed for two minutes before sample
examination.
3.3. Release time profile of carboxyfluorescein from PLGA-PEGMA
micelles
PLGA-PEGMA copolymer (200 mg) and carboxyfluorescein (20 mg)
were co-dissolved in acetone (3 ml). The solution was then added
dropwise into lOmL distilled water under stirring. The acetone and part
of the water were then evaporated under reduced pressure.
The micellar solutions were passed through a Sephadex column (PO-lO
Desalting column) to remove excess of un-entrapped
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carboxyfluorescein. The micelle fractions were subsequently put into
500mL distilled water to study the release of the dye over time.
Samples were collected from the media at pre-determined intervals
(correction for volume changes due to sampling were made) and
emission spectra were recorded from 502 nm to 600 nm at excitation
wavelength of 492 nm using fluorescent spectrophotometer
3.4. Cellular uptake of PLGA-PEGMA micelles by 3T3 fibroblast cell
line
3T3 mouse fibroblasts were seeded at a density of 10,000 cells.mL-1 in
24-well tissue culture plastic plates and allowed to attach for 24 hrs in
DMEM supplemented with L-glutamine (2mM),
antibiotic/ antimycotics (penicillin-l00units.mL-1, streptomycin-
O.Img.mlrt, amphotericin B-O.25J,lg.mL-1),foetal calf serum (FCS) (10%).
The cells were then washed with warm PBS and incubated with a
suspension (lOOul) of FITC-Ioaded PLGA-PEGMA micelles (0.2 mg. mL-
1) in HBSS (Hank's Balanced Salt Solution) for 0 min, 15 min, 1hr, 2hr
and 6 hrs at 37°C. Cell monolayers were subsequently washed with
PBS several times prior to microscopy. For nuclei staining, DAPI
standard solution (Invitrogen, 1 drop) was added to each well and the
stain allowed to enter the cells over a period of 10 min. Cells were
imaged using a Leica DM IRB microscope and images were processed
using Leica DC200 using DC viewer, version 3.2.0.0 software.
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3.5. Results and Discussion
3.5.1. Polymer syntheses
In the past decade, poly (lactide) PLA and poly (D, L- Lactide-co-
glycolic) PLCA polymers have been used in various biomedical
applications'", Recently, ring opening polymerisations of these
materials have gained increasing interest because of growing demand
for biocompatible and biodegradable materials. As it has been
mentioned in (chapter 1 Section 1.7.1), ring opening polymerisation can
be conducted by a numbers of metal complexes, however, tin (II) 2-
ethylhexanoate remain the favoured catalyst even for industrial
production as it has approval from the Food and Drug Administration
(FDA). Therefore we have chosen to use tin (II) 2-ethylhexanoate to
catalyse the polymerization of DL, lactide and glycolide monomer.
It has been reported that, in order to obtain PLCA based polymer with
control over the molecular weight and in relatively fast polymerisation
rate, the tin (II) 2-ethylhexanoate catalyst has to be combined with a
protic agent, typically an alcohol. The aim of this work was to
synthesize the diblock copolymer composed of PLCA and PEGMA475.
The latter is considered hydrophilic and also PECMA475 has been
successfully polymerised by RAFT process with good control over the
molecular weight and polydispersities. Therefore, to prepare PLGA-
PEGMA475 diblock copolymer, first, BSTSE (2-
benzylsulfonylthiocarbonylsulfonyl) ethanol was used as a
heterobifuntional RAFT agent. BSTSE has one hydroxyl group (to use
as a protic agent) on the z-group of the trithiocarbonate chain-transfer
agent to initiate the ring opening polymerisation of lactide and
glycolide monomers in the presence of tin (II) 2-ethylhexanoate catalyst.
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Structure of BSTSE (RAFT agent)
Using lactide monomers alone or with glycolide monomer at the ratio
of 50:50 resulted in both PLA and PLGA polymers which were end-
capped with BSTSE as the ring opening polymerisation propagated
from the hydroxyl group of the BSTSE agent. The ratio of 50:50 of
lactide to glycolide monomer was chosen as this is known to give
polymers with a faster degradation rate compared to other ratio of 75:25
of80:20
BSTSE agent and tin (II) 2-ethylhexanoate rapidly generated a complex-
equilibrium forming highly reactive alkoxides from the alcohol.
Varying the concentration of BSTSE agent compared to the
concentration of lactide and glycolide monomers, it was possible to
prepare different molecular weight of PLGA-end capped with BSTSE
and relative good control over the molecular weight distribution (see
Table 3-1,Pl- P4)
The PLA and PLGA-end capped with BSTSEwas isolated by dilution in
THF and subsequent precipitation in methanol. It should be noted that
Methanol is an excellent solvent for the low molecular weight BSTSE
(RAFT agent) (see the structure of BSTSE in Figure 3-2, compound 1)
and lactide and glycolide monomers. So residual BSTSE and unreacted
monomers can be efficiently removed by using this purification
method.
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The RAFT process has been shown to provide an extremely versatile
route to well-defined macromolecular architectures and polymers or
copolymers exhibiting narrow polydispersitiesw P. PEG-methacrylate
monomers have been successfully polymerised using RAFT process
with very good control of the molecular weight distribution.
In this work, PEGMA475monomers were polymerised using PLA,
PLGA-end capped with BSTSEagent.
As a result of this polymerisation a series of amphiphilic block
copolymers were prepared, which are composed of a highly
hydrophilic segment of Poly(ethylene glycol) methyl ether methacrylate
as one block and hydrophobic segment of Poly (lactic acid) or
Poly(D,L-lactic acid-co-glycolic acid) as second block following the
concept of combining two different types of polymerisation, ROP and
RAFT.
Good control over the molecular weight dispersity was achieved and
good agreement between the experimental and theoretical molecular
weight was observed (PS-PS, Table 3-1). It worth noticing that the
polydispersity of the block copolymers PS - PS after the RAFTprocess
was similar to that of the precursor polymers P1 - P4, indicating a good
level of control in the RAFT-mediated reactions.
These block copolymers thus combined the properties of being
biodegradable and biocompatible, and have well-defined structure with
controlled molecular weight and polydispersity. Although
poly(caprolactone) and PEG-methacrylate polymers have very recently
been described/s perhaps surprisingly there were no prior reports of
PLGA-PEGMA475block co-polymers synthesised by controlled routes at
the start of this study.
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The chemical syntheses of the polymers used in this study are shown in
Figures 3-3 and 3-4.
D,L Lactide
s
()
)l_ ~OH
+ S S
.Q
(1)
BSTSE (Raft agent)
ii
(PS)
Figure 3-3. Syntheses of Polymers (P1 and PS) i) Sn (II), 140 oC, 24 h, ii)
THF, AIBN, 80 °C 24 h, (see Materials and Methods section).
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D,L Lactide Glycolide
V~~OH+ S S~
(1)
BSTSE(Raft agent)
S I 1 0vs)ls~Oy~O~O;H
(P 2) x : y = (50:50)
ii
(PS)
Figure 3-4. Synthesis of Polymers (P2 and P6) i) Sn (II), 140 oc. 24 h, ii)
THF, AIBN, 80 oC 24 h, (see Materials and Methods section).
The properties of PLA / PLGA - PEGMA475copolymers synthesised by
ROP and RAFT are summarised in table 3-1, describing the molecular
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weight and molecular weight distributions based on results obtained
from gel permeation chromatography.
Table 3-1. Characteristics of PLGA-PEGMA475 diblock copolymer
synthesised by ROP and RAFT process.
Mn Mn Mw
Entry Polymer (theo)*103 (GPC)*103 (GPC)*103 MwiMn
P1 BSTSE-PLA 4.9 5.4 9.1 1.6
P2 BSTSE-PLGA 4.9 5.5 8.7 1.5
P3 BSTSE-PLGA 9 8.1 13.7 1.5
P4 BSTSE-PLGA 9.S 13.3 20.1 1.5
P5 PLA-PEGMA 10.9 11.5 16.3 1.4
PS PLGA-PEGMA 10.9 12.S 20.4 1.S
P7 PLGA-PEGMA 17 18 29.2 1.6
P8 PLGA-PEGMA 27 27.1 48.1 1.7
a was calculated by multiplying the conversion with the targeting
molecular weight
3.S.2. Polymer characterisation
3.S.2.1 NMR spectroscopy and FrIR
The IHNMR spectrum of BSTSE compound was studied in (CD03)
(Figure 3-5.); this compound has been prepared as mentioned in
literature. The structure of the compound was confirmed by
comparison with literature data. It was possible to assign the peaks
from the spectrum of BSTSE as follow: the peak of 3.59 (t, 2H, CHl-D),
3.85 (t, 2H, Cfh-S), 4.62 (s, 2H, CH:z-Ph), 7.31 (m, 5H, Ph). FTIR (cm")
2860-2940 cm'" (C-H), 1760 cm-1 (C=O).
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Figure 3-5. IHNMR spectrum of BSTSE (RAFT agent) (representative of
trithiocarbonate RAFT agent).
The structure of the PLGA polymer end-capped with BSTSE was also
confirmed from IH NMR spectrum obtained in (CDCb) (Figure 3-6.).
The peaks which are labelled in Figure 3-6 referred to the protons of the
backbone of PLGA polymer (a-c) and the end group for BSTSE (d). 8 =
5.18 (m, 1H, CH- C=O), 4.82 (m, 2H,CH2- C=O), 1.58 (d, 3H, CH3-CH), 7.3-
7.4 (m, 5H, Ph). FTIR (cm") 2860-2940 cm-I (C-H), 1760 cm-I (C=O).
Owing to the low intensity of the phenyl proton adsorption compared
to the protons of the PLGA in the IH NMR spectrum, it was difficult to
calculate the molecular weight via IH-NMR alone, however using the
integration on the spectrum, it was possible to confirm the 50:50 ratio of
lactide to glycolide units in the polymer which was the target in the
synthesis of the polymer.
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Figure 3-6. IHNMR spectrum of BSTSE-PLGA
From the IH NMR spectrum of PLGA-PEGMA475 block copolymer, it
was possible to characterise the structure by assigning the peaks as
shown in (Figure 3-7). The peaks labelled from e-g were assigned to the
protons on the PLGA block. The peaks labelled (h) were assigned to
PEGMA units.
5 = 5.18 (m, lH, CH- C=O), 4.82 (m, 2H, CH2- C=O), 3.94-4.14 (m, CH2,
CH2-0- C=O), 3.4-3.8 (m, CH2CH20), 1.58 (s, 3H, CH3), 1.6-1.9(m, CH2),
0.7-1.3 (s, CH3). FTIR (cm") 2860-2940 cm? (C-H), 1760 cm-I (C=O).
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Figure 3-7. lHNMR spectrum of PLGA-PEGMA.
3.5.3. Molecular weight determination
a
I i
[ppm]
Gel permeation chromatography was used to determine the molecular
weight and polydispersity of the polymers. The GPC traces of BSTSE-
terminated PLGA polymers (P I-P 4) and PLAjPLGA block copolymers
(P 5-P 8) are shown in Figure 3-8.
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Figure 3-8. GPC chromatographs for polymers (see Table 3-1) in
chloroform eluent. Note, some traces are overlapped due to similarity
in retention times.
The molecular weights and the polydispersity indices of the polymers
BSTSE-PLGApolymers and PLGA-PEGMA475diblock copolymer were
determined by GPC (Gel permeation chromatography), and
summarised in Table 3-1. The PDls of BSTSE-PLGApolymers (p 1-P 4)
are between 1.5-1.6 which is typical for polymers produced by ring
opening polymerisation.
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On the other hand, the PDIs of PLGA-PEGMA475 diblock copolymers
(PS-PS) are slightly different from the BSTSE-PLGA polymers which
indicate the efficiency of RAFT polymerisation. The GPC results
showed a decrease in retention time of PLGA-PEGMA in comparison to
the GPC curve of the first block (BSTSE-PLGA). This was a preliminary
indication that the second block (PEGMA) was inserted to the polymer
chain between the trithiocarbonate unit and PLGA.
The curves were unimodal and symmetric indicating relatively good
control over the polymerisation. This is typical for tin (II) catalysed ROP
of the monomers using standard hydroxyl initiators. The GPC curves
for the PLGA-PEGMA475 (PS-PS) block copolymers (see Figure 3-8)
indicated progressive chain extension of the PLGA upon block
copolymerisation with PEGMA475.
There was a slight change in the molecular distribution of PLGA-
PEGMA in relative to BSlSE-PLGA which confirmed the efficient RAFT
process. More importantly, all GPC traces were unimodal suggesting
that block copolymers were indeed formed and that the presence of
either PLGA or PEGMA homopolymer was low.
3.5.4. Micelle formation and characterisation
The amphiphilic nature of the block copolymer PLGA-PEGMA
provided the opportunity to form water stable micelles. The
hydrophilic PEGMA segment was expected to form the shell of the
micelle structure whereas the PLGA segments assembled into a
hydrophobic core. Pyrene fluorescence emission intensity spectra were
used to evaluate critical micelle concentrations (CMC) owing to the
sharp increase in fluorescence intensity as the hydrophobic dye
transferred into the micellar cores. CMC values obtained from these
plots were in the range 0.3- Img.L" (Figure 3-9).
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Size distributions of co-polymer micelles were determined by dynamic
light scattering above the CMC. The micelles from co-polymers PS-P8
exhibited two populations, with the majority fractions in terms of mass
distributions exhibiting radii of ....12-16 nm, with a second population
consisting of much larger species with diameter 60-180 nm. In the
absence of an acid-catalyst, the micelles were stable in PBS,as shown by
DLS, over a 24 hr period; this suggests that the micelles and vesicles
were stable to aggregation, at least over the time periods of the
experiments.
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Figure 3-9. Graph representing change in pyrene emission intensity as
a function of polymer concentration for PLGA-PEGMAco-polymer 8.
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Table 3-11.Dynamic Light Scattering data for polymer micelles
PS
Fraction 1 Fraction 2
%Area RH (nm) %Area RH (nm)
45.9 15.5 54.1 59.5
64.1 14.7 35.9 79.5
71.9 13.6 28.1 128.8
72.0 11.9 28.0 175.6
Polymer
PS
P6
P7
Representative DLS plots for Polymers P 5 and P 8 together with TEM
images are shown in Figure 3-10.
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Figure 3-10. DLS and TEM data of block co-polymer micelles formed
from polymers P 5 (a) and P 8 (b).
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The spherical shape of the micelles is apparent in TEM, and the
presence of larger micelle-type assemblies is most clearly seen in the
larger DLScomponents and TEMfeatures in (b) for polymer P 8.
3.5.5. Drug release studies.
Controlled drug release is the longer-term goal of these studies with
degradable, hydrophobic core co-polymer micelles. Two dye molecules
were chosen as model drugs, carboxyfluorescein (CF) and fluorescein
isothiocyanate (FITC),which differ in their hydrophilicity, in order to
evaluate drug encapsulation and release by the co-polymers.
Carboxyfluorescein is relatively hydrophilic but unreactive, and thus is
a good candidate to evaluate incorporation into hydrophobic-core
micelles. The protocol used to prepare CF-Ioaded micelles was the same
as described for blank micelles, except that the model drug was co-
dissolved with PLGA-PEGMA copolymer prior to addition into the
aqueous phase and excess of un-entrapped CFwas removed by passage
of the suspension through Sephadex columns (PD-10 desalting
column). The release kinetics of CF from co-polymers PS-PSare shown
in Figure 3-11. A typical cumulative release curve was recorded and
showed that sustained release was observed over a period of four days.
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Figure 3-11. Release of carboxyfluorescein (CF) with time from PLGA-
PEGMA block co-polymers in water. The starting concentrations of CF
and co-polymers used to form the micelles were the same in all cases.
Cumulative release correlated well with PLGA block length, with
polymers P 5 and P 6, containing PLGA blocks of Mn 5.5 kDa (GPC)
releasing CF at the same rate and to the same extent. By contrast,
polymers P 6 and P 7, with Mn (GPC) of PLGA blocks of 8.1 kDa and
13.3 kDa, respectively, released more CF and to a higher overall extent.
This also linked with calculated molar volumes by DLS, with P 8 (3.2 X
10-2 I1m3.mole-l) exhibiting several-fold higher cumulative release than
P 5 and P 6 (~1.0 X 10-3 um-.mole').
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The relative proportion of hydrophobic to hydrophilic blocks is also
important in micelle stability,55 with higher hydrophobic block
proportion able to stabilise micelles and reduce CMC. The higher
proportion of hydrophobic blocks in P Sand P 6 were thus expected to
reduce release rate compared to polymers P 7 and P 8, and this was
borne out by the pattern of release shown in (Figure 3-11) . The profile
of release from all the polymers was similar to those of previously-
reported PLA/PLGA-PEG co-polymers/s indicating that the change to
PEGMA as the outer hydrophilic block compared to PEG was not
detrimental in terms of potential drug delivery applications.
Importantly, however, these data showed that it is possible to alter
model drug incorporation and release via changes in co-polymer
structure - the enhanced control inherent to the synthesis of these
PLGA-PEGMA block co-polymers by combined ROP and RAFT allows
much better flexibility in co-polymer preparation than the anionic
routes needed for PLA-PEG systems.
3.5.6. Cell uptake studies of micelle-entrapped dye
Preliminary cell uptake studies were carried out using the 3T3
fibroblast cell line, as a representative target for micellar drug carrier
systems. 57 Fluorescein isothiocyanate (FITC) was used as a convenient
probe, owing to its accessible excitation and emission wavelengths and
its reactivity to amine-containing biomolecules. FITC was considered as
complementary to CF as it is more hydrophobic and therefore a better
model for more hydrophobic drugs, but also its reactivity would mean
that any release into an environment with amine-containing
biomolecules would lead to rapid and permanent staining. FITC was
incorporated into polymer PS and PS micelles using the same methods
as for CF, and as before free drug was removed by passage of micelles
down a Sephadex column. The loaded micelles were added to the 3T3
cells at 37°C and at concentrations above CMC: again the cells were
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immediately washed to remove any free dye in solution. As is apparent
from microscopy (Figure 3-12), uptake was rapid and the FIIe
fluorescence was apparent in microscopy images of cells incubated with
either polymer P5 or P8 within 15 min, with intense fluorescence after
one hour.
Time
Omin
P 5 (Table 3-1)
Bright field FITC+ DAPI
15min
1 hr
P 8 (Table 3-1)
Time Bright field FITC+DAPI
Omin
15 min
1 hr
Figure 3.12. Microscopy of 3T3 fibroblasts after incubation with FIIC-Ioaded
polymers 5 (top six images) and 8 (bottom six images).
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Micrographsobtained in bright field are on the left-sideof the image, and
combined images obtained under DAPI and FITC filters are shown on the
right-handside.
Analysis of uptake via counts of fluorescent cells detected in FITC and
DAPI stains compared to total cell numbers in bright field (ScionImage,
NIH) suggested that - 70 % of 3T3cells were fluorescent after one hour
after incubation with polymer 5, compared to - 50 % for those
incubated with polymer 8 at the same concentrations. This was most
likely due to the greater number of micelles of < 200 nm diameter
exhibited by polymer 5 than for polymer 8, as size ranges of 150-200run
are often cited as the most highly taken up by passive endocytosis. It is
important to note that at all stages the polymers were present in
suspension with cells above their CMC, so although the micelle-unimer
equilibria would enable some FITC to be liberated, it is likely this effect
will have been small compared to micellar uptake and subsequent
dilution of micelles inside the cell, leading to enhanced intracellular
drug release. Incubation of 3T3 cells with 'free' FITC added to DMEM
solution resulted in a different pattern of staining, with a high
background fluorescence at t = 0, and strong labelling of the outsides of
the cells after a few minutes, in contrast to what was observed for the
micelle-encapsulated FITC.
These cell uptake experiments are preliminary and it is also the case
that quantification with fluorescent dyes as model drugs is
experimentally difficult owing to self-quenching effects and pH
differences in sub-cellular compartments (FITC, for example, is not
strongly fluorescent at the lower pH values found in late endosomal
compartments). However, the data nevertheless shows that these di-
block micelles are capable of rapid entry into a representative cell line,
an important requirement for any drug delivery system.
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3.6. Conclusions
In this chapter it is shown that it is possible to synthesise block co-
polymers based on biodegradable PEG-methacrylate and PLGA
components in a facile one-pot procedure and with good control over
block length, proportion and final molar mass. These copolymers
assembled in aqueous solution into micellular nanostructures to
encapsulate model drug compound (carboxyfluorescein). Control over
the hydrodynamic diameter size as well as the release pattern profile of
carboxyfluorescein from the micelles were successfully achieved by
choosing copolymers (PSto PS)which are different in overall molecular
weights. Release studies with carboxyfluorescein as a fluorescent model
drugs showed that overall release was higher with micelles formed
from PS copolymer compared to PS and P6, which the latter, showed
the lowest releasing profile. Successful uptake of micelles into 3T3 cells
was shown for two block co-polymers used, polymers P 5 and P 8.
The combination of ROP and RAFTchemistries'" used in this chapter to
establish a synthetic, flexible route to make PLGA-PEGMA475
copolymers offered many advantages compared to existing routes
which utilised limited molecular weight PEG based polymers to make
PLGA-PEGtype copolymers. The tailoring of co-monomer type and the
wide variety of methacrylate and acrylate functional materials available
that can be polymerised via RAFT or ATRP means that fine-tuning of
drug incorporation and release should be possible,59-62and therefore,
the developed route in this chapter to make such biocompatible
copolymers will be very beneficial to the field of controlled drug
delivery system.
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So far, the successful synthetic platform was developed by utilising
advanced polymerisation technique to fabricate biocompatible
copolymers to make core-shell type nanostructure. The core-shell type
nanostructure, prepared in this chapter, has potentially better colloidal
stability compared to physically surface-coated nanostructures which
were used in chapter two.
Although the synthesised block copolymers in this chapter can be
utilised to make core-shell nanopartic1es for delivery of DNA, using
conventional double emulsion technique. But, the lack of specific
targeting or active release of DNA will hamper their application.
Therefore, we have developed another synthetic route that also utilised
controlledj"living" polymerisation technique to make the
aforementioned block copolymers but also allow the incorporation of
bioresponsive functionality (to trigger the release of DNA inside the
cell) and to attach targeting moieties. The synthesis of such copolymers
to make core-shell nanopartic1es is studied in detail in chapter four of
this thesis.
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Chapter4
Multifunctional Bioresponsive Cell-
Targeted Block Co-polymer
Nanoparticles for Gene Delivery
4. Introduction
Carrier materials for therapeutic biopolymers must fulfil a number of
demanding criteriast.and for nucleic acid delivery the hurdles are
especially challengings+, DNA and RNA delivery vehicles are required
to package the polynucleotide, protect it during transport in and across
numerous biological environments and barriers, and then release the
biopolymer in the correct cellular location. The delivery materials
should also be non-toxic, and ideally should be biodegradable. Block
co-polymer micelles, vesicles and nanoparticles have been extensively
investigated as carriers for nucleic acids5-8, as the core-shell
architectures enable packaging of DNA or RNA into a protected
interior phase. In addition, judicious choice of functional monomers,
synthetic routes and formulation conditions allows self-assembly into
finely-structured nanomaterials that can display bioactive ligands for
cell or tissue-specific targeting above a hydrophilic corona for enhanced
biodistributiont, Prior work10-16 has established the principle of poly
(ethylene glycol) (PEG) block co-polymer micelles for drug and gene
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delivery, utilizing the ability of PEG to reduce opsonisation and
clearance from the body.
Increased stability via PEGylation can have the downside of reducing
cell uptake and accordingly several groups have prepared block co-
polymers or conjugates wherein the PEG block is connected to the
hydrophobic component or drug via cleavable or
reversible/ disruptable linkers17-19• This enables the PEG-corona to
separate from the core, exposing the contents for release, in a manner
analogous to the shedding of viral coat proteins. Another strategy for
restoring activity of PEGylated or other co-polymer micelles is to
introduce cell targeting functionality, for example by attaching a ligand
to the outside of the PEG layer that can be recognized by a specific cell
surface receptor and marked by the cell for uptake. The overexpression
of the folic acid receptor on certain cancer cells has been explored by a
number of groups, who have end-functionalised polymer drug delivery
systems with folic acid or folates to enhance uptake via folate receptor
mediated endocytosis13,20, 21.
Unfortunately, the availability and cost of heterobifunctional PEGs for
concurrent co-polymer micellisation and ligand decoration has been a
limiting factor and so strategies for controlled synthesis of block co-
polymers and nanopartic1es with more easily functionalisable end-
groups have emerged22.23.Installation of folate groups at end-groups of
polymers prepared by Atom Transfer Radical Polymerization (ATRP)
has been carried out with high control and good yields24•
ATRP offers an additional advantage in that the many commercially
available acrylic ester monomers can be polymerized with a high
degree of control25, 26. A number of poly(ethylene glycol)methacrylate
(pEGMAs) can be obtained that vary in side-chain length and water
solubility, enabling control not only of molar mass and polydispersity
via ATRP, but also the hydrophilicity and architecture of the surface
corona of a micelle or vesic1e27-29•
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PEGMAs have shown good biocompatibility30,31 and their combination
with a hydrophobic polymer block such as poly(lactic acid-co-glycolic
acid) (PLGA - which is widely used clinically), has been shown to
produce well-defined and biocompatible nanopartic1es32,33. For
encapsulation of biopolymers such as DNA however, simple micelle
formation with these block materials is of limited utility as the nucleic
acids do not easily partition to the interior phase. Water/oil/water
(W/O/W) emulsion systems can be used to encapsulate nucleic acids
via their initially entrapped aqueous regions and block co-polymer
surfactants have been used to enhance DNA incorporation into PLGA
nanoparticles by this route34-35. PLGA-PEGMA block co-polymers are
obvious candidates to use for interfacial stabilization of w/ o/w
emulsions, while the ability to tune block co-polymer structure in
PLGA-PEGMA systems through controlled synthesis also in principle
allows for further control of emulsion stability via this route.
In this chapter the combination of multiple factors, i.e. controlled block
co-polymer synthesis, functionality for receptor-mediated uptake and
the formulation into well-defined nanopartic1es via w/o/w /routes
leads to selective and active gene delivery vectors. This is achieved
through the synthesis of PLGA-S-S-PEGMA diblock and PLGA-S-S-
PLGA homo block co-polymers with surface-displayed folic acid
functionality for enhanced uptake and DNA release in the clinically-
important Calu-3 cell line.
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4.2 Materials and Methods
4.21. Instrumentation
Number average molecular weight (Mn), weight average molecular
weight (Mw) and polydispersity Index (PDI=Mw/ Mn) of the prepared
copolymers were obtained by Gel Permeation Chromatography (Gpc)
(PL-120and PL-SOPolymer Labs) with a refractive index detector. The
columns (7.5 x 300 mm Resipore Mixed-D, 2 in series) were eluted by
chloroform and calibrated with polystyrene standards. All calibration
and analysis were performed at 40 °C and a flow rate of 1 mL min-I.
All of the products were dissolved in chloroform and passed through
0.2 urn filter prior to column chromatography.
lH NMR spectra were recorded at 20°C on a Bruker-DRX instrument
operating at 400 MHz. Chemical shifts (6) are reported in parts per
million (ppm), referenced to CDCh (6 ppm = 7.26). The data was
processed using the TOPSPIN 2 software.
Infrared spectra were measured on an Avatar 360 Nicolet Ff-IR
spectrophotometer in the range of 4000-500 cm-1by preparation of KBr
discs. Sample analyses were carried out by the E2OMNIC software for
analysis. Mass spectra (TOF-ES) were recorded on a Waters 2795
separation module/micromass LCTplatform.
Values of hydrodynamic radius of the nanoparticles were determined
via scattered light recorded at 90° angle to incident radiation in
Dynamic Light Scattering (DIS) using a Viscotec Model 802 instrument
equipped with an internal laser (825-832 nm) with a maximum
radiation power of 60 mW. The samples were diluted with filtered,
deionised water and at least five measurements of each sample were
taken. The mean and standard deviation were calculated. Data
processing was performed with the software program 0mniSize2.
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Zeta potential (~ measurements of the nanopartic1es were performed
by laser Doppler anemometry using a Malvern Zetasizer 2000equipped
with a 10 mW He-Ne laser operating at a wavelength of 633 nm.
Measurements were performed in low ionic strength buffer, 1.0 mM
Phosphate buffer adjusted to pH 7.4. The mean value and standard
deviation for each sample was calculated from at least five
measurements.
Morphology of the particles was examined using Transmission Electron
Microscope (TEM) 0001 [em 1010 electron microscope, [apan)c. A
sample of particle suspension was diluted with a solution of
phosphotungstic acid (3%w]», pH 7.4) and observed under TEM.One
drop of sample was placed for 1minute on a copper grid coated with a
formvar carbon film. The excess of sample was wicked away with the
aid of filter paper prior to imaging by TEM.
All solvents and reagents were of analytical or HPLC grade and
purchased from Sigma or Fisher Scientific unless otherwise stated.
Deuterated solvents were from Sigma. The two monomers DL-Iactide
and glycolide were obtained from Purac biochem. The monomers were
recrystallized from ethyl acetate prior to use. Polyethylene glycol
methyl ether (pEGMA-ME475,Mn = 475)were purchased from Sigma
Aldrich and purified before use by passing through a column filled
with neutral alumina. Copper (II) bromide (CuBr2, 99%), 2-bromo-2-
methylpropionyl bromide, L-ascorbic acid (99%), N, N, N', N", N'''-
Pentamethyldiethylenetriamine (PMDTA, 98%) and tin (Il)- 2-
ethylhexanoate were used as received from Sigma Aldrich. N, N-azobis
(isobutyronitrile) (AIBN,98%,Aldrich) was recrystallized from ethanol.
Plasmid DNA gWIZ-Iuc, containing the firefly luciferase gene was
supplied as 5mg/ml solution by Aldevron (South Fargo,USA) and used
without further treatment.
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The luciferase detection kit was acquired from Promega (Southampton,
UK) and contained cell culture lysis reagent (5 x solutions), Luciferin
reagent and Luciferase assay buffer. Phosphate Buffer Saline (PBS) was
used as received from Fisher Scientific. Dialysis membrane (MWCO
3500, regenerated cellulose) was used as received from Spectrapor.
4.3. Polymer syntheses
4.3.1. Synthesis of 2-bromo-2-methyl-propionic add 2-(2-hydroxy-
ethyldisulfanyl)-ethyl ester (2)
The heterobifunctional ATRP/ROP initiator was prepared as follows.
Dithiodiethanol (12 g, 0.077 moles) was added to a 100m! round bottom
flask equipped with three-way stopcocks connected to either an argon
line or a vacuum pump, and dried via azeotropic distillation with
anhydrous toluene (3X 20ml) under reduced pressure. After complete
evaporation of toluene, anhydrous THF (20m1)was added via a syringe
under an argon atmosphere. Triethylamine (2.3 g, 0.023 moles) was
added to the solution which was maintained at 4 °C during slow
addition of a-bromoisobutyryl bromide (2.6 g, 0.011 M). The solution
was allowed to warm to room temperature and left overnight The
solution was then filtered to remove the salt and the crude product was
recovered by evaporation of THF. The product was purified by passing
through silica column chromatography using ether as eluent (yield
90%)
IH NMR (CDCh, 400 MHz»: 1H NMR (CDC13, 400 MHz): 6 ""4.48-4.44
(t, j- 6.68 Hz, 2H, CH2-OH)., 3.92-3.8 (qapparent, japp a 5.94 Hz, 2H, CH2-
o.c-<J), 3-2.97 (t, J - 6.62 Hz, 2H, CH2-S), , 2.91-2.89(t, Ja 5.835, 2H,
CH2-S), 2.1(t, J - 6.185,H). 1.95 (s, 6H, CH3).
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13(: NMR (CDCh): B = 171.9, 63.7, 60.4, 55.6, 41.5, 36.6, 30.B. HR-MS
(FS+) calcd for CBH15Br03S2 (MH+) 301.965 and 303.237, found
301.B102 and 303.8056. FTIR (cm-t) 3410, (-OH), 2927, (C-H), 1734,
(C=O).
4.3.2. Synthesis of PLGA polymer using 2-bromo-2-methyl-propionic
acid 2-(2-bydroxy-ethyldisulfanyl)-etbyl ester (P 9)
PLGA, Poly (DL-Iactide-co-glycolide) was synthesized by ROP (ring
opening polymerization) using 2-«2-hydroxyethyl) disulfanyl) ethyl 2-
bromopropanoate as initiator. First, DL-Iactide (1.B2 g, 0.012 moles),
glycolide (1.47 g, 0.012moles), and 2-«2-hydroxyethyl)disul£anyl)ethyl
2-bromopropanoate (0.4g, 0.0014 moles) were added to a
polymerization tube and purged with argon several times before being
heated in an oil bath to BOOCand purged with argon for a further 2
hours. The reaction mixture was then heated to 140 OCin order to
conduct the polymerisation in the melt phase. At this point, tin (II) 2-
ethylhexanoate (0.106 g, 0.00027moles) was added, and the mixture
was stirred for 24 hours. The polymerization tube was then removed
from the oil bath and cooled down to room temperature. The polymer
was recovered by dissolution in THF and precipitated in methanol
three times to remove unreaded monomer. The precipitate was filtered
and dried under reduced pressure to give a white product (yield 95%).
The molecular weight of the polymer and poly dispersity index was
determined by gel permeation chromatography using chloroform as
eluent.
IH NMR (CDCh,4OO MHz): 5 = 5.18 (m, lH, CH- C=O), 4.82 (m, 2H, CH2-
C=O), 4.2-4.3(m, 4H, CH2-0- C=O), 2.8-2.9 (m, 4H, CH2-S), 1.8-1.9 (s, 6H,
CH3), 1.58 (d, 3H, CH3-CH). 13CNMR (CDCh): 5 = 169.5, 166.3,69.1, .60.8,
53.5, 16.9. FfIR (em") 2860-2940 cm" (C-H), 1760 cm-1 (C=O).
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4.3.3. Synthesis of PLGA-S-S-PEGMAt7S block copolymer using (P 10)
The PLGA-S-S-PEGMA475 block copolymers were prepared by Atom
Transfer Radical Polymerization (ATRP) using the PLGA-S-S-Br block
as macro-initiator For PLGA-S-S-PEGMA475block copolymers, PLGA-
S-S-Br (1.5 g, 0.0003 moles, Poly(ethylene glycol)methyl ether
methacrylate 475 (2.8 g, 0.0063 moles), CuBr2 (0.067 g, 0.0003 moles)
and PMDTA (63 IJ.L,0.0003 moles) were added into a round bottom
flask, the flask purged with argon several times, followed by addition
of butanone (10m1) and degassed for 20min under an argon
atmosphere. L-ascorbic acid (0.022 g, 0.00012 moles) was added to the
polymerisation solution under argon condition. The mixture was then
heated in oil bath to 50 OCand stirred for 3.5 hours. The polymerization
product was precipitated in a mixture of hexane/ ether (50:50), and then
the polymer was passed through a short alumina column to remove
copper salts. Finally, the solvent was evaporated and the product dried
under reduced pressure (yield 85%). The product was characterized by
NMR and GPC using chloroform as eluent.
IH NMR (CDCh, 400 MHz): 6 = 5.18 (m, lH, CH- C=O ), 4.82 (m,
2H,CH2- C=O), 3.94-4.14 (m, CH2, CH2-O- C=O), 3.8-3.4 (m,
CH2CH20), 3.2-3.38 (S,-CH3), 1.58 (s, 3H, CH3), 1.6-l.9(m,CH2), 0.7-1.3
(s,CH3). 13(: NMR (CDCh): 6 = 169.5, 166.3, 71.9, .70.5, 59.2, 16.9 FTIR
(cm-I) 2860-2940 cm-l (C-H), 1760 cm-I (C=O).
4.3.4. Synthesis of Azide-Terminated PLGA-S-S-PEGMA47S block
copolymer (P 11)
Sodium azide (0.04 g, 0.00062 moles) was added to a round-bottom
flask containing PLGA-S-S-PEGMA47S block copolymer (4 g, 0.0003
moles) dissolved in DMF (12 mL). The reaction mixture was stirred at
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50 OCfor 24 hours after which time it was allowed to cool down to room
temperature, After elimination of DMF under reduced pressure,
toluene (15 mt) was added, and the insoluble salt was removed by
centrifugation (1()()()()rpm at 25°C for 25 min). Finally, the toluene was
evaporated under reduced pressure (yield 95%). The product was
characterized by FTIR, IH-NMR and GPC.
IH NMR (CDCh, 400 MHz): 0 = 5.18 (m, IH, CH- C=O ), 4.82 (m,
2H,CH2- C=O), 3.94-4.14 (m, CH2, CH2-O- C=O), 3.8-3.4 (m,
CH2CH20), 3.2-3.38 (s,CH3), 1.58 (s, 3H, CH3), 1.6-1.7(m, CH2-N3), 0.7-
1.3 (s,CH3). FTIR (cm-') 2860-2940 (C-H), 2106 (N3), 1760 (C=O).
4.3.5. Synthesis of Propargyl Folate (3)
This was accomplished by a method modified from the literature21.
Folic acid (1.0g, 0.0022 moles) was dissolved in DMF (10 mt) and
cooled in a water/ice bath. N-Hydroxysuccinimide (0.26 g, 0.0025
moles) and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide
hydrochloride (EOC, 0.44 g, 0.0025 moles) were added, and the
resulting mixture was stirred in an ice bath for 30 min to give a white
precipitate. A solution of propargylamine (0.124 g, 2.25 moles) in DMF
(5.0 mt) was added, and the resulting mixture was allowed to warm to
room temperature and stirred for 24 h. The reaction mixture was
poured into water (100 mt) and stirred for 30min to form a precipitate.
The orange-yellow precipitate was filtered, washed with acetone, and
dried under vacuum to give a product in (yield 90%). Analytical data
corresponded to those of the literature reported product.
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IH NMR (DMSO-d6, 400 MHz): 8.64 (s,1H, PtC7 H), 8.29-8.24 (d,1H,
PtC6-CH2NH-Ph),8.04-8.02 (d,1H, -CONHCHC02H), 7.67-7.65 (d,2H
,Ph-C2H and Ph-C6H) 6.93 (br s, 2H, NH2, 2H), 6.65-6.63 (d,2H, Ph-
C3H and Ph-C5H), 4.49-4.48 (d,2H, PtC6-CH2NH-Ph), 4.32-4.30
(m,1H,-CONHCHC02H),3.84-3.81 (m,2H, -CONH-CH2C=CH), 3.07-
3.05 (t, 1H, -CONHCH2C=CH), 2.88 (s, 1H, -CONH-CH2C-=CH,), 2.72
(br 8,1H, OH,), 2.31-2.20 (m, , 2H, -CH2C02H), 1.98-1.96 (m,1H, -
CHCH2CH2), 1.87-1.85 (m,1H, -CHCH2CH2). Note: Pt = pteridine.
4.3.6. 'Click' reaction of azide terminal of PLGA-S-S-PEGMA475
blocks copolymer with propargyl folate (P 12) and propargyl alcohol
(P13)
In a 25ml round bottom flask, PLGA-S-S-PEGMA475-N3 (2 g, 0.0002
moles, Mn = 9000 g/rnol), PMDTA (0.034 g, 0.00002 moles) and
propargyl folate (0.014 g, 0.00024 moles) were dissolved in DMF (10m1)
and purged with argon for 30 minutes. The solution was then
transferred via a degassed canulla needle to another tube equipped
with a magnetic stir bar containing CuBr (0.028 g, 0.0002 moles) under
argon atmosphere. The mixture was stirred at 26 OCfor 24 h in the
absence of oxygen. After the reaction, the mixture was exposed to air,
and the solution was passed through a column of neutral alumina.
DMF was removed under vacuum. The resulting folate-terminated
PLGA-S-S-PEGMA475was dissolved in THF and filtered to remove the
excess of propargyl folate. The product was further purified by dialysis
in acetone using regenerated cellulose membrane molecular cut off of
3500 Da. Finally, the polymer was dried under vacuum for 6 hours and
the product was characterized by FfIR, IH-NMR and GPC (yield 80%).
The synthesis of (P 13) was exactly analogous except propargyl alcohol
was used inplace of propargyl folate (yield 82%).
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P 12: IH NMR (CDCh,400 MHz): 0 = 8.5, 8.2, 7.5, 6.5 (weak multiplets,
folate terminus), 5.18 (m, lH, CH- C=O ), 4.82 (m, 2H,CH2- C=O), 3.94-
4.14 (m, CH2, CH2-O- C=O), 3.8-3.4 (m, CH2CH20), 3.2-3.38 (S,-CH3),
1.58 (s, 3H, CH3), 1.6-1.9(m,CH2), 0.7-1.3 (s,CH3). I3CNMR (CDCh): 0 =
169.5, 166.3, 71.9, .70.5, 59.2, 16.9. FTIR (crrrt) 2860-2940 crrr? (C-H),
1760 crrr? (C=O).
P 13: IH NMR (CDCh, 400 MHz) 0 = 5.18 (m, lH, CH- C=O ), 4.82 (m,
2H,CH2- C=O), 3.94-4.14 (m, CH2, CH2-O- C=O), 3.8-3.4 (m,
CH2CH20), 3.2-3.38 (S,-CH3), 1.58 (s, 3H, CH3), 1.6-1.9(rn,CH2), 0.7-1.3
(s,CH3).). I3CNMR (CDCI3): 0 = 169.5, 166.3, 71.9, .70.5, 59.2, 16.9. FTIR
(crrr") 2860-2940 ern-I (C-H), 1760 cm! (C=O).
4.3.7. Synthesis of PLGA-S-S-PLGA homo-polymer, using 2, 2-
Dithiodiethanol as bifunctional initiator (P 14)
PLGA-S-S-PLGA homopolymer, Poly (DL-Iactide-co-glycolide-S-S-DL-
lactide-co-glycolide) was synthesized by ROP (ring opening
polymerization) using dithiodiethanol (2) as bifunctional initiator. First,
DL-Iactide (2.7g, 0.018 moles), glycolide (2.1 g, 0.018 moles), and
dithiodiethanol (0.3g, 0.0019 moles) were added to a polymerization
tube and purged with argon several times before being heated in an oil
bath to 80 OCand purged with argon for a further 2 hours. The reaction
mixture was then heated to 140 CC in order to conduct the
polymerisation in the melt phase. At this point, tin (II) hexanoate
(0.078g, 0.0002 moles) was added, and the mixture was stirred for 24
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hours. The polymerization tube was then removed from the oil bath
and cooled down to room temperature.
The polymer was recovered by dissolution in THF and precipitated in
methanol (this was repeated three times to remove unreacted
monomer). The precipitate was filtered and dried under reduced
pressure to leave a white solid product (yield 94%).
IH NMR (CDCh,400 MHz): 0 = 5.18 (q, lH, CH- C=O), 4.82 (q, 2H,
CH2- C=O), 4.36-4.4 (m, 4H, CH2-O- C=O), 2.87-2.96 (m, 4H, CH2-S),
1.58 (d, 3H, CH3-CH). I3C NMR (CDCh): 0 = 169.5, 166.3, 69.1, .60.8,
53.5,16.9. FTIR (cm-I) 2860-2940 cm-I (C-H), 1760 cm? (C=O).
4.3.8. Synthesis of PLGA·TEG·PLGA homo-polymer, using
tetraethylene glycol (TEG) as bifunctional initiator (P 15)
Poly (DL-Iactide-co-glycolide-TEG-DL-Iactide-co-glycolide) was
synthesized by ROP (ring opening polymerization) using tetraethylene
glycol initiator (3). First, DL-Iactide (2.1g, 0.014 moles), glycolide (1.7 g,
0.014 moles), and tetraethylene glycol (0.3g, 0.0015 moles) were added
to a polymerization tube and purged with argon several times before
being heated in an oil bath to 80 OCand purged with argon for a further
2 hours. The reaction mixture was then heated to 140 OC in order to
conduct the polymerisation in the melt phase. At this point, tin (II) 2-
ethylhexanoate (0.062g, 0.00015 moles) was added, and the mixture was
stirred for 24 hours. The polymerization tube was then removed from
the oil bath and cooled down to room temperature. The polymer was
recovered by dissolution in THF and precipitated in methanol (this was
repeated three times to remove unreacted monomer). The precipitate
was filtered and dried under reduced pressure to yield a white solid
product (yield 93%).
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1H NMR (CDCb, 400 MHz): 6 = 5.18 (m, 1H, CH- C=O ), 4.82 (m,
2H,CH2- C=O), 4.27-4.34 (m, 2H, CH2-0- C=O), 3.6-3.65 (s, 8H,
CH2CH2-O), 3,67-3.72 (m, 4H, CH2CH2-O- C=O), 1.58 (d, 3H, CH3-
CH). 13(:NMR (CDCb): 6 = 169.5, 166.3,69.1, .60.8, 53.5, 16.9. FI1R (cm-
1)2860-2940 cm-1 (C-H), 1760 cm-1 (C=O).
4.4. Fabrication of non-loaded nanoparticles
Nanoparticles with PLGA-S-S-PLGA (P14): PLGA-S-S-PEGMA475 (Pl2)
ratios of 50:50 were prepared using a modified solvent diffusion
technique. P12 and P14 SOmg of each were dissolved in of
dichloromethane (2ml). The organic solution was then mixed by vortex
agitation for 30 seconds with an aqueous phase (200 ul.). The obtained
emulsion was then poured into a polar phase (25 ml of ethanol) under
moderate magnetic stirring, resulting in an immediate precipitation of
polymer nanoparticles. The suspension was diluted with ultra-pure
water (25 ml) and stirred for 1 hour. The organic solvent was
evaporated under reduced pressure at 300c. The final particles solution
was passed through a Sephadex column (PO 10) and then characterised
by dynamic light scattering (DLS), Zeta Potential measurements and
transmission electron microscopy (TEM).
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4.4.1. Charaderisation of nanopartic1es
4.4.1.1. Dynamic light scattering
The size and polydispersity of nanoparticle suspensions were
determined by dynamic light scattering. An aliquot was added in a
quartz cuvette and the sample was examined on a Viscotek 802
dynamic light scattering instrument.
Scattered light from a 50 mW laser source (830 run) was recorded from
an internal light detector aligned at 900 from source. From standard
auto correlation functions, measured correlation coefficients were
related to hydrodynamic radii at varying temperatures via the Stokes-
Einstein equation, RH = KT/ 6nllD , where RH is the hydrodynamic
radius, k is the Boltzmann constant, T is the temperature and 11is the
viscosity of the solvent. The size distribution of the scattering particles
was determined by the average mass number of the particles.
4.4.1.2. Surface charge measurement (Zeta Potential)
The surface charge of the particle was measured on a Malvern
Instruments Zetasizer 2000. To determine the zeta potential, the
measurements were performed in lmM phosphate buffer solution at
pH 7.4. Mean values were obtained from three different batches, each
measured three times.
4.4.1.3. Microscopy
The morphology of the nanoparticles was examined by Transmission
Electron Microscopy (TEM). Samples were imaged using a JEOL (JEM-
1010) electron microscope. A few drops were added onto the copper
grid and allowed to dry in air. The particles were negatively stained
with 3% phosphotungstic acid solution.
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4.4.2.Determination of plasmid DNA encapsulation efficiency
The theoretical loading of plasmid DNA was 0.4% (w/w) in regards to
the total amount of P14 in the nanoparticles. For the determination of
the actual amount of encapsulated DNA, an extraction method was
used. Briefly,nanoparticles (lOmg), loaded with plasmid DNA were re-
suspended in 0.5 N NaOH (1.5mI) under horizontal shaking at 37 CC
until a clear solution was obtained. The DNA content in the resulting
solution was quantified by UV spectrophotometry (Shimadzu 1204,
Tokyo, Japan) at 260nm by means of a standard absorption curve
derived from DNA in water. The encapsulation efficiency was
calculated as the ratio between the actual and theoretical DNA loading
percentages. Each experiment was performed in triplicate.
4.4.3.Release profile of plasmid DNA from the nanopartides
The in vitro release of DNA in presence/absence of glutathione (as a
representative intracellular reducing agent) was investigated as follows.
Nanoparticles (10mg) were suspended in glutathione solution (1.5ml,
5mM) at 37 CCunder continuous agitation. At various time intervals,
the supernatant was withdrawn and fresh buffer was replenished. The
amount of plasmid DNA in the supernatant was determined by UV
spectrophotometry at 260 run. For control experiments, phosphate-
buffered saline (PBS)pH 7.4 was used instead of glutathione solution
and non-reducible PLGA nanoparticles were also studied in the
presence of GSH and PBS. The experiments were performed in
triplicate.
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4.4.4.Cell toxicity assay
M1S assay was performed to evaluate the effect of nanoparticles on cell
metabolic activity. Calu-3 cells were seeded on 96-well plates at a
density of 10,000 cells per well and cultured in the EMEM medium.
Prior to the test, cell medium was removed and replaced by sample
solution comprising of nanoparticles in HBSS.The samples contained
(4mg.mL-l)concentration of nanopartic1es. 0.1%Triton-X 100 and HBSS
were used as a positive and negative control, respectively.
Cells were incubated under standard conditions with the samples or the
controls for a period of two hours, after which they were removed.
Cells were then washed with PBS following which the M1S assay was
performed according to the manufacturer's instructions.
4.4.5.Cellular uptake experiments
Prior to the experiment, the culture medium was removed, the cell
monolayers rinsed with phosphate buffer saline (PBS)and then allowed
to equilibrate for 1h at 37 OCin Hanks Balanced Salt Solution (HBSS)
with 15mM 4(2hydroxyethyl)-lpiperazine-ethane sulfonic acid (Sigma).
A series of batches of nanoparticles were prepared, varying in the mass
ratio of P12: P14 from (5% to 75%)and a batch of P13: P14 of 75%mass
ratio (used as control). All the batches were labeled with Coumarin 6 as
a label to assess the cellular uptake. Nanopartic1es samples composed of
(2mg.mL-l) concentrations of nanoparticles suspended in HBSSbuffer
were applied and the uptake study performed for a period of four
hours. The samples were then removed and the cell monolayers were
washed with buffer. In the next stage, the cellswere digested with 0.2N
NaOH in0.5%Triton X-lOOand centrifuged at a speed of 13000rpm for
30 sec (Eppendorf 5417R centrifuge-AG 22331Hamburg).
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The fluorescence intensity of the supernatant was measured by
Fluorescence Spectrophotometer (MFX Microtiter Plate Fluorometer,
The Microtiter Company, and UK).
For inhibition experiments, Immol/ L free folate was added prior to
application of nanoparticles.
4.4.6.Transfection study
Twelve well plates were seeded with 1 x lOS cells per well and the cells
were incubated at 37°C and under atmosphere of 5% CDl for 24 h.
After 24 h, the medium was aspirated off from the wells and gently
replaced with Iml DNA-loaded nanopartides. A volume of
nanoparticles containing 4pg of DNA were prepared as described
above. The cells were incubated for 4 h at 37 CC and 5% C02.
Following this incubation, the nanoparticles were removed and
replaced with RMPI-1640medium and the cells were incubated for a
further 24 h before analysis.
4.4.6.1.Detection of luciferase
The medium was removed from the cells, which were then washed
with PBS twice. Luciferase detection was performed with a luciferase
detection kit. Cell lysis buffer (300 pL) was added to each well. A
pipette tip was used to scrape all cells from the well substrate, after
which the lysate was centrifuged at 13,500rpm for 5 minutes and the
supernatants were collected. The luciferase activity of each sample was
measured by gently mixing reconstituted luciferin reagent (100 pL)
with ceUlysate (20 pL) in a scintillation vial insert, and inserting into a
luminometer (TO 20/20, Progema).
194
Chapter4 Materials and Methods
4.4.6.2.Determination of cellular protein
Cellular protein contents were assayed by the Bradford method. Bovine
serum albumin (BSA)standards were prepared from a 1 mg.mL-l stock
solution by diluting with one-10th strength lysis buffer to 0.6, 0.5, 0.4,
0.3, 0.2 and 0.1 mg.ml,". Aliquots of each standard (10 ul) were
transferred into a 96-assay plate, then 200 ul Bradford assay reagent
was added and the As9s was measured after 15 minutes. From samples
prepared in the luciferase detection protocol, 20 Jil of each sample was
placed in an eppendorf and diluted with 180 ul of water (interference
from lysis buffer, need to dilute lOx). Again aliquots of 10 J11 were
transferred to the wells of a 96-well assay plate and 200 Jil Bradford
reagent was added. The mixtures were allowed to stand for the same
time as the standards and then the As95 measured. A standard curve
was prepared and a linear curve fit used to give the equation relating
As9s to protein concentration, which was employed to calculate the
protein concentration in the samples. Results in light units/ ml obtained
from previous sections were divided by mg protein/ m1 from this assay
to give a final value of light units/ mg cellular protein.
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4.5. Results and Discussion
The concept underlying the work was the generation of surface
functionalized multi-component core-shell drug delivery systems,
containing chemistries to enable cell surface receptor targeting,
prevention of extracellular protein adsorption and opsonisation,
intracellularly triggered loss of the polymer shell and ultimately,
biodegradation. In addition, the plan was to combine block components
such that the co-polymers could assemble into well-defined
nanoparticles in water/oil/water (w/o/w) emulsions, in order to
encapsulate and protect sensitive biopolymers such as DNA.
Accordingly, block copolymers were chosen of poly (DL-lactic-co-
glycolic acid) (PLGA - the hydrophobic core block) and (polyethylene
glycol methyl ether) (PEGMA415 - the hydrophilic outer block),
connected by a bioreducible disulfide bridge. In addition, facile
derivatisation of the hydrophilic block terminus was required to install
a ligand for cell receptor targeting. The synthetic strategy therefore
combined two different polymerisation techniques, ring opening
polymerisation (ROP) and Atom Transfer Radical Polymerisation
(ATRP), using an initial heterobifunctional initiator 2-bromo-2-methyl-
propionic acid 2-(2-hydroxy-ethyldisulfanyl)-ethyl ester (1), followed
by well-established Iclick' chemistries as shown in Figure 4-2.
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Figure 4-2. Synthetic strategy for end-functional block co-polymers.
4.5.1. Synthesis of (2-bromo-2-methyl-propionic acid 2-(2-hydroxy-
ethyldisulfanyl)-ethyl ester) (2)
A heterobifunctional unit was required to initiate the two
polymerization route Le. ROP for the synthesis of the core PLGA block
and ATRP for the synthesis of the polyPEGMA475exterior block. The
link between the two blocks needed to be cleavable, for which a
disulfide bridge was chosen as reduction of disulfides by intracellular
glutathione (GSH) has been previously described. Compound (2) was
accordingly obtained by esterification of dithiodiethanol with 2-bromo-
2-methylpropionyl bromide.
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The structure of the resultant 2-(2-hydroxyethyl) disulfanyl) ethyl 2-
bromopropanoate was confirmed by IR (Figure 4-15), IHNMR, and
mass spectrometry (Figure 4-9).
4.5.2. Synthesis of PLGA-S-S-Br polymers (P 9)
Addition of D,L-Iactideand glycolide to 2-«2-hydroxyethyl) disulfanyl)
ethyl 2-bromopropanoate in the presence of tin (II) - 2-ethylhexanoate
as catalyst resulted in ring-opening polymerization of the monomers
initiated from the hydroxyl terminus of (1). The targeted molar mass
for the PLGA block was (.....5000 Da) and, as apparent from gel
permeation chromatography (Table 4-1, Figure 4-20). The first block
was synthesized in the desired molar mass range and with good
polydispersity. IH NMR spectra (Figure 4-10) showed the expected
resonances of the polymer backbone at 5.1 ppm and 1.57ppm (methine
and methyl protons of poly (lactic acid), and at 4.8 ppm (methylene
group of poly (glycolicacid).
4.5.3. Synthesis of PLGA-S-S-PEGMA475 block copolymer (P 10)
Atom Transfer Radical Polymerisation (ATRP)of PEGMA475from the 2-
bromo-2-methyl-propanoate-tipped PLGA was carried out using the
AGET ATRP method36,37. The polymerization was stopped at low
conversion to control polydispersity and ensure a high degree of
bromine end-functionality for subsequent derivatisation. The
polymerisation of the second block was confirmed by GPC (Figure 4-20)
which showed a decrease in retention time of the PLGA-S-S-PEGMA47s
in comparison to PLGA-S-S-Br.
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The GPC traces were unimodal, indicating successful synthesis of the
second block from the first block via the ATRPprocess. The molar mass
distribution of the PLGA-S-S-PEGMA475block copolymer was
essentially the same as that of the precursor PLGA block which per se
demonstrated controlled polymerisation for the second component. The
structure of the diblock copolymer was confirmed by lH NMR spectra.
(Figure 4-11) and the composition and ratios of each block in the
copolymer were determined by relative peak integrals of PLGA and
PEGMAproton resonances.
4.5.4.Synthesis of PLGA-S-S-PLGA (P 14)
A reducible 'homo-diblock' PLGA polymer, designed to act as a
bioresponsive core of the particles, was synthesized from
dithiodiethanol and DL-Iactide and glycolide monomers via tin (11)-2-
ethylhexanoate catalysed ROP as before. The targeted molar mass
weight was again -5.000 Da, but in this case the copolymer grew from
both ends of the dithiodiethanol initiator. GPC traces (Figure 4-20)
showed relatively good control over polydispersity of the polymer,
with the unimodal feature of the GPC traces suggesting successful
progressive chain extension on either side of the initiator the structure
of the diblock was also confirmed by spectroscopy.
4.5.5. Synthesis of Azido-and Folate Terminated PLGA-S-S-
PEGMAc75diblock copolymers (P 11 and P12)
The bromine-terminated PLGA-S-S-PEGMA475diblock copolymer was
transformed into an azide-terminated diblock copolymer via
nucleophilic substitution with sodium azide38,39.The molar mass of the
azide-terminated PLGA-S-S-PEGMA475was unchanged compared to
the bromo-precursor as indicated by GPC (Figure 4-20).
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The 1H NMR spectrum (Figure 4-12)was similar to that of the bromide
terminated block copolymer with the exception of the methylene
residue at the terminus: this resonance shifted from 1.9 ppm in the Br-
terminated polymer to 1.7 ppm in the azide-derivative suggesting a
complete substitution of the terminal bromine by azide. FT-IR spectra
confirmed the presence of azide functionality through a strong
absorption band at .....2110 cm-1. (Figure 4-18) The final step in the
synthetic procedure involved modification of the terminal azide via
copper-mediated Iclick' coupling with an acetylene-tipped folic acid
derivative, propargyl folate in DMF at room temperature. N, N', Nil,
Nil', N'II' -Pentamethyldiethylenetriamine (PMDTA) was employed to
enhance reaction rate and increase end-terminal modification. GPC
again confirmed no change in molar mass occurred during the IIclick"
reaction (Figure 4-20). FT-IR demonstrated the loss of azide group
absorption at 2110 cm-1 (Figure 4-19) and 1H NMR showed the
presence of folate aromatic protons at 5 =6-8ppm (Figure 4-14). UV
absorptions at 363nm, representative of folate provided further support
for the presence of azide functionality (Figure 4-23).
The number of folate residues per diblock copolymer of PLGA-S-S-
PEGMA475was determined to be .....1 as expected. The properties of the
co-polymers are summarized in Table 4-1.
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Table 4-1. Properties of polymers and diblock copolymers using ROP
and ATRP methods
Polymer Mntheo x1()3a Mn x1()3b Mwx1Q3 Mw/Mn
PLGA-S-S-Br (P 9) 4.9 4.9 6.5 1.3
PLGA-S-S-PEGMA475.Br (P 10) 9 8.4 10.2 1.2
PLGA-S-S-PEGMA475.N3 (P 11) 9 8.1 9.7 1.2
PLGA-S-S-PEGMA475.Folate(P12) 9 9.4 12 1.3
PLGA-S-S-PEGMA475-OH (P 13) 9 9.4 12 1.3
PLGA-S-S-PLGA (P 14) 4.9 4.2 5 1.2
PLGA- TEG-PLGA (P 15) 4.9 4 4.7 1.2
a Theoretical, from monomer/initiator ratio. b From GPC (CH03) ,30
CC, poly(styrene) standards).
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4.6. Fabrication of nanopartides
The PLGA-S-S-PEGMA475and PLGA-S-S-PLGA block copolymers were
then used to prepare blend matrix nanostructures as shown in Figure 4-
3.
, _ _-
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(i)
DNA solution added into organic phase
to form primary emulsion
Aqueous phase GJ(pDNA solution)
Organic phase
(
CH
2
CI
2 + co·e,~~~:.~~.~~.... (ii)
Primary emulsion added
to ethanol (polar phase):
precipitation of PLGA
Polar phase (ethanol)
(iii)
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Figure 4-3. Preparation of core-shell nanoparticles using a w /0/ w
emulsion technique. In (A) DNA In water is added into
dichloromethane (DCM) containing PLGA-S-S-PEGMA475 polymers.
Addition of this primary emulsion to ethanol (B) results in collapse of
the hydrophobic core as the DCM partitions into the bulk phase.
Solvent evaporation (C) yields the final nanoparticles.
The double emulsion technique was selected to encapsulate DNA as the
formation of nanoparticles by this route occurs via solvent diffusion,
under conditions that are mild and which avoid the shear-induced
degradation of DNA prevalent during conventional nanoparticle
formation. To accomplish this, an aqueous solution of plasmid DNA
was added into dichloromethane (organic phase) containing PLGA-S-S-
PLGA and folate terminated PLGA-S-S-PEGMA475.
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The primary emulsion needed only a mild vortex to form, which was
most likely to have been a result of the amphiphilic nature of the folate
terminated PLGA-S-S-PEGMA475. Addition of this emulsion to a more
polar phase (ethanol) resulted in the immediate formation of
nanoparticles as dichloromethane diffused from the inner oil phase to
be replaced by ethanol, a non-solvent for the PLGA block. The final
nanoparticles obtained after solvent evaporation were of low
polydispersity and of net negative charge. Several batches of
nanoparticles were prepared by this route using different ratios of
PLGA-S-S-PLGA to folate terminated- PLGA-S-S-PEGMA475 diblock
copolymer. The properties of these particles are shown inTable 4-11.
Table 4-11 Mean Particle Size, and Zeta Potential of the different Blank
and Plasmid loaded PLGA-S-S-PLGA and PLGA-S-S-PEGMA475-folate
Nanoparticles (mean ± S. D., n = 3).
Plasmid- Plasmid
Bateh Ratio· Blank Mean loaded Blank-Zeta loaded Zetasize(nm) b Mean Potential (mV) Potential
s!!!:{nm} !mV)
NPS1 9S:Sc 14B±1 -1S.63±0.25
NPS2 9O:10c 14S±1.6 -14.13±0.OS
NPS3 7S:2Sc 12B±3.6 -6.93±O.37
NPS4 5O:S0c 1OS±4 96.2±1 -7.2±O.17 -9.9
NPSS 25:7S c 9S±3.1 -4.S±O.40
NPS6 5O:5Od 110±4.7 -13.3±0.26
NPS7 25:7Sd 139±2.7 -lS.10±0.17
NPS8 SO:5Ocl 111±1.4 98±2.7 -8.S -9.S
NPS9 50:50 dl 107.6±1 102.1±1 -13.1 -13.6
a The (wt/wt %) ratio of PLGA-S-S-PLGA :PLGA-S-S-PEGMA47S-
folate, b mean diameter size based on relative mass distribution. C; -
derived from P3a (folate-terminated), d - derived from P3b (hydroxyl-
203
Chapter4 Results and Discussion
terminated). c1,dl both are derived same as c, d but in these two
formulation P5 (pLGA-TEG-PLGA)was used instead of P4
As apparent from Table 4-11,increasing the PEGMA475-folate:PLGA-S-
S-PLGA ratio (NPSl-5) decreased both particle size and zeta potential.
This was due to the greater interfacial stabilization during primary
emulsion formation as the PEGMA475content was increased, and the
shielding of PLGA-carboxyl groups as the PEGMA475-folateIcorona'
was enlarged. Particle sizes were similar for NPS4 and NPS6, which
contained PLGA-S-S-PEGMA475-folate:PLGA-S-S-PLGA (50:50 mole
%), and PLGA-S-S-PEGMA475-OH:PLGA-S-S-PLGA(50:50 mole %),
respectively, at ....110 nm, when DNA was not encapsulated. Similarly,
NPSBand NPS 9, which were of the same molar ratio of PLGA-S-S-
PEGMA47S-folateor PLGA-S-S-PEGMA47S-OHbut with a non-reducible
PLGA-TEG-PLGA in place of PLGA-S-S-PLGA, were formed as
.....llOnm particles in the absence of DNA. However, for NPS4, 8 and 9,
the encapsulation of DNA decreased both particle size and zeta
potentials. These differences in size and charge of the particles
containing DNA indicate that the nucleic acids may also have played a
role in stabilizing the initial 0/w interface in the primary emulsion.
Microscopy of nanoparticles (3% phosphotungstic acid negative
staining) showed consistent spherical shapes across the compositional
ranges, Figure 4-4. Particle sizes determined from TEM micrographs
were slightly less than the hydrodynamic diameters recorded by
dynamic light scattering (DLS), most likely due to air-drying of the
nanoparticles on the copper grid leading to collapse of hydrated
(pEGMA475)segments on the outer shells. The apparent particle size
range by TEMwas higher than observed in DLS,which may reflect the
relative insensitivity of light scattering techniques in detecting smaller
compared to larger particles.
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Figure 4-4. Transmission Electron Micrographs (TEM) of different
(wt/wt%) ratio of PLGA-S-S-PEGMA47s-folate to PLGA-S-S-PLGA a)
10% wt, b) 25% wt, c) 50% wt and d) 75 %wt.
4.6.1. Encapsulation of plasmid DNA
The combination of the 'homo-diblock' PLGA-S-S-PLGA and the
amphiphilic diblock PLGA-S-S-PEGMA475 polymers with the double
emulsion method resulted in efficient encapsulation of plasmid DNA
(GWiz luciferase). The extent of incorporation was 80 % of the DNA in
solution, corresponding to a theoretical loading of 0.4% with respect to
the mass of polymer in the emulsion (- 4ug DNA per mg of polymer).
Recovery of DNA from the nanoparticles following treatment of the
dried copolymers with 0.5% N NaOH indicated that 3.2ug/mg of
plasmid DNA had been encapsulated as determined by UV
spectroscopy and comparison to standard absorption values at 260 nm
(Figure 4-21).
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4.6.2. In vitro release profiles of plasmid DNA from nanoparticles
The release profiles of DNA from the nanopartic1es were investigated
under conditions designed to mimic reducing and non-reducing
environments in the cytosol, Figure 4-5. Co-polymer particles in 50:50
molar ratios of PLGA-S-S-PEGMA47s to either PLGA-S-S-PLGA
(reducible) or PLGA-TEG-PLGA(non-reducible) were loaded with the
same amounts of plasmid DNA (3.2mg.mg-1polymer) and incubated in
PBS pH 7.4 in the presence or absence of 5 mM glutathione (GSH). As
apparent from Figure 4-5, the disulfide core- based nanoparticles
showed 85% release of DNA over 16 hours in presence of 5mM GSH
compared to 40% release in PBS buffer alone. Furthermore, there was
no significant difference between release of DNA from nanopartic1es
containing the non-reducible PLGA-TEG-PLGA core system in the
presence and absence of 5mM GSH (45%and 46% release, respectively).
100 • PLGA-S-S-PLGA in PBS 7.4 + 5mM GSH
• PLGA-TEG-PLGA in PBS 7.4+ 5mM GSH
• PLGA-TEG-PLGA in PBS 7.4
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Figure 4-5. Cumulative releases (%) of plasmid DNA from
nanoparticles.
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4.6.3. Uptake of nanoparticles in Calu-3 cell line
The lung cancer cell line Calu-3 was chosen as a suitable model and
clinically relevant in vitro test of nanoparticle efficacy. Recent studies
have indicated that pemetrexed, a folate antimetabolite, is a potent and
effective therapeutic in the treatment of lung cancers'? a finding that
suggests that folate-receptor (FR)mediated targetingv might be highly
suitable for lung cancer cell lines. Accordingly, Calu-3 monolayers were
grown and incubated with nanoparticle suspensions when the cells
were confluent and linked via tight junctions as shown by trans-
epithelial electrical resistance (TEER)measurements. The nanoparticles
in the uptake assay contained progressively increased molar ratios of
PLGA-S-S-PEGMA475-folater lative to the PLGA-S-S-PLGAand PLGA-
TEG-PLGA 'cores', while 'non-functional' PLGA-S-S-PEGMA475-
OH:PLGA-S-S-PLGA nanoparticles were used as a control for the
PEGMA-folate surface. As a positive control, a second set of assays was
carried out, this time in the presence of ImM free folic acid, to block any
specific FR-mediated uptake. The results of these assays are shown in
Figure4-6.
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Figure 4-6. Folate mediated cellular uptake of nanoparticles by Calu-3
cell lines.
Cell uptake of nanoparticles increased with increased amounts of the
folate-tipped block co-polymers in the matrix, although there was only
a marginal difference between uptakes of the 75 % folate-tipped
particles (NPSS) compared to 50 % (NPS4). Uptake of the hydroxyl-
terminated particles (NPS9)was significantly lower (p = 0.002) than the
folate-terminated systems. In all cases, addition of free folic acid
suppressed uptake, consistent with a folate-receptor mediated uptake
mechanism, rather than that due to the small variations (+/ - 10 %) in
particle size over the nanoparticle samples.
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The key experiments, bringing together all the design components of
the system i.e. DNA incorporation, core-shell architecture with surface-
displayed cell targeting ligands and intracellularly reducible core for
enhanced release, involved evaluation of trans gene expression in Calu-
3 monolayers, utilizing the GWiz luciferase plasmid. Three nanoparticle
systems were chosen: NPS9 with a non-reducible core and a PEGMA47s
shell with no folate-termini, NPS8 with a PEGMA47s-folatesurface but a
non-reducible core, and NPS4 with both PEGMA47sfolate surfaces and
the PLGA-S-S-PLGA reducible core. As a further probe of activity,
transfections with NPS4 were also carried out with addition of
glutathione mono-ethyl ester (GSH-MEE), which is converted into
active GSH intracellularly, four hours after initial incubation of the cells
with the particles. Light production due to expressed luciferase in Calu-
3 is shown in Figure 4-7.
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Figure 4-7. Transfection assays in Calu-3 monolayers with nanoparticles
with/without cell-targeting and bioreducible functionality. RLU =
relative light units, a measure of luciferase expression.
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Overall transgene expression was higher for the bioreducible and
folate-targeted nanoparticles, with the highest light production for cells
incubated with NP4 with addition of GSH-MEE. Transfection increased
5-fold for the folate-functional NPs compared to the non-targeted non-
reducible NPs, and lO-fold by incorporation of the additional reducible
component in the cores. Boosting the intracellular GSH resulted in an
overall increase of - 4-fold, indicating the importance of the
bioreducible core.
4.6.4. Cell viability
MTS assay was chosen to determine the cytotoxicity of the
nanoparticles on Calu-3 cells. Low toxicity of the nanoparticles was
expected since the PLGA-S-S-PLGA and PLGA-S-S-PEGMA-folate
copolymers used in the nanoparticles formulation were previously
shown to be biocompatible. Figure 4-8 shows the toxicity of the NPSl
and NPS5 nanoparticles in the Calu-3 cell line. The results indicated
that the nanoparticles did not present any toxic effect on the Calu-3 cells
since viabilities for NPSl and NPSS were above (87%) even at the
highest nanoparticle concentration (4mg.mL-l).
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HBSS TritonX NPSl NPSS
Figure 4-8. Cytotoxicity of NPSI and NPS5 were compared to TritonX
(positive control) and HBSS (negative control). Viability levels are
represented as a percentage with respect to the level obtained for the
negative control.
Taken together, the results of the uptake assays in the absence and
presence of free folic acid and/or 'non-functional' OH-terminal
particles, combined with the enhancements observed for transgene
expression using folate-functional particles with bioreducible disulfide
cores, are strong indicators of the success of the design strategy.
Overall goal was to establish the chemistries necessary for
incorporating a wide range of potential biotherapeutic agents, such as
proteins and nucleic acids, inside protective drug delivery vehicles that
should be biocompatible, easily functionalisable for cell targeting, and
bio-responsive. An important part of the strategy was that the
components are in effect, modular, so different parts could be combined
together or replaced, dependent on a particular desired application. The
PLGA core was chosen because this polymer has been extensively used
clinically, and the degradation rate can be tuned by co-monomer
content and degree of crystalllnityv. For gene delivery applications,
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rapid release is required, but for a slower degradation profile as might
be considered for tissue engineering applications, poly (caprolactone)
(PCL) or other polyesters could be used instead of PLGA. For more
rapid release, PGA or other more hydrolytically sensitive polyesters
could be employed as the inner block. In addition, the use of the
disulfide linker allows further control of release rate43,44 as a variety of
disulfide containing blocks that are themselves rapidly cleavable could
be used to grow PLGA cores. Examples exist of cysteine-terminated
peptides used in drug and gene delivery45,46suggesting further possible
mechanisms of triggered release. The outer component, poly (PEGMA),
enables yet more flexibility in delivery vehicle design. PEGMA475
homopolymer grown by ATRP was utilised, but co-polymers with
other PEG-methacrylates offer the possibilities of tumour targeting
through a thermally-responsive phase transition28,29, while additional
functionality than folate is readily accessible through the wealth of
'click' chemistries reported in the literatures", Recent data has indicated
biocompatibility of PEGMA-based polymers grown by controlled
radical routes30 providing catalyst residues are effectively removed/"
and thus it is likely that a platform of therapeutic carrier materials
could be produced by this route.
Finally, the use of the double emulsion method allows blending of
different polymers to tune degree of core-vs-shell components, and to
encapsulate a variety of potent yet delicate biomacromolecules with
high efficiency.
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4.6.5. Conc:lusions
Modular block co-polymers were assembled via ROP, ATRP and click
chemistry routes to generate biocompatible, cell-targeted and
bioresponsive gene delivery vehicles. Block copolymers of PLGA-S-S-
PLGA and PLGA-S-S-PEGMA475were synthesized using the above
polymerisation techniques. These two polymers are connected by
disulfide bridges to afford reduction in the presence of reducing agents.
The terminal of the hydrophilic block, in this case PEGMA475has been
used to install folate for receptor targeting. Double emulsion techniques
were used to encapsulate DNA with high efficiency, and uptake of the
resultant nanoparticles was shown to take place in Calu-3 cells via a
specific folate-receptor mechanism. The reporter gene expression
studies demonstrated that selective receptor-mediated and
intracellularly triggered drug delivery took place, and the ability to do
this in the clinically important Calu-3 cell line offers promise for future
therapeutic applications.
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4.7. Supplementary Figures (Figure 4-9 to 4-24)
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Figure 4-9. IH NMR (400 MHz) spectrum of 2-2((2-hydroxyethyl)
disulfanyl) ethyl 2- bromo-2methylpropanoate in CDCh. Note: the
OH signal at 2.2 ppm was not always visible, the presence of this
signal was found to be dependent on the sample concentration.
b a
f
'Q?rl ~I e 5 ~ °UarHI ,Q C "io "-- i'T
»: bX dSeOfy
d
./
[ppm)
Figure 4-10. IH NMR (400MHz) spectrum of PLGA-S-S-Br.in CDCh.
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Figure 4-11. -H NMR (400 MHz) spectrum of PLGA-S-S-PEGMA475 in
CDCh
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Figure 4-12. lH NMR (400 MHz) spectrum of AIZDE end-terminal
PLGA-S-S-PEGMA475 in CDCh.
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Figure 4-13. IH NMR (400 MHz) spectrum of acetylene folate in DMSO-
d6.
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Figure 4-14. IH NMR (400 MHz) spectrum of PLGA-S-S-PEGMA47s-
folate in CDCb.
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Figure 4-15. IR spectrum of 2-((2-hydroxyethyl) disul£anyl) ethyl 2-
bromopropanoate, FTIR (cm+) 3410, (-OH), 2927, (C-H), 1734, (C=O).
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Figure 4-16. IR spectrum of PLGA-S-S-Br, FTIR (cm") 2860-2940 em-1
(C-H), 1760 cm-I (C=O).
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Figure 4-17. IR spectrum of PLGA-S-S-PEGMA475, FTIR (cm+) 2860-
2940 cm"! (C-H), 1760 cm-I (C=O).
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Figure 4-18. IR spectrum of AIZDE end-terminal PLGA-S-S-PEGMA475,
FTIR (crrr-) 2860-2940 (C-H), 2106 (N3), 1760 (C=O).
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Figure 4-19. IR spectrum of PLGA-S-S-PEGMA47s-folate, FTIR (cm")
2860-2940 crrr ' (C-H), 1760 crrr ' (C=O).
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Figure 4-20. GPC chromatogram for polymer and diblock copolymers
in chloroform eluent.
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Figure 4-21. Standard calibration curve of GWIZ luciferase Plasmid in
water.
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Figure 4-22. Standard calibration curve of folic acid inDMSO.
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Figure 4-23. UV-vis spectra of the two different concentration of PLGA-
S-S-PEGMA475-folate compared to AZIDE terminal PLGA-S-S-
PEGMA475.
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5.1. From Plain Nanoparticles to the Design of an Advanced
Multifunctional Nanoparticle "Platform" as a Drug and Gene
Delivery System
Despite intensive research and numerous clinical trials over the last
two decades, successful results for gene therapies in humans to treat
both acquired and inherited diseases remains elusive. The approach
of using viral vectors to express genes for therapeutic intentions still
suffers from cytotoxicity and immunogencity problems'- 2. This is
highlighted by the recent (Iuly 2007) death of a participant in a gene
therapy trial a few days after the intra-articular injection of an adeno-
associated viruses AAV vectors, In contrast, nonviral vectors have
merit due to their low immunogenicity. Thus, research on the
designing and synthesis of nonviral based gene delivery systems has
accelerated to replace viral vectors. However, the efficacy of nonviral
delivery methods is still far below that of viral vectors',
The existence of many extracelullar and intracellular barries limits
the transport and biodistribution abilities (pharmacokinetics) of
nonviral gene delivery systems resulting in low transfection
efficiency. In addition to these barriers, there are other factors that
have an effect on the overall efficacy of delivery systems which are
directly related to the intrinsic properties of the carrier systems, these
include physical properties (size, surface charges), loading efficiency
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of DNA, release profiles and presense of specific targeting moities to
ensure localistion of the delivery carriers where they are needed.
Factors affecting on transfection efficiency of nonviral gene delivery system
,
Extracellular barriers
- Opsonisation
- Nulease degradation
- Liver clearance
Intracellular barriers1
- Endolysosomal degradation
- Nuclear membrane
Physical properties
- Hydrodynamic diametre size
- surface charge
- Morphology
Others factors
- Loading efficiency
- Release profile
-Targeting moities
,
(from point of injection to the surface of cellular target of interest)
1(from cellular uptake to intracellular trafficlng and nuclear entry)
Figure 5-1. Factors affecting transfection efficiency of nonviral gene
delivery systems.
The main current challenges in gene therapy are the design of more
sophisticated nonviral gene delivery systems that are able to
circumvent physiological barriers. In addition, controlling the
physicochemical properties of the carrier (e.g. size, surface charges
and morphology) and formulation parameters (e.g. loading
efficiency, release profile and specific targeting) are considered to be
crucial in determining the overall transfection efficiency of nonviral
gene delivery vectors. Moreover, the long term safety of these
carriers for in vivo applications requires formulations which are
composed of biodegradable and biocompatible materials.
Therefore, combining all these properties that are required for the
development of an ideal nonviral gene delivery system in a single
227
ChapterS Final Conclusion
vector remains a difficult task and has been focus for many groups
over the last few years.
5.2. Enhancing encapsulation efficiency of DNA in PLGA
nanopartic1es
Synthetic copolymers of poly(lactic-co-glycolic acid) PLGA are the
most widely studied polymer-based delivery system due to their
demonstrated FDA-approved track record as a vehicle for drug and
protein delivery. Although PLGA based delivery systems are safe
and useful for protein delivery, their application for delivery of
plasmid DNA suffers several drawbacks.
Drawbacks of PLGA based carrier for plasmid DNA delivery:
1- Low encapsulation efficiency; owing to the large size and
hydrophilic nature of DNA, the encapsulation of nucleic acids
in hydrophobic PLGA particles is a challenge.
2- Degradation of DNA during formulation of nanoparticles;
double emulsion techniques were commonly used to
encapsulate pDNA in the matrix of particles and this requires
high shear forces (e.g. homogenisation and sonication) to
reduce the particle size to micro- and nanoscale range.
3- Hydrolytic degradation of PLGA polymer generates an acidic
climate with a pH as low as 1.5 inside the nanoparticle matrix
and potentially results in degradation of DNA and
compromising of biological activity.
4- The rate of pDNA release is often too slow, this may be due to
unwanted interaction between DNA and PLGA polymer and
thus in case of DNA vaccination, this may prevent an optimal
immune response.
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5- Plain PLGA based delivery systems lack the targeting
specificity and have short circulation times owing to the
absence of a protective hydrophilic shell or targeting ligands.
Therefore, given the limitations with PLGA based delivery systems,
further developments and modifications are needed to obtain a
carrier that fulfils the requirements of an ideal gene delivery system.
Several approaches have been developed already to improve the
PLGAdelivery system such as encapsulation of excipients into PLGA
micro and nanoparticles to buffer the acid microenvironment so as to
protect the DNA from degradation. Cationic polymers were used to
condense DNA before encapsulation in PLGA matrix to enhance
encapsulation and also to protect DNA from degradation through
buffering the acidic microenvironment (through protonation of
amine groups) generated inside the PLGA particlest. A similar
approach, using poly (ethyleneimine), or chitosan has been reported
for loading PLA particles with DNA6.Although these modifications
have shown some success, there is concern over the potential
cytotoxicity of some of the excipients.
These previous works have given an insight into the limitations of
PLGA-based delivery systems and some current approaches which
have been used to optimise the efficiency of the system. In addition
to that, whilst modifying the PLGAbased delivery system, it is very
important to keep a good safety profile by using excipients which are
also biocompatible or biodegradable.
Therefore, the next step adopted in this thesis was to use
biocompatible excipients with PLGA based systems in order to
overcome the limitations which are mentioned earlier. Csaba et al,
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have explored a new nanocarrier system composed of PLGApolymer
blended with PEO derivatives (poloxamers and poloxamines) to
enhance the encapsulation efficiency of pDNA as well as improve
release profile, details of this work have been discussed in Section 2
of Chapter 2. Although this work offered a versatile technique with
very mild conditions to encapsulate pDNA and also provided a
continuous release profile, the encapsulation efficiencies of pDNA
were only achieved up to 35% - 45%. This has created a gap to
introduce other excipients which could possibly improve the release
profile of pDNA as well as increase the encapsulation efficiencies
while keeping the good safety profile of PLGAbased system.
5.3. PLGA Jeffamine blended nanopartic1es as DNA delivery
system
The initial aims of this thesis were set on the development of blend
nanoparticles based on PLGA polymer and Jeffamine™ (Poly
(ethylene glycol) bis (3-aminopropyl) terminated. The rationale for
choosing and adding Jeffamine™ to PLGAas excipient were mainly
to obtain a higher encapsulation efficiency compared to available
systems and also to improve release profile of DNA. The formation
of these mixed systems is based on the phenomenon that PLGA
polymer and Jeffamine are readily miscible via hydrogen bonding.
Moreover, Jeffamine polymers have PED backbones with two
accessible amine groups at the ends of each polymer chain.
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Therefore, the initial thoughts were to investigate the effect of
blending Jeffamine with PLGA polymer on encapsulation efficiency
of cDNA and releasing profile. Jeffamine polymers have the
following characteristics:
1- Can bind with cDNA via hydrogen bonding as well as
electrostatic interaction between negative phosphate groups
on the cDNA (calf thymus DNA) backbone and positively
charged amine groups (protonation of the terminal amine
groups).
2- Upon protonation of terminal amine groups on Jeffamine
polymer, they may play a role in buffering the acidic
microenvironment which generates from hydrolytic
degradation of PLGApolymers.
3- The presence of Jeffamine within the matrix of PLGAparticles
can improve the release profile via formation of hydrophilic
channels upon erosion of the PLGAmatrix.
A similar double emulsion techniques developed by Csaba et al were
used for work in this thesis; it offers mild conditions during
encapsulation of DNA in the matrix.
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Enhancing encapsulation efficiency of cDNA
PLGA
Electrostatic interaction between terminal amine groups
on Jeffamine chain polymer and phosphate groups of DNA
"" fCalfthymusDNA f • F
+ + W/O/w
Jeffamine ~
r»:»
Hydrogen bonding between PLGAand Jeffamine
PLGA :jeffamine blended nanoparticles
-200nm
Improving release profile and protecting cDNA
from acidic degradation
Formation of hydrophilic channels
upon degradation of PLGA polymer
matrix
Lowering pH produces addk microenvironment
and the amine groups on Jeffamine protonated
to buffer the acid
Figure 5-2. Schematic presentation of PLGA: Jeffamine nanoparticles
system
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E.E. (%) =
Theoretical loading of DNA - un-encapsulated DNA
x 100
Theoretical loading of DNA
From the comparisons of percentage of encapsulation efficiencies for
different PLGA: excipient blended system, it appears that
nanopartic1es composed of PLGA and Jeffamine have higher
encapsulation efficiency. This may be due to presence of positive
charges on amine groups in Jeffamine polymer in the mixture which
could be protonated at low pH and enabling electrostatic interactions
with negative phosphate groups in DNA backbone, this is in addition
to binding via hydrogen bonding between Jeffamine and DNA
molecules. Although the value of encapsulation efficiency for this
new blended system was much higher when compared to PLGA:
poloxamers or poloxamines system with equal amount of theoretical
loading, this partially may be due to that fact that Calf Thymus DNA
was used instead of circular plasmid DNA which is linear and has
smaller size. Nonetheless, these new blend system of PLGA and
Jeffamine offer potential advantage for DNA delivery.
Generally, the release of DNA from PLGA nanopartic1es follows a
tri-phasic pattern". There is an initial burst release of DNA molecules
that are loosely associated with the surface of the particles and
entrapped during solvent diffusion process of the double emulsion
technique. The second is characterised by a slow erosion of the PLGA
matrix. In the final phase, the DNA molecules start to release in a
more controlled manner through the formation of hydrophilic
channels in the matrix. Therefore, it can be said that hydrolytic
process of PLGA is important in determining the rate of release of
DNA. Blending of hydrophilic polymers such as Jeffamine in the
hydrophobic matrix can have a positive effect on the release of DNA
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molecules. Therefore the effect of blending of Jeffamine has been
investigated in this section of the thesis and the results were
indicative of continuous release pattern. This is believed to be due to
strong hydration of the PLGAmatrix by the presence of Je££amineas
hydrophilic polymer. A similar result has been obtained by other
groups by blending poloxamines and poloxamers within PLGA
nanoparticles.
Despite the works that have been carried out in this section of the
thesis to enhance encapsulation efficiency of DNA within
hydrophobic PLGA nanoparticles as well as improve release profile,
the PLGA: Je££amine blended nanoparticles still lacked the
hydrophilic protecting shell on the surface to prevent interaction
between particles and with an in vivo environment. Uncoated
particles can be easily recognised by mononuclear phagocyte system
(MPS) and rapidly cleared from blood; this is attributed to the
hydrophobic nature of the PLGAparticles that favour the adsorption
of blood components such as opsonins. Therefore, the next challenge
was to coat the surface of developed PLGA: Jeffamine blended
nanoparticles with hydrophilic polymers; this is discussed in next
section.
5.4. Surface modifications of PLGA: Jeffamine blended
nanoparticles
The conventional approaches for surface modification of PLGA
nanoparticles consisted of simple physical adsorption of block
copolymerst. Surface modifications of PLGAnanoparticles have been
carried out using either adsorption via electrostatic interactions or
adsorption via hydrophobic interaction. PLGA polymers that form
the bulk matrix of the nanoparticles impart hydrophobic character to
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the surface of nanoparticles: whereas, the exposed carboxylic groups
on surface of PLGA nanoparticles produce considerable negative
charges of about - 50 mV (zeta potential) when measured in low
ionic strength solution of PBSat fixed pH value of 7.4. It should be
mentioned that blending of Jeffamine with PLGA polymers led to a
less negative surface charges of about - 30 mV and this still allowed
for surface modification to carry out via electrostatic interaction.
In order to test the two approaches, pDMAEMA-PEGMAand PLGA-
PEGMA block copolymers were obtained. In both cases PEGMA
segments represented the hydrophilic blocks whereas, pDMAEMA
and PLGA represented the cationic block and hydrophobic block
respectively. Itwas possible to adsorb these two block copolymers on
the surface of PLGA: Jeffamine blended nanopartic1es since the
hydrophobic PLGA blocks can anchor on the surface via
hydrophobic interaction and pDMAEMA via electrostatic
interactions. On the other hand, the hydrophilic PEGMA can
protrude towards the aqueous medium and provide a protective
shell through steric hindrance.
The surface adsorptions of these block copolymers were studied by
measuring the zeta potential value before and after the adsorptions.
In both cases, the zeta potential values changed to near zero, an
indication of successful adsorption of the block copolymers on the
surface of the nanopartic1es.
Despite the success of the adsorption experiment, there are
limitations to physical adsorption methods. Owing to nonspecific
attachments, these block copolymers can be easily displaced by
serum proteins.
This undesired displacement can ultimately compromise the stability
of the nanopartic1es in the circulation and expose the particles to
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aggregation. To overcome this problem, the alternative approach to
provide the particles with a protective shell would be the synthesis of
block copolymers, in particular, via controlled living polymerisation
technique which allows designing the copolymers with control over
the molecular weight and functionality, (discussed in next section).
Uncoated PLGA:Jeffamine blended nanoparticles
~
pOMEMA PEGMA
Adsorption via electrostatic interaction Adsorption via hydrophobic interaction
Figure 5-3. Schematic illustration of physical adsorption of
pDMAEMA-PEGMA (left) and PLGA-PEGMA (right) on the surface
of PLGA: Jeffamine blended nanoparticles.
236
ChapterS Final Conclusion
5.5. Synthesis of biocompatible and degradable block copolymer
Conventionally, amphiphilic copolymers of PLA-PEG and PLGA-
PEG were prepared for variety of purposes ranging from micelles,
nanoparticles formulation or physically adsorbed on PLGA based
nanoparticles to increase stability. The PEG block was used to
provide II stealth" properties to enhance pharmaceutical profiles of
therapeutics ranging from small molecules to proteins. Whereas, PLA
and PLGA block were utilised to serve as reservoir for variety of
drug compounds. Depending upon the molecular weight ratio of
PLA, PLGA blocks to PEG block, a series of block copolymers with
different solubilities and hydrophilicities can be obtained. Moreover,
by changing the composition ratio of the two blocks, varieties of
formulation can be prepared ranging from micelles, nanopartic1es to
vesicles. In addition to that, by varying molecular weight one can
also control the encapsulation efficiency of drug compounds, release
profile by changing the PLA, PLGA molecular weight and
biodistribution by changing the diameter size. However, fine-tuning
of the properties of these co-polymers is more difficult owing to the
limited availabilities of PEGs with appropriate functional chain-ends
and ranges of molar mass. By contrast, PEG-side-chain polymers,
exemplified by PEG-methacrylate (PEGMA) can be synthesised via a
variety of routes, and very fine manipulation of properties can be
exerted through controlled polymerisation strategies. Controlled
radical polymerisations, primarily ATRP and RAFT have enabled
PEG-methacrylates and co-polymers with exciting new properties to
be produced.
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In Chapter 3 of the thesis, and for the first time, a series of PLA-
PEGMA and PLGA-PEGMA copolymers were prepared via
combining controlled living polymerisation and ring opening
polymerisation techniques.
The main objectives of this work were to combine ring opening
polymerisation (ROP)with Radical Addition Fragmentation Transfer
(RAFT)technique to synthesise a series of PLA-PEGMAand PLGA-
PEGMA block copolymers. These copolymers were varied in co-
monomer content and block length with low polydispersities. Owing
to the amphiphilic nature of these block copolymers, the materials
can form micelles in aqueous solution. In contrast, it is possible to
obtain nanoparticles by using emulsion techniques such as single or
double emulsion techniques. This new synthesis approach offer
significant advantages not only because these block copolymers are
biocompatible and biodegradable, but also through fine control over
the properties of the system. The tailoring of co-monomer type and
the wide variety of methacrylate and acrylate functional materials
available that can be polymerised via RAFTor ATRPmeans that fine-
tuning of drug incorporation and release should be possible.
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A)
Blocornpatible and biodegradable
Amphiphilic copolymer
PLGA-PEGMA micelles
B)
Hydrophobic Hydrophilic
~
PLGA PEGMA
~ targeting moiety
Punctionalised micelles
Fine-tuning of molecular weight._..
Tunable properties:
- Encapsulation efficiency
- Releaseprofile
- Diameter size( biodistribution)
Figure 5-4. Schematic illustration of A) PLGA-PEGMA micelles and
functionalised micelles. B) Tuning the properties of the micelles by
changing the molecular weight.
The choice of RAFT agent was important to combine the two
techniques, ROP and RAFT polymerisations. Therefore, BSTSERAFT
agent, which has an incorporated hydroxyl moeity on the R group,
was chosen to initiate the ROP of lactide and glycolide monomers.
The obtained PLA and PLGA polymers carrying the RAFT agent at
the end of the chain were subsequently utilised as macro-initiator to
grow the second polymer in a controlled manner. After synthesis of
different molecular weights of PLA-PEGMA and PLGA-PEGMA, the
next step was to investigate the effect of molecular weight on size,
encapsulation efficiency and release profile. This was a crucial
experiment to show that the developed synthetic system for this
particular copolymers could be utilised to control the properties of
the micelles system. A model drug (carboxy fluorescein) was
encapsulated in the hydrophobic core of PLA-PEGMA and PLGA-
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PEGMA copolymers. The results have shown that, by increasing the
molecular weight of PLGA bock in the copolymer, not only the size
of the micellular system can be tuned but also the release profile can
be controlled. The release of carboxyfluorescein may be due to
partitioning through the core to the aqueous medium but for long
term release is due to the hydrolytic degradation of the PLA and
PLGA in the core of the micelles.
Generally, PLA polymer is more hydrophobic than PLGA polymer.
PLGA is known to have faster degradation rate owing to presence of
glycolide unites which hydrolyse more easily than lactide in water.
However, this seems to have no effect on the release profile of the
chosen model drug (carboxyfluorescein), this is more likely to be due
to the nature of this molecules which is not strongly hydrophobic.
Therefore, its retention in the hydrophobic core of the micelles was
not significantly affected by using PLA or PLGA polymer.
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Figure 5-5. Schematic illustration of CF release profile varies by
changing the molecular weight of the copolymer.
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By comparing the new developed synthetic system to conventional
techniques to prepare PLGA-PEGcopolymers, in the new system it is
more easily possible to alter model drug incorporation and release
via changes in co-polymer structure. Although this was not fully
explored in ths thesis, the enhanced control inherent to the synthesis
of these PLGA-PEGMAblock co-polymers by combined ROP and
RAFTallows much better flexibility in co-polymer preparation than
the anionic routes needed for PLA-PEGsystems.
Cellular uptakes is an important requirement of any drug delivery
system, therefore, the next stage was to examine the uptake of these
micellar system by a representative cell lines for which 3T3fibroblast
cell line has been chosen.
Fluorescein isothiocyanate (FITC)was selected as complementary to
CF as it is more hydrophobic and therefore a better model for more
hydrophobic drugs. These cell uptake experiments were preliminary
and it was also the case that absolute quantification with fluorescent
dyes as model drugs was not possible owing to self-quenching effects
and pH differences in sub-cellular compartments (FITC,for example,
is not strongly fluorescent at the lower pH values found in late
endosomal compartments). However, the data nevertheless showed
that these di-block micelles were capable of rapid entry into a
representative cell line, an important requirement for any drug
delivery system.
To this end, it has been shown that copolymers based on
biodegradable PEGMA and PLGA components can be prepared by
combining ROP and RAFT chemistries with control over the
molecular weights and polydispersity. The advantages of this
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approach over the already existing methods to formulate drug and
gene delivery systems have also been highlighted.
Despite the benefits that these materials have rendered to drug and
gene delivery systems, some applications remain challenging; for
instance, specific targeting to the action site or efficient drug/ gene
delivery inside the target cell. In this context, the design of
multifunctional carrier systems could significantly improve already
existing carrier characteristics and help to surmount these challenges.
In case of nucleic acid delivery, the hurdles are much more
complicated. DNA and RNA delivery vehicles are required to
package the polynucleotide, protect it during transport in and across
numerous biological environments and barriers, then release the
biopolymer in the correct subcellular location. Therefore, the design
and synthesis of more sophisticated carrier systems (multifunctional
carriers) was the focus of Chapter 4, potentially for gene and drug
delivery system.
5.6. Multifunctional Bioresponsive Cell-Targeted Block Co-
polymer Nanopartides for Gene Delivery
For DNA-based therapies the target is the cell nucleus, whereas for
RNA, delivery to the cytoplasm is required. Many designed
polymeric nucleic acid delivery systems (usually termed 'vectors')
have been developed by analogy with viruses, which are, of course,
natural DNA or RNA carriers that are able to deliver their payloads
to cells with extreme efficacy.The requirements for these vectors are
stringent: for example for DNA, the nucleic acid (which can be
several million Da in molar mass) must be condensed to a small size
or encapsulated, and protected from serum and intracellular
nucleases. The DNA must be delivered to the target cell, cross the
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external cell membranes passively or actively, leave the endosomal
compartments (avoiding degradative enzymes and escaping traffic to
the lysosomes), then it must translocate into the nuclear
compartment ready for transcription. The vector must thus protect
the DNA and help transport it across multiple cell barriers, yet
release it at the correct time.
In addition, for an injectable DNA delivery formulation, the vectors
with encapsulated/ complexed DNA must be capable of extended
circulation in the bloodstream in order to have chance to reach their
cellular target. They must also be small enough to gain access to
tissues and cells - typically this will put a size limit of <250 nm for
the hydrodynamic diameter of the vector system in circulation.
Above all, the vectors must be safe, i.e. non-toxic, non-immunogenic
and fully cleared from the body after use. Block co-polymer micelles,
vesicles and nanoparticles have been extensively investigated as
carriers for nucleic acids, as the core-shell architectures enable
packaging of DNA or RNA into a protected interior phase.
Designing and synthesis of a carrier system that can overcome all the
challenges associated with DNA, RNA delivery pathways remain a
difficult task to accomplish. Although there are many systems that
have been already reported, but these systems do not have all the
properties required for advanced gene delivery system in a single
construct or they have been synthesised through many difficult
chemistry steps. Moreover, one of the present limitations for the
combination of multiple functions on a single particle is the surface
chemistry required. Most of the developed systems rely on non-
covalent strategies, such as electrostatic and biospecific interactions
or hydrophobic adsorptions, which do not enable control over the
composition, size and multifunctionality of the nanoparticulate
system.
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Multifunctional nanopartlcles strategies for constructing multifunctional nanoparticles
(1) Stability, biocompatibility to prolong blood circulation, therefore
improving specificity (e.g. PEG,PEGMA)
(2) Specific targeting to Increase efficiency, reduce toxicity
(e.g. Antibodies, Folic acid or Aptamers)
(3) High encapsulation efficiency
(4) Stimulus-sensitive release to Control bioavailability, reduces toxicity
(e.g. pH-labile, Thermosensitive or Redox sensitive)
Figure 5-6. Schematic illustration of multifunctional nanoparticles for
drug and gene delivery.
To build multifunctional nanoparticles that include all the above
listed properties (Figure 5-5) in a single construct still represents a
challenge but it is a goal that is becoming increasingly realistic and
was the main focus of Chapter 4. In order to fabricate the
multifunctional nanoparticles, the following strategies have been
implemented:
1- Block copolymers of PLGA (the hydrophobic core block) and
PEGMA475 (the hydrophilic outer block) were synthesised
using ring opening polymerisation (ROP) and Atom Transfer
Radical Polymerisation (ATRP), these two blocks connected by
bioreducible disulfide bridge.
2- Homopolymers of PLGA prepared which were also connected
by bioreducible disulfide bridge.
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3- Derivatisation of the hydrophilic block terminus to install a
ligand for cell receptor targeting, folic acid has been chosen as
targeting moeity.
4- Double emulsion technique, water in oil in water (W/O/W)
was utilised to encapsulate pDNA in the matrix of the
nanoparticles composed of a blend of PLGA homopolymer
and PLGA-PEGMAdiblock copolymer suface-functionalised
with folic acid.
The synthetic strategy to prepare the diblock copolymer of PLGA-S-
S-PEGMA relied on the combination of two different polymerisation
techniques, ROP and ATRP. The selection of ATRP method was
because many commercially available acrylic ester monomers can be
polymerised with a high degree of control. Moreover, polymers
prepared by ATRP techniques enable the derivatisation of the
terminal polymer via well established click chemistries. This is
crucial and versatile method for installing targeting moieties such as
folic acid.
This approach is considered to be superior to conventional method
which require to use heterobifunctional PEG in order to obtain such
diblock copolymer with functionalised end-terminal.
The first key compound in the synthetic strategy was the
heterobifunctional initiator (incorporated disulfide brigdge) which
was used to initiate the ROP of lactide and glycolide monomers at
one end using hydroxyl moiety and then polymerisation of PEG-
methacrylate monomers at the other end (pLGA-S-S-PEGMA)using
a bromine centre. The second key compound was the commercially
available dithiodiethanol compound. This has been utilised to grow
PLGApolymer from both ends simultaneously (PLGA-S-S-PLGA).
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It was possible to transform the bromine at the end of the PLGA-S-S-
PEGMA chains into an azide terminal groups in a single step which
subsequently were used in a II click chemistry" reaction to install
derivatised folic acid at the end of the PEGMA chain. The reason for
using II click chemistry" was to make a versatile method to attach
different molecules (targeting moieties or imaging agent or both
together) derivatised with acetylene. Secondly, the "click chemistry"
reaction used was very specific, compatible with various
bioconjugation techniques and was efficient which allowed to obtain
a very high yield of product.
The next stage was the fabrication of core-shell blended
nanoparticles via double emulsion technique ( previously described
in chapter two of the thesis). The copolymers of PLGA-S-S-PEGMA-
folate and PLGA-S-S-PLGA were mixed together in the organic
solution of the double emulstion technique. The hypothesis was that
blending of PLGA-PEGMA-folate in the initial steps of double
emulsion technique may enhance the encapsulation efficiecy of
pDNA. This may occur through stabilisation of the primary emulsion
by PLGA-PEGMA-folate which is amphiphilic in nature (surfactant)
and thus prevents pDNA leakage.
246
Chapter 5 Final Conclusion
=:': Primary emulsion (W/O)
Aqueous phase
(pONA solution)
vortex
Organic phase
PLGA-s-s-PLGA
+
PLGA-s-s-PEGMA-folate
(A) (B)
(A) Organic solution of PLGA-s-s-PLGA and PLGA-s-s-PEGMA-folate Hydrophilic Hydrophobic
(B) Primary emulstion, accumulation of PLGA-s-s-PEGMA-folate
at the aqueous/oraganic interface (stabilisation of water droplets) PEGMA
Figure 5-7. Schematic illustration of primary emulsion stabilised by
PLGA-S-S-PEGMA-folate diblock copolymers.
Using double emulsion technique and blend copolymer systems
made it possible to achieve higher encapsulation efficiency up to
80% of plasmid DNA. The next step was to enhance pDNA release
from the nanoparticles, this is a crucial step to ensure efficient
delivery of the pDNA inside the cell and this has been performed
using the following strategies
1- Incorporation of disulfide bridge in PLGA-S-S-PEGMA-folate
to trigger the loss of the polymer shell intracellularly
(mammalian cells contain ~ 5mM glutathione concentration as
reducing agent).
2- Incorporation of disulfide bridge in PLGA-S-S-PLGA polymer
which mainly form the bulk matrix of the nanoparticles (i.e.
disulfide bridge distrubuted throughout the matrix). This is in
addition to hydrolytic degradation of PLGA polymer
backbone.
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Extracellular
bioreducible core-shell nanoparticle
Intracellular
(3)
Glutathione -SmM \ DNA molecules
/l
(1) Reduction of PLGA-s-s-PEGMAdisulfide bond by intracellular glutatione, shell detatchment
(2) Reduction of PLGA-s-s-PLGAdisulfide bond & hydrolysis of PLGA backbone, erosion of matrix
(3) Enhance release of DNA molecules in cytoplasm
Figure 5-7. Schematic illustration of reducible core-shell
nanoparticles, intracellular unpackaging in the presence of
glutathione (reducing agent) to enhance the release profile of
encapsulated DNA.
Once the reducible nanoparticles were internalised, the nanoparticles
followed dual degradation stages. First, the presence of intracellular
glutathione triggered the loss of the shell and secondly
biodegradation of the particles took place via reduction of the
disulfide bridges. The final degradation stages involve the hydrolytic
degradation of PLGA polymer backbone which result in the erosion
of the matrix and further release of the II cargo", (although in the
thesis the full degradation of the PLGA was not evaluated).
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So far, the concepts and strategies for construction of reducible core-
shell nanoparticles with higher encapsulation efficiency and
improved release profile have been discussed. The next step was to
surface functionalise the nanoparticles to achieve specific targeting.
Receptor-targeted drug and gene delivery systems can potentially
claim two advantages over conventional nontargeted therapies,
depending upon the nature of the targeting ligand. The advantages
are as follow:
1- Enhance cellular uptake by desired cell populations, such as
diseased cells and thus increasing therapeutic efficiency.
2- Reduce cellular uptake by non-diseased cell, thereby reducing
toxicity to intact cells.
Cellular uptake mechanism is a complex biological process and
involve many intracellular trafficking pathways. The fate of the
internalised vectors generally rely on types of the receptors involved
and related intracellular trafficking. Therefore, to ensure safe and
efficient delivery of the therapeutic molecules to the targeting site,
careful selection of the receptors for targeting is crucial. In the
delivery of RNA and DNA molecules, the site of actions are
cytoplasm and nucleus respectively. Targeting moieties such as
antibodies or hormones are internalised by cells as a method of
clearing the ligands from their cell surfaces (Le. once a hormone
signals through its receptor, it must be removed and destroyed to
prevent continuous signaling for the life of the cell). In contrast, folic
acid is taken up by the cells via the folate receptor, an essential
element required for cell functions, and therefore, vectors conjugated
with folic acid are not delivered to lysosomes, but rather are released
into cytosol.
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In addition, the significant upregulation of folate receptor on most
cancer cells and high biniding afinity of folic acid have generated
extensive interest in folic acid to utilise as targeting moiety for
delivery of many therapeutic molecules.
In this work, folic acid was chosen as the model of targeting ligand
and conjugated to the surface of reducible core-shell nanoparticles
via II click chemistry". The lung cancer cell line Calu-3 was also
chosen as a clinically relevant model to examine the uptake efficacy
of folate functionalised nanoparticles. Owing to high binding afinity
of folic acid and folic acid conjugate to its receptor, saturation of the
receptor is more likely to occur. Therefore, the cellular experiment
assay was carried out in a way that the amount of folic acid on the
nanoparticles were progressively increased to achieve maximum
cellular uptake and avoid receptor saturation. To confirm the FR
mediated cellular uptake of the nanoparticles, the folate receptors on
the calu-3 cell lines were saturated by adding excess amount of free
folate.
5.7. Concluding Remarks
Gene therapy provides great opportunities for treating inherited and
acquired diseases such as cystic fibrosis and cancer. The success of
gene therapy relies on the availablity of efficient and safe delivery
carriers to transport therapeutic DNA into desired cell populations.
Polymeric gene delivery systems have been developed as alternatives
to viral vectors for reasons of their avoidance of cytoxicity and
immunogenecity. PLGA is biodegradable and biocompatible, and is
an FDA approved polymer that has a significant potential for
delivery of biomacromolecules such as pDNA and proteins in the
form of micro and nanopartic1es.
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The primary limitations to PLGA particulate delivery systems
includes exposing pDNA to harsh condition ( high shear forces)s
during nanoparticle formulations, low encapsulation efficiencies and
poor release profile (burst release). Several strategies have been
considered to overcome these problems, in particular, preserving the
integrity of pDNA during particule formulation, among which was
the addition of other biocompatible polymers to form blended
particulate systems such as poloxamers and poloxamines.
In Chapter 2 of the thesis, a new blended particulate system based on
biocompatible and biodegradable polymers (PLGAand Jeffamine™)
has been reported with significant improvement to the encapsulation
efficiency of DNA as well as the releasing profile. The data analyses
for the new blended system have confirmed the success of the
hypothesis and a strategy was undertaken to circumvent the
aforementioned problems associated with PLGAdelivery systems.
The block copolymers of PLGA-PEGMAand PEGMA-PDMAEMA
have been synthesised and physically adsorbed on the new blended
PLGA: Jeffamine system to provide a hydrophilic protecting shell
which is crucial in preventing particle aggregation and in vivo
stability.
To avoid the controversy around the in vivo stability of particles
physically coated with hydrophilic polymers, in chapter three of the
thesis, new strategies have been developed to formulate particles
coated with hydrophilic polymers via covalent bonds. Overall it has
been shown that it is possible to synthesise block co-polymers based
on biodegradable PEG-methacrylate and PLGA components in a
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facile one-pot procedure and with good control over block length,
proportion and final molar mass.
These polymers assemble in aqueous solution into micelles that can
encapsulate model drug compounds or can be processed in double
emulsion techniques to encapsulate DNA molecules.
Release studies with fluorescent model drugs showed that overall
release was higher with micelles formed from polymers that, at the
same mass, exhibited higher micellar volume, but that release rates
were lower for co-polymers with a higher proportion of
hydrophobic:hydrophilic blocks. Successful uptake of micelles into
3T3 cells was shown for two block co-polymers used, polymers 5 and
polymer 8.
The combination of ROP and RAFT chemistries used here to make
the PLGA-PEGMA polymers offers many advantages compared to
existing routes to PLGA-PEG type co-polymers for future studies of
controlled release systems. The tailoring of co-monomer type and the
wide variety of methacrylate and acrylate functional materials
available that can be polymerised via RAFT or ATRPmeans that fine-
tuning of drug incorporation and release should be possible, and via
external or biological triggers for targeted therapies.
In Chapter 4 of the thesis, significant steps have been made toward
the construction of multifunctional nanoparticles that fulfill all the
requirements for a successful nonviral gene delivery system in a
single carrier. Overall, the work that has been carried out was
concluded as the syntheses of modular block copolymers, based on
PLGA and PEG-methacrylate, assembled via combination of
ROP,ATRP and click chemistry routes to generate biocompatible,
cell-targeted and bioresponsive gene delivery vehicles.
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Double emulsion techniques were used to encapsulate DNA with
high efficiency,and uptake of the resultant nanoparticles was shown
to take place in Calu-3 cells via a specific folate-receptor mechanism.
The reporter gene expression studies demonstrated that selective
receptor-mediated and intracellularly triggered drug delivery took
place, and the ability to do this in the clinically important Calu-3 cell
line offers promise for future therapeutic applications.
5.S. Future Work
The developed nanoparticulate systems seem to be rather promising
and potential candidates as drug and gene delivery systems. The
synthetic strategies to prepare diblock copolymers in a controlled
manner and the possibility of subsequent functionalisation offer
great opportunities to prepare carriers with tailored properties.
Despite the success of in vitro studies for the developed
nanoparticulate systems, in vivo experiments need to be carried out
in order to evaluate the efficacy of the systems for clinical
applications. Depending upon the desired size, biodistribution and
fate of the nanocarrier, the length of the block and composition of the
polymers can be tuned for specific applications. The release profile
also can be improved depending on the specific properties needed.
Bolus release (immediate) or prolonged release can be obtained by
incorporation of different functionalities or by changing the
composition of lactide to glycolide units in the PLGA polymer.
Finally, it would be advantageous to incorporate more than one
therapeutic agent together in a single nanoparticulate system to
achieve combinatory doses in a single dosage to produce a
synergistic effect such as in the case of cancer which requires
combination therapies.
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